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Structure-Function Studies of the Vaccinia Virus Complement Control Protein 
 
Scott Alan Smith 
 
March 27, 2002 
 
 The vaccinia virus complement control protein (VCP) is involved in the 
modulation of the host inflammatory response during vaccinia virus infection.  It 
possesses the ability to inhibit both classical and alternative pathways of complement 
activation, as well as bind to heparin or heparan sulfate proteoglycans, making it a unique 
multifunctional protein with therapeutic potential.  VCP is able to block complement 
activity through its ability to bind C3b and C4b.  Other very novel activities arise from 
VCP's ability to bind heparin and heparan sulfate proteoglycans, allowing the protein to 
attach itself to cell surfaces.  The goal of this research was to fully ch racterize the 
structure and various functions of VCP. 
 The structural basis for VCP's ability to bind heparin was investigated using 
heparin affinity chromatography, surface plasmon resonance analysis, and homology 
modeling with well-characterized heparin binding proteins.  VCP was found to possess 
two regions involved in heparin binding, one involved in weak binding located at the 
junction of complement control protein (CCP) modules 1 and 2, and a second involved in 
strong binding located at the extrem  C-terminal tip of the protein.  Additional functions, 
involved in blocking molecular interactions with cells, were also identified and 
determined to be a result of VCP's ability to bind heparin. 
 vii 
 The structural basis for VCP's ability to bind complement was investigated using 
the hemolysis assay, surface plasmon resonance analysis, and homology modeling with 
well-mapped complement regulatory proteins.  VCP was found to be the smallest 
functional unit able to bind and cause factor I cleavage of C3b/C4b, thus inhibiting 
complement activity.  VCP was also shown to possess the ability to simultaneously bind 
and inhibit complement activation, using its entire exposed surface, while remaining 
attached to heparin by its C-terminal heparin binding site. 
 The structure of VCP and its structural and functional stability were determined 
using X-ray crystallography, NMR, DSC, and the hemolysis assay.  VCP was found to be 
an elongated filamentous protein, with defined CCP modular regions with limited 
intermodular interfacing, existing as a monomer in solution.  VCP was found to possess 
the ability to structurally withstand temperatures in excess of 90oC.  In addition, VCP was 
able to retain functional integrity following exposure to many adverse physical 
conditions, which would result in irreversible denaturation of most other proteins. 
 Lastly, the in vivo pharmacokinetics of VCP was investigated in rats.  VCP was 
injected as a bolus at different routes and using various concentrations.  Continuous and 
intermittent itravenous injection strategies were also investigated.  In all cases, the 
serum CH50 was monitored over time to determine the half-l fe of VCP activity in the 
serum.  Traces of intact VCP was detected in urine by SDS-PAGE analysis, giving clues 
to its excretion and elimination from the body. 
 This research has provided greater understanding of the architectural features of a 
protein that contribute to heparin and complement binding.  In addition, this research may 
prove important for the future use of VCP as a novel immunomodulating agent, as well as 
 viii 
future protein-engineering efforts to design a better treatment for many complement 
mediated diseases, such as: Alzheimer's disease, central nervous system (CNS) injury, 
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POXVIRUSES: VACCINIA VIRUS 
 
Introduction 
This chapter contains material adapted from the following publications: 
Smith S.A., and Kotwal G.J.  Virokines: novel immunomodulatory agents.  Exp. Opi . 
Biol. Ther., 1(3):343- 57, 2001. 
 
Smith S.A., and Kotwal G.J.  Vaccinia virus.  In: Encyclopedia of Molecular Medicine.  
John Wiley & Sons Inc., Vol. 5, pp. 3324-3330, 2001. 
 
Smith S.A., and Kotwal G.J.  Immune response to poxvirus infections in various animals.  
Crit. Rev. Microbiol., In press, 2002. 
 Vaccinia virus (VV), the most widely studied member of the poxvirus family, 
serves as a model to enhance our understanding of this extraordinary family of complex 
DNA viruses.  Like other poxviruses, which have the largest virions of any animal virus 
family, VV virions are substantial in size.  They appear as smooth, rectangular sacks, 
approximately 350 nm in length by 270 nm in width.  Because of its relatively large size, 
VV was the first animal virus to have beeen seen microscopically, in 1886.  Vaccinia
virus contains a large, linear, double-stranded DNA genome of over 191 kbp.  This large 
genome is responsible for encoding all the proteins necessary for vaccinia's unique 
cytoplasmic lifestyle.  Like other members of the poxvirus family, VV replicates almost 
entirely independent of the infected cell nucleus.  Therefore, being unable to utilize the 
host cell's machinery to synthesize RNA or replicate DNA, VV must encode these 
important proteins in its own genome.  Another interesting feature of the vaccinia 
genome is the presence of terminal hairpin loops.  The ends of the double- trand d DNA 
are covalently linked to form a continuous single-stranded polynucleotide chain (figure 
1).  This unique telomeric structure seems to be very important in replication. 
Upon entry into the host cell, the VV life cycle is naturally divided into three 
stages according to gene expression: early, intermediate, and late.  Early genes are 
expressed via transcriptional regulatory proteins packaged within the infecting virion.  It 
is during this time that the genome is replicated to high numbers in cytoplasmic factories 
(virosomes) through the formation of large concatemers, utilizing many proteins 
produced during this early stage of gene transcription.  The intermediate stage of vaccinia 
replication is defined by a strong spike in gene expression, falling shortly after the 
initiation of DNA replication and before the expression of the more abundant late genes.  
Late gene expression is responsible for production of the major virion components, 
including those that are structurally important and those necessary for early stage gene 
expression upon entry into a new host cell.  Late gene expression continues to produce 
structural proteins that accumulate in large amounts in the cytoplasm, allowing for viral 
assembly and maturation for at least 48 hours after infection.    
In addition to those viral proteins encoded by VV required for transcription, 
replication and virion assembly, there are several nonessential proteins utilized by VV to 
establish a suitable habitat.  Vaccinia virus encodes a growth factor that, when secreted 
from infected cells, results in the proliferation of neighboring cells, increasing the number 
of local cells that can be infected by viral progeny.  Other interesting nonessential 










Figure 1.  Vaccinia virus genome organization.  The vaccinia virus genome is a very 
large double stranded DNA.  The end 5% of the genome is made up of inverted terminal 
repeats and the very ends are covalently closed by terminal hairpin loops.  The ge ome is 
divided into three main areas: variable left end, conserved central region, and variable 
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interleukin one receptor (IL-1R) homologue, tumor necrosis factor receptor (TNFR) 
homologue, and interferon receptor (IFNR) homologue.  Although not all of the 
nonessential proteins have been studied, each is presumed to play an important role in 
modulating the host's immune response to infection, thereby maintaining the viral habitat.   
Vaccinia virus also played an important role in the eradication of the de dly 
variola virus.  Edward Jenner, in 1796, started immunizing individuals with a very close 
relative of VV, cowpox virus (CPV).  Eventually, VV replaced CPV as the chosen 
vaccine, and the World Health Organization (WHO) launched its extremely successful 
eradication campaign.  Interestingly, the exact origin of VV still remains a mystery today.  
It is postulated that VV arose in the 19th or early 20th centuries from all the mixing of 
vaccine strains (or possibly variola and cowpox), since the nature of viruses was still quit 
unknown at that time.  Therefore, it is still believed that the lack of a natural host 
reservoir and broad host range exhibited by vaccinia virus is due to its creation in a 
laboratory.   
As mentioned earlier, the poxvirus family, Poxviridae, has the largest virions of 
any animal virus family.  They appear oval or brick shaped, approximately 350 nm in 
length and 270 nm in width.  Poxviruses contain a large, linear, double-stranded DNA 
genome of 130-280 kbp.  This large genome is responsible for encoding all the proteins 
necessary for their unique cytoplasmic lifestyle.  Members of the poxvirus family 
replicate almost entirely independent of the nucleus of the infected cell.  Unable to utilize 
the host cell's enzymes to synthesize RNA or replicate DNA, they encode these essential 
proteins in their own genome.  In addition to those proteins encoded by poxviruses 
required for transcription, replication and virion assembly, there are several nonessential 
5 
proteins employed to establish a suitable habitat.  Several interesting nonessential 
proteins encoded by poxviruses include: complement control protein, IL-1R homologue, 
TNFR homologue, and IFNR homologue (Kotwal, 1997).  These nonessential proteins, 
and several others, play an important role in modulating the host's immune response to 
the infection, thereby maintaining the viral abitat (Howard et al., 1998). 
The family Poxviridae is divided into two subfamilies, Chordopoxvirinae, which 
are vertebrate poxviruses, and Entomopoxvirinae, which are insect poxviruses – w  will 
only discuss the Chordopoxvirinae (Moss, 1996).  There are eight genera of vertebrate 
poxviruses – see table 1.  Poxviruses have been found to infect vertebrates ranging from 
birds to humans.  Some of these infections can be highly fatal; smallpox virus (variola), 
which replicates only in humans, has killed more people than any other infectious 
disease.  In addition, myxoma virus, which infects rabbits, can have as high as a 99% 
mortality rate.  Much of the success of poxviruses as pathogens is due to the immune 
evasion strategies they employ (Kotwal, 1997).   
The poxvirus infection generally follows one of two courses, a localized infection 
resulting in benign skin lesions, or a systemic infection resulting in viral dissemination 
and usually death.  Local pathogenesis of molluscum contagiosum virus (MCV) and 
Shope fibroma virus (SFV) infection has been well documented.  Although the 
pathogenesis and host response to infection is quite different, both poxvirus diseases are 
self-limiting and remain localized to the skin.  The generalized infections, however, are 
characterized by several stages, ending in an explosion of viral lesions.  Ectromelia virus 
infection of mice starts with an infection of the skin, usually via the footpad.  After some 
replication, the virus spreads through the local lymphatics to the bloodstream, resulting in 
6 
7Table 1.  Poxvirus classification.The familyPoxviridae, subfamilyChordopoxvirinae
is composed of eight genera.  Listed are the most studied members of each genus. 
primary viremia.  The virus then replicates to high titers in the spleen and liver before 
reentering the blood, resulting in a secondary viremia.  Finally, the virus spreads to the 
skin and a severe rash of ulcerating lesions very rapidly overcomes the mouse.  The 
disease progression of variola virus infection in humans occurs similarly, with high 
mortality rates – ee figure 2. 
The immune response to poxvirus infection is very complex.  Each arm of the 
immune sy tem plays a vital role in the segregation and elimination of a poxvirus 
infection.  Early in the infection, the innate immune response attempts to keep the 
infection under control, while the acquired immune response is mounted.  Complement, 
interferon (IFN), NK and inflammatory cells help control the early infection.  Within a 
few days, a very strong humoral immune response is mounted, and poxvirus-specific 
antibodies are produced.  The antibodies can then help control the infection through a 
variety of mechanisms, including virus neutralization and complement activation, 
opsonization, and ADCC.  In addition, a cell-mediated immune response is mounted a 
few days into the infection.  Poxvirus-specific CTLs are generated and attack virus-
infected cells, ultimately resulting in clearance of the poxvirus infection. 
Animal models have been used quite extensively for the study of poxvirus disease 
pathogenesis and exploring the therapeutic potential of poxvirus immunomodulatory 
proteins.  To gain a better understa ing of the infection processes and genes involved in 
interactions with the host, several animal models have been developed to study various 
poxvirus diseases and recombinant mutant poxviruses.  Animal infection models are 
important for testing the efficacies of new anti-viral drugs or to explore new treatment 






Figure 2.  Smallpox virus pathogenesis.  Smallpox virus infection occurs via the 
respiratory route or direct skin- o-skin contact with a lesion.  An incubation period of 
approximately 10 to 12 days follows while the virus replicates in the draining lymph 
node(s).  After this incubation period, the virus enters the blood and disseminates 
throughout the body, causing fever, malaise, headache and backache; these are the first 
signs of sickness.  For the next 3 to 6 days, the virus can be recovered from the patient's 
blood.  An eruptive exantham ten ensues, starting as small macular lesions of the mouth 
and pharynx, face and forearms, before spreading to the trunk and legs.  The rash 
becomes popular, then pustular and often protrudes from the skin before scabbing over on 
the eighth or ninth day of the rash.  If the individual recovers, permanent damage to the 
skin (pockmarks) becomes evident.  Overall there is a 20-50% mortality rate associated 
with smallpox infection, however, in the rapidly progressing type of infection, mortality 
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(Photographs from the World Health Organization)
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poxvirus infection, analyzing the degree of inflammation and cellular infiltration both 
quantitatively and qualitatively.  This allows for a better understanding of the genes 
associated with poxvirus pathogenesis and results in better characterization of mutant 
strains.  Understanding pathogenesis assists in the generation of more attenuated vaccine 
strains and poxvirus vectors for use in live vaccines, in hopes of reducing complications 
associated with traditional vaccines.  Animal models have also been instrumental in the 
study of poxvirus immune modulating proteins.  Several poxvirus immunomodulatory 
proteins have been investigated extensively for their potential use as therapeutic agents.  
These immune blocking proteins have very powerful anti-inflamma ory properties that 
may be employed for treatment of many injuries or diseases that involve excessive 
inflammation.  Animal model systems have been used to test the value of these proteins 
for use in transplantation, vascular injury, CNS injury, sepsis, arthritis, and restenosis.  












 Several methods utilizing electron microscopy have been used to visualize viral 
particles.  Thin section electron microscopy (often using immunostaining) and 
cryoelectron microscopy are widely used and have played  very important role in 
deciphering both VV morphology, as well as the various intracellular stages of its life 
cycle.  Vaccinia virus virions appear as large, smooth surfaced rectangles (350 nm by 270 
nm) when their surface is viewed by cryoelectron microscopy.  When fixed, stained, and 
viewed as thin sections, the vaccinia virions appear much more elliptical.  The dumbbell-
shaped virion core (within which resides the large double-stranded DNA genome and 
essential proteins) can also be seen through this method along with the lateral bodies 
(unknown function) lying adjacent, within its cavities.  This characteristic shape is now 
believed to be an artifact caused by dehydration during section preparation.  Regardless 
of the method used, however, a 30 nm exter al surface membrane can be clearly seen 
surrounding the entire virion.   
One very interesting feature of the VV is how it makes many intracellular and 
extracellular morphological forms, two of which are infectious.  During virion 
maturation, several structurally unique forms can be discerned by electron microscopy: 
the immature virus (IV), the infectious intracellular mature virus (IMV), the intracellular 
enveloped virus (IEV), the cell-associated enveloped virus (CEV), and the infectious 
extracellular enveloped virus (EEV) – see figure 3.  The immature virus (IV) occurs early 
and is characterized by a single outer membrane and incompletely formed core.  The 
intracellular mature virus (IMV) also contains a single outer membrane; however, its core 
is completely formed, allowing the virus to be infectious when released by cell lysis 
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Figure 3.  Life cycle of the vaccinia virus.  (1) Either of the two infectious forms of vaccinia 
virus (IMV or EEV) may bind a receptor on a host cell, allowing for membrane fusion, and viral 
core entry into the cytoplasm of the cell.  (2)Essential viral core proteins are then able to initiate 
early gene transcription from the viral genome (completely independent of the host cell's 
nucleus).  (3) Early viral mRNA is translated by host cell ribosomes into early proteins (many are 
involved in inhibition of the host's immune response).  (4) Many early proteins aid in the 
replication of the vaccinia virus genome.  This replication involves the formation of large 
concatomeric structures.  (5) After the genome is replicated to high numbers, transcription factors 
(early protein) and a cellular protein (Vitf2), relocating from the nucleus, allows for transcription 
of intermediate genes from the newly synthesized genomes.  (6) These intermediate mRNAs are 
then translated to proteins by host cell ribosomes.  (7) Transcription factors produced during the 
intermediate stage then lead to late gene transcription.  (8) Again, the host cell ribosomes 
translate the late vaccinia virus mRNAs into late proteins.  (9) Lat  structural proteins and mature 
genomes assemble on intracellular membranes and form immature virus particles (IV).  (10) 
Cleavage of core proteins occurs and the IV becomes an intracellular mature virus (IMV).  (11) 
The IMV may escape the host cell by lysis and infect a neighboring cell.  (12) Alternatively, the 
IMV may bud through the golgi network and acquire two additional membranes and becomes an 
intracellular enveloped virus (IEV).  (13  The IEV can then polymerize actin and push to the cell 
membrane, where it fuses and becomes known as a cell-associ ted enveloped virus (CEV).  The 
CEV may bud free of the host cell, losing one of its three membranes and becoming known as an 
extracellular enveloped virus (EEV).  This form of vaccinia virus is also infectious and may be 
























































(Hollinshead et al., 1999).  After acquiring two additional membranes, the IMV becomes 
known as the intracellular enveloped virus (IEV), possessing three membranes in total.  
The IEV can move to the plasma me brane (through actin polymerization), fusing to 
become known as the cell-associated enveloped virus (CEV).  This morphological form 
may be released by further budding through the membrane, losing one of its membranes, 
and is known as the extracellular envelop d virus (EEV).  This form of VV is also 
infectious and is responsible for cell-to-cel  transmission as well as dissemination 
















 The complete sequence of VV, Copenhagen strain, has been known for many 
years now.  This large linear, double-stranded genome was found to be 191,636 bp, 
possessing 263 open reading frames, 65 of which are contained within a larger open 
reading frame (ORF) (Johnson et al., 1993).  The genome as a whole is roughly divided 
into three general regions: variable left end, variable right end, and conserved central 
region – see figure 1.  The variable left and right ends of the genome, for the most part, 
contain nonessential ORFs responsible for encoding proteins used in host specificity and 
modulating host defense.  Some of these areclo homologues of host immune proteins, 
clearly indicating that genes were derived and adapted from the host cell.  The conserved 
central region of the genome contains ORFs that encode all the essential proteins required 
for replication in cell culture.  This includes those proteins necessary for RNA synthesis, 
DNA replication, and virion assembly.  The extreme ends of the VV genome are 
composed of identical, but oppositely oriented, inverted terminal repeats.  Contained 
within the 12 kbp inverted terminal epeats found at either end of the genome are several 
tandem repeating sequences of approximately 70 bp in length. 
 As mentioned earlier, the far ends of vaccinia virus's DNA are covalently linked 
hairpin loops, which form a continuous polynucleotide chain.  These terminal hairpin 
loops are composed of highly A+T rich sequence that do not fully base-pair.  This 
telomeric structure allows DNA replication to occur through a continuous simple 
elongation step, creating large concatemers, resulting in large numbers of replicated 
genomes.  Just adjacent to the terminal loop lies an extremely conserved 100 bp region.  
This region contains the resolution sequence  – se  figure 4 - responsible for the precise 
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cleavage of these large concatemeric DNA structures into individual genomes, which are 



























Figure 4.  Important sequences for transcription and concatemer resolution.  Listed 
are the important nucleotides involved in early, intermediate, and late promoter function.  
An important spacer region between the core promoter and initiation site, responsible for 
proper positioning of the polymerase, in noted.  The early termination signal, which is 
highly conserved among early genes, results in termination of the mRNA 20-50 base 
pairs downstream of this sequence.  The efficiency of terminati n is about 80%.  The 
concatemer resolution site is highly conserved and located at the far end of the genome.  










Important Sequences for Transcription and Co catemerResolution.
Early A A A A T AG AA A/GA T
Intermediate AT T T A A A AA T A A
TLate A/T Rich G/ATA AA
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Virus Life Cycle 
 Vaccinia virus replicates exclusively within the cytoplasm of host cells in three 
stages temporally regulated by viral transcriptional activating proteins (B aud, 1995).  
The various stages of replication - early, intermediate, and late – are summarized in 
figure 3.  Infection is initiated through attachment of the virion, followed by entry of the 
core into the host cell.  The cellular receptor responsible for VV attachment and entry has 
recently been shown to be heparan sulfate proteoglycan (Chunget al., 1998).  A protein 
present on infectious VV binds this very common cell surface component, allowing for 
membrane fusion and ultimately core entry.  The ubiquitous nature of this receptor helps 
explain the broad host range exhibited by this virus.  As soon as the VV core en ers the 
cytoplasm of the host cell, early transcription is initiated.   
Early viral mRNAs, synthesized by the transcription system packaged in the core, 
are detectable in the cytoplasm within 20 minutes and reach a maximum level between 
one and two h urs after entry.  Approximately one hour after entry, intermediate viral 
mRNAs are detected and reach a maximum level in two hours.  In addition, two hours 
after infection, late viral mRNAs can be detected and will continue to be expressed until 
the end of infection, approximately 48 hours after initial entry.  Various transcriptional 
activating proteins control the temporal regulation of these various stages of gene 
expression.  Early gene expression occurs through the specific promoter binding (figure 
4) of early transcription activating proteins, produced and packaged into infectious 
virions during the late stage of infection.  Intermediate gene expression occurs similarly 
through the specific promoter binding of intermediate transcription activating proteins, 
20 
produced during the early stage of gene expression.  Late genes are expressed through the 
binding of transactivating proteins produced in the intermediate stage of infection. 
During early transcription, all of the necessary proteins required for DNA 
replication are synthesized and immediately utilized to replicate the genome.  Large 
concatemers of DNA are thereby synthesized within cytoplasmic foci often referred to as 
factory areas or virosomes.  The process occurs with very little help from the host cell 
nucleus.  This has been demonstrated through various experiments using enucleated cells.  
Genome replication occurs very rapidly and results in around 10,000 new genomes per 
cell (only half of which will be packaged into virions).  The speed at which n w DNA 
can be synthesized is greatly enhanced by several viral enzymes involved in synthesizing 
deoxyribonucleotides, increasing the cytoplasmic precursor pools.  The large 
concatemers that result are then cleaved into genome length segments by a specific 
enzyme that recognizes a region of DNA located near the terminus of the mature genome.  
The specific enzyme responsible for this is still not known.  The most likely candidate, 
however, seems to be the virally encoded DNA topoisomerase I enzyme, known for site-
specific cleavage of DNA (Berger, 1998). 
Once late transcription has been initiated, and structural proteins accumulate in 
the cytoplasm, mature genomic DNA can be packaged along with proteins required for 
early gene transcription.  The assembly process probably occurs in association with an 
internal host cell membrane, presumably the Golgi network.  After acquiring a double 
membrane through association with the Golgi network, an immature virus (IV) is formed.  
Further maturation from this immature state then results in the development of an 
intracellular mature virus (IMV) that is fully capable of binding and infecting other cells, 
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but only through lysis of the host cell.  Alternatively, this IMV may acquire two 
additional double membranes via the golgi network (three double membranes total), 
becoming an intracellular enveloped virus (IEV) (Hollinshead et al., 1999; Wilton et al., 
1995).  By polymerizing cellular actin, the IEV is able to force itself to the cell surface, 
allowing the outermost membrane to fuse with the plasma membrane, where it becomes 
known as a cell-associated enveloped virus (CEV).  The CEV is now capable of escaping 
the host cell and disseminating, or may pass directly into a neighboring cell.  The 
extracellular enveloped virus (EEV) that results from budding out of the host cell still 















 In order to defend themselves from the many arms of the immune system, 
poxviruses must constantly evolve new, more powerful methods of modulating the host 
immune response.  Being large DNA viruses, poxviral genomes have enough capacity to 
encode proteins not directly involved in replication.  Therefore, they often encode a 
repertoire of proteins involved in habitat formation and immune evasion – see figure 5.  
These proteins cover a wide range of activities, reflecting the scope and complexity of the 
immune response that they counter in their host.  The survival of the virus depends on its 
ability to create and perfect strategies to conceal itself from this much larger and more 
sophisticated oppnent.  The creativity and potency of the resulting proteins is fascinating 
and cover both intracellular and extracellular processes.  Thus far, most of the proteins 
that have been discovered are secreted and extracellular.  The term "virokine" was coined 
and used to describe virally encoded proteins that are secreted from the infected host cell.  
Most virokines are powerful viral immune modulating proteins created by capturing and 
modifying genes responsible for regulating the host immune response.  These viral 
proteins therefore share many structural and functional features similar to that of the host 
proteins.  However, since there is limited room within the viral genome, only those genes 
very useful to the virus are possibly maintained and constantly adapted to make them 
smaller and more potent.  There have been virokines discovered and shown to modulate 
many important aspects of the immune response.  Many cytokine (IL-6, IL-10) and 
cytokine receptor (TNFR, INFgR, IL-1bR) homologues (also referred to as vir ceptors or 
virokines that mimic receptors) have been shown to significantly disrupt cytokine-
signaling pathways.  This often results in the masking of the host immune system from 
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Figure 5.  Poxvirus immune modulation: (1) Poxvirus binds the host cell, allowing for core 
entry and early gene transcription to initiate.  At this time, many viral proteins are produced to 
interfere with the host's immune response, in order to establish a suitable habitat for optimal 
growth.  (2) Vaccinia virus complement control protein (VCP) is produced and secreted from 
infected cells.  VCP can block the activation of complement through its ability to bind C3b and 
C4b complement components.  VCP can also bind heparan sulfate proteoglycans on the cell 
surface, blocking many molecular and cellular interactions with the cell, like chemokine and 
antibody binding.  (3) Poxviruses also produce a soluble interleukin one receptor homolog (vIL-
1bR) that is secreted from the cell, binding up soluble IL-1b before it has a chance to reach the 
cell's receptor.  (4) Chemokine binding proteins, such as T1 and T7, inhibit chemokine binding to 
heparan sulfate proteoglycans on the cell surface.  (5) Soluble viral interleukin ten (vIL-10) is 
secreted from the cell, binds to IL-10 receptors on inflammatory cells, blocking cell activation.  
(6) Soluble poxvirus interferon gamma receptor homologue (vIFN-gR) is also secreted from 
infected cells, binding and preventing host IFN-g from binding the cellular receptor.  (7) Another 
poxvirus early protein that is responsible for immune modulation, soluble tumor necrosis factor 
receptor (vTNFR) homologue, binds host TNF and prevents its interaction with the cellular 
receptor.  (8) Poxvirus interleukin eighteen binding protein (vIL-18BP) is secreted form the 
infected host cell and binds soluble IL-18, inhibiting its pro-inflammatory functions.  (9) Orf 
virus encoded granulocyte-macrophage colony stimulating factor-inhibitory factor (GIF) is 
secreted and binds to granulocyte-marophage colony-stimulating factor (GM-CSF), blocking its 
ability to stimulate the production and secretion of IFNa.  (10) Myxoma virus SERP-1, which is 
the only secreted poxvirus serpin, blocks several serine proteases, leading to reduction of 
inflammation.  (11) The intracellular poxvirus serine protease inhibitor proteins, such as SPI-2, 
serp-2, and crmA, block the conversion of pre-caspase to active caspase one, thereby blocking its 













































the viral infection, allowing the virus to replicate to high titers.  Chemokine homologues 
and chemokine inhibitors (some of which are chemokine receptor homologues) were 
found to have a dramatic effect on leukocyte chemotaxis.  These virokines have been 
shown to either help the virus evade immune detection, in some cases by blocking th  
influx of leukocytes into the area of infection, or in other cases, actually cause the 
recruitment of leukocytes to increase the pool of new host cells to allow for better 
dissemination.  Chemokine inhibitors have been identified and shown to block cellular 
influx into the areas of infection.  There are also virokines that block one of the most 
important aspects of the innate immune system, the complement system.  These proteins 
are very powerful; they not only prevent the formation of the membrane attack complex 
(MAC), but also block the complement cascade at multiple sites upstream to block the 
formation of proinflammatory factors.  They are therefore also able to greatly reduce the 
migration of leukocytes into the area of viral infection.  
 In addition to those proteins encoded by poxviruses that are secreted from the host 
cell, there are also proteins that act intracellularly.  The most studied group of 
intracellular poxvirus immune modulating proteins are the serine proteinase inhibitors 
(serpins) (Kettle et al., 1997).  Many poxviruses have been found to encode serpins that 
modulate programmed cell death, apoptosis.  By blocking the cysteine proteinase 
interleukin-1b-converting enzyme (ICE), and the serine proteinase granzyme B, the 
cowpox cytokine response modifier A (CrmA), vaccinia virus SPI-2, and myxoma virus 
Serp-2, all have been shown to inhibit apoptosis (Nash et al., 1999).  By blocking these 
intracellular enzymes, the poxvirus serpins are able to prevent TNF- and IFN-induced, as 
well as T-lymphocyte-mediated, Fas-induced apoptosis (Tewari et al., 1995).  By 
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protecting the infected cell from programmed cell death, the virus is able to replicate to 
higher titers and continue host evasion. 
 
Complement Regulatory Proteins: 
Many poxviruses encode proteins that mimic components of the host complement 
system in order to block the activation of complement and thereby modulate the 
inflammatory response mounted by the host (Kotwal, 2000).  See the section below for 
information on the vaccinia virus complement control protei , the best-studied poxvirus 
complement regulatory protein. 
 
Cytokine Homologues: 
 The parapoxvirus, Orf virus, which often infects sheep and goats (sometimes 
humans), has very recently been shown to encode a viral homologue of IL-10 (vIL-10) 
(Fleming et al., 2000).  This protein shows the greatest degree of homology, 80%, to 
sheep IL-10.  Endogenous IL-10 plays many important roles in down regulating the 
immune system.  One very important function is to suppresses activation of macrophages, 
thereby blocking their ability to act as accessory cells to activate T-cells (especially TH1) 
or natural killer (NK) cells via IL-12 production and secrete cytokines.  Thus, IL-10 acts 
as a potent anti-i flammatory agent and a powerful immunosuppressor.  Because of this 
activity, it is believed that the Orf virus produces vIL-10 in order to inhibit expression of 
various cytokines that regulate the immune response against viral infection, suppressing 
activation of macrophages.  The benefits of vIL-10 production for the virus are thereby to 
mask viral infection from the immune system long enough to replicate to high titers.   
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 Very recently, a new virokine, having homology to human interleukin-18 binding 
protein (hIL-18BP), was uncovered in molluscum contagiosum virus (MCV) (Xiang and 
Moss, 1999).  Since this time, it has also been found in other poxviruses, including 
ectromelia, vaccinia, and cowpox (Smith et al., 2000).  IL-18 is a proinflammatory 
cytokine important in activating natural killer (NK) cells, inducing a T-helper 1 response, 
and inducing the production of interferon gamma (IFNg).  The MCV vIL-18BP has been 
shown to bind to both human and murine IL-18 and inhibit the production of IFNg in a 
dose dependent manner (Xiang and Moss, 1999).  Deletion of the gene encodi g vIL-
18BP in VV was shown to dramatically attenuate the virus (Smith et al., 2000).  In 
addition, the ectromelia virus vIL-18BP was shown to block IL-18 induced NF-kB 
activation and induction of IFNg.  This strategy of viral evasion therefore also acts to 
indirectly block the strong antiviral effects of IFNg.   
 
Cytokine Receptor Homologues (Viroceptors): 
 Many members of the poxvirus family, including myxoma, vaccinia, and cowpox, 
encode homologues of the tumor necrosis factor receptor (TNFR).  This viral tumor 
necrosis factor receptor (vTNFR) was originally described in myxoma virus where it is 
known as T2, and in Shope fibroma viruses (SFV), and the term viroceptor was proposed 
to describe them (Upton et al., 1991).  TNF is a very important cytokine for the early 
response to viral infection.  It is a very powerful proinflammatory agent, triggering 
numerous immunological events, including apoptosis of virally infected cells.  In order to 
block the effects of this powerful cytokine, these poxviruses have captured and modified 
the host gene for TNFR so that it may be secreted in large amounts from the infected cell.  
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The vTNFR can bind soluble TNF present in the nearby area, preventing its binding to 
the cellular TNFR, thereby blocking the action of this cytokine.  Many poxviruses encode 
several copies of this gene; cowpox virus, for example, contains three separate copie , 
showing its importance to viral replication (Loparev et al., 1998).  In addition, when 
vTNFR (T2) was deleted from myxoma virus the virulence was significantly reduced.  
Interestingly, vTNFRs show a great deal of host specificity.  Myxoma virus vTNFR, T2, 
will only bind to rabbit TNF (not at all to human), while the vTNFR encoded by vaccinia 
and cowpox viruses will bind human, mouse, and rat TNF effectively. 
 Many poxviruses, including variola, ectromelia, vaccinia, cowpox, and camelpox, 
also encode an additional interesting cytokine receptor homologue, viral IFNg receptor 
(vIFNgR).  These proteins greatly resemble the N-t rminal, ligand-binding (extracellular 
domain) region of their mammalian counterparts.  As with vTNFR, these cytokine 
receptor homologues are also very species specific.  The first and most extensively 
studied of these proteins comes from the myxoma virus and is known as T7 (Upton et al., 
1992).  T7 is a 37 kDa N-glycosylated protein that is the most abundantly secreted 
protein of myxoma virus.  Exhibiting great species specificity, T7 was shown to bind and 
block the effects of rabbit IFNg, but had no effect in blocking human or murine IFNg.  I  
contrast, vaccinia virus, which has a broad host range, can bind and block a number of 
mammalian IFNgs.  The importance of this encoded protein to myxoma virus virulence is 
evident, not only because it i  the most abundantly secreted protein, but also because 
deletion of the gene eliminates the 99% mortality rate exhibited by the virus, and all 
infected rabbits recover.  Therefore, the T7 protein represents the major virulence factor 
of myxoma virus.  The importance of this protein to viral virulence is due to IFNg's 
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powerful antiviral effects.  IFNg serves numerous functions, including switching on many 
intracellular antiviral activities, and giving the signal to nearby cells that a viral infection 
is occurring.  Another cytokine receptor homologue, produced most notably by the 
orthopox members, vaccinia and cowpox viruses, is viral interleukin 1 receptor (vIL-1R).  
This 33 kDa protein was first identified with vaccinia virus, and found to have the ability 
to bind murine IL-1b in 1992 (Alcami and Smith, 1992).  A similar ORF was later 
identified in cowpox virus and the protein product was found to bind murine IL-1b.  
Interestingly, supernatants taken from vaccinia virus-infected cells were found to inhibit 
IL-1 induced murine lymphocyte proliferation.  In dditio , recombinant vaccinia, unable 
to express vIL-1R, showed remarkable attenuation in vivo, compared to the wild type 
(Spriggs et al., 1992).  This demonstrates how the protein plays a critical role in the 
pathology of vaccinia virus infection.  The importance of IL-1 in combating viral 
infection is large, and was demonstrated many years ago (Vacher n et al., 1990).  
Expression of IL-1 is induced early on in many viral infections, and results in a broad 
spectrum of inflammatory responses.  NK cells and B-cells proliferate in response to IL-
1, neutrophils degranulate, and T-cells produce IL-2 and proliferate. 
 Another very recently identified virokine was found encoded by the parapoxvirus, 
Orf (Deane t al., 2000).  The Orf virus produces a secreted protein, termed granulocyte-
macrophage colony stimulating factor-inhibitory factor (GIF), which was shown to bind 
to and block the activity of GM-CSF, as well as IL-2.  Both of these cytokines are very 
important in host antiviral immunity; IL-2 is essential for its role in the activation of T-
cells, and GM-CSF for its ability to stimulate the production and secretion of IFNa.  This 
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remarkable virokine plays a very novel role in modulat on of host defense as a means of 
preserving viral habitat. 
 
Chemokine Homologues: 
 Many poxviruses encode proteins that inhibit chemokines; the CC (b) chemokine 
homologue encoded by the molluscipoxvirus, molluscum contagiosum virus (MCV), 
designated as molluscum contagiosum chemokine homologue (MCCH) or MC148, was 
only recently discovered (S nkevich et al., 1996).  This human disease-causing virus 
presumably utilizes this virokine to block leukocyte trafficking to the site of infection.  
MC148 is highly homologous to members of the CC or b chem kine family; however, it 
is truncated in the N-terminus of the protein.  The N-terminal portion of the chemokine is 
required for proper binding and activation of the cell (Senkevich et al., 1996).  Therefore, 
the MC148 chemokine homologue of MCV acts by binding to the chemokine receptor, 
identified as being specifically CCR8, thereby blocking endogenous chemokine binding.  
The overall result of this protein is reduced cellular influx and therefore reduced 
inflammation.  This protein seems to be geared toward specifically blocking monocyte 
infiltration and dendritic cell function.   
 
Chemokine Inhibitors: 
 Many poxviruses encode a protein that blocks the effects of chemokines.  
Collectively these virokines have been termed the T1/35kDa family, all of which possess
eight conserved cysteine residues, and are shown to interact with members of the CC 
and/or CXC classes of chemokines (Graham et al., 1997).  The myxoma virus T1 and T7 
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proteins are the most widely studied members of this group.  T1 shows no homology to 
any host chemokine or chemokine receptor and binds strongly ( pecifically) to members 
of the CC class of chemokines, but only weakly (nonspecifically) to CXC chemokines 
(Kettle et al., 1997).  Because of this ability, T1 has been shown to block human 
monocyte migration, in the presence of MIP-1a, in vitro.  Deletion of the coding 
sequence for T1 resulted in a pronounced increase in infiltrating monocytes and 
macrophages in the site of infection in vivo (Graham et al., 1997).  However, the loss of 
T1 had no significant effect on mortality, indicating that this gene does not play a critical 
role in the pathogenesis of the infection.  T7, on the other hand, has been shown to inhibit 
the activity of members of C, CC, and CXC classes of chemokines in a nonspecies 
specific manner.  This protein, which is most noted for its anti-IFNg activity, has been 
shown to nonspecifically bind to the heparan sulfate proteoglycan binding domain of the 
chemokine, preventing gradient formation along the vascular wall, and inhibiting 
chemotaxis (Lalani et al., 1997).  Addition of excess soluble heparin completely prevents 
this activity of the T7 protein, supporting this hypothesis.  Since the T7 protein also 
exhibits no homology to any known chemokine, this strategy of chemokine inhibition is 
quite novel. 
 
Serine Protease Inhibitors: 
 Several poxviruses have been shown to encode proteins that are able to prevent 
apoptosis, programmed cell death.  The cowpox cytokine response modifier A (CrmA), 
vaccinia virus SPI-2, and myxoma virus Serp-2 have all been shown to i hibit apoptosis 
through the ability to block both, the cysteine proteinase interleukin-1b-converting 
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enzyme (ICE), and the serine proteinase granzyme B (Nash et al., 1999; Quan et al., 
1995; Turner t al., 1999; Kettle et al., 1997; Turner t al., 1999).  By blocking these 
intracellular enzymes, these poxvirus serine protease inhibitor (serpins) proteins are able 
to prevent TNF and IFN-induced, as well as T-lymphocyte-mediated (Ca+2-independent), 
Fas-induced apoptosis (Nash et al., 1999; Tewari et al., 1995; Kettle et al., 1997).  
Therefore, these proteins prevent destruction of infected cells, even if they are recognized 
as being infected, thus maintaining a habitat conducive to virus replication. 
Many members of the poxvirus family encode proteins that inhibit serine 
proteases intracellularly, but only myxoma virus encodes one that acts as a serine 
protease inhibitor (serpin) and issecreted extracellularly.  First identified in 1990, this 
secreted glycoprotein, Serp-1, has structural features that place it in the serpin family of 
serine protease inhibitors (Upton et al., 1990).  Before its discovery, intracellular serpins 
were found with VV (Kotwal and Moss, 1989).  Serpins have many functions in 
maintaining homeostasis of eukaryotic systems, from complement activation and blood 
clotting, to the inflammatory response.  In addition, mutations in serpins have been linked 
to over 90 human diseases.  Given the importance of these proteins, many pathogens have 
evolved to carry their own serpins to disrupt host processes.  Myxoma virus Serp-1, for 
example, has been shown in vivoto weaken the inflammatory response to viral infection.  
When this gene is deleted from the virus, a much greater inflammatory process is 
observed and the infection is resolved much more rapidly.  Purified recombinant Serp-1
has been shown to bind a variety of proteases, including plasmin, thrombin, tissue-type 
plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA), although 
the exact target has not been found (Lomas et al., 1993).  This protein acts as a 
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pseudosubstrate for these serine proteases, forming a stable complex, preventing the 
protease from binding its true substrate.  Due to the role of Serp-1 in modulating 






















Vaccinia Virus Complement Control Protein (VCP) 
The vaccinia virus complement control protein (VCP) was the first soluble 
microbial protein shown to have complement binding activity and postulated to have a 
role in evasion of host complement (Kotwal and Moss, 1988).  In the years since its 
discovery, VCP has become one of the best studied and the best characterized virokine.  
Structurally, it is composed of four complement control protein (CCP) modules [also 
called short consensus repeats (SCR)], making it and other homologous proteins 
members of the regulators of complement activation (RCA) superfamily.  VCP exhibits 
functional similarity to factor H (fH), membrane cofactor protein (MCP), decay-
accelerating factor (DAF), complement receptor one (CR1), and is structurally most 
similar to human complement 4b binding protein (C4b-BP).  Purified bioactive VCP has 
been shown to inhibit both the classical and alternative pathways of complement 
activation through its ability to bind C3 and C4 and act as a cof ctor for factor I cleavage 
of C3b and C4b (Sahu et al., 19 8).  VCP, secreted from virally infected cells, is believed 
to protect the cell and the released viral progeny from host complement attack.  In 
addition, by blocking complement activation at multiple sites, there is a large reduction of 
C3a, C4a, and C5a proinflammatory chemotactic factors, resulting in reduced cellular 
influx and inflammation.  VCP has also been shown to possess the ability to bind heparin, 
as well as, heparan sulfate proteoglycans (heparin-like molecules) on the surface of 
human endothelial cells.  Because of this activity, VCP has been shown to exhibit many 
properties that all other complement control proteins are lacking.  In vivo studies have 
indicated that FITC-labeled VCP, when injected intravenously, becomes localized in the 
endothelium.  This very interesting property of VCP has been shown in vitro t  reduce 
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chemotactic migration of leukocytes in the presence and absence of the chemokine MIP-
1a (Reynolds et al., 2000).  This suggested that VCP could interfere with molecular 
interactions with infected cells, and possibly prevent antibody-depe dent cell-mediated 
cytotoxicity (ADCC) as well as other cytotoxic cell interactions with target cells.  
Amazingly, VCP was shown to block interactions between pig aortic endothelial cells 
(PAECs) and naïve neutrophils and NK cells, preventing cell killi  (Al-Mohanna et al., 
2001).  In addition, cell culture studies demonstrate that VCP blocks complement-
mediated killing of PAECs by human serum, in a dose-dependent manner.  VCP is 
































EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF VCP 
 
VCP from VV Infection of Mammalian Cell Culture 
This chapter contains material adapted from the following publication: 
 
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, 
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J. 
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on 
poxvirus complement control proteins serve as putative heparin binding sites and 
contribute to inhibition of molecular interactions with human endothelial cells: a 
novel mechanism for evasion of host defense.  J. Virol. Jun. 74(12):5659-66, 2000 
[Cover of J. Virol. Oct. 74(20), 2000]. 
 Natural VCP, produced by VV during a natural infection process of cultured cells, 
was produced in large quantities with technical assistance.  Briefly, RK-13 cells were 
grown to confluency in large cell factories before infecting with VV WR strain.  After 48 
hours the media was harvested, filtered through a 0.22 mm filter, and concentrated to ~50 
ml using an Amicon stirred-cell (with 10 kDa molecular size cut-off).  Heparin HiTRAP 
(Pharmacia) chromatography was then performed on the media for specific purification 
of VCP.  A NaCl step gradient (100 mM – 1 ) was used to rinse and elute VCP from 
the column.  Finally, the fractions were examined by SDS-PAGE and Coomassie blue 
staining.  VCP eluted from the heparin column and was primarily located in the 400 mM 
NaCl elution fraction.  All fractions containing VCP were then pooled, the protein 
concentration was estimated using a Bio-Rad protein assay kit, and the protein's activity 
estimated using the hemolysis assay (described in chapter 4) (Kotwal and Moss, 1988).  
Natural VCP was frequently isolated at greater than 90% purity (using SDS-PAGE 




















Pichia pastoris Yeast Expression System 
 Nick P. Mullin from the Edinburgh Center for Protein Technology, University of 
Edinburgh, UK expressed VCP and fragments of VCP in Pichia pastoris using the 
secretory expression vector pPIC9, see figure 6.  The fragments corresponded to amino 
acids 18-146 (rVCP~1,2), 82-204 (rVCP~2,3), 145-263 (rVCP~3,4) and 18-262 
(rVCP~1-4).  Genomic DNA from vaccinia virus was used as template for the 
amplification of the DNA fragments encoding the above protein fragments by PCR.  In 
all cases except for VCP~3,4 the oligonucleotides used introduced a 5’ Ec  RI site nd a 
3’ Not I site which were used for cloning the fragments into the expression vector.  For 
VCP~3,4, cloning was carried out as described arlier (Wiles et al., 1997). 
Selection of clones and expression of rVCP~3,4 has been described previously 
(Wiles et al., 1997).  For rVCP~1,2, rVCP~2,3 and rVCP~1-4 clones transformed with 
the expression vectors described above where selected on the basis of their ability to 
grow on histidine deficient medium.  Small-scale expression screening was performed by 
inoculating 5 ml of buffered minimal glycerol (BMG) and incubating at 30 oC until the 
OD600 reached between 6 and 10.  The cells were harvested and resuspended in 2 ml (for 
KM71 cells) or 15 ml (for GS115 cells) of buffered minimal methanol (BMM).  Cells 
were grown with vigorous shaking for 4 to 5 days with daily addition of methanol to 
reach a concentration of 0.5% [for activation of gene expression (see figure 5)].  Media 
from these inductions wa analysed by SDS-PAGE and the highest-l vel expressers 
selected.  For rVCP~1,2, ~2,3, and ~1-4, the KM71 cell line proved to produce the most 
protein.  For large-scale growth of rVCP~1,2 and rVCP~1-4, 100 ml of BMG was 










Figure 6.  Pichia pastoris yeast expression system.  Listed are the steps used for cloning 
and growth using the Pichia pastoris yeast expression system by Invitrogen.  Also 
shown, is the pPIC9 expression vector used in the cloning of VCP and the various VCP 











1) Select the appropriate expression vector.
2) Clone your desired gene into vector.
3) Transform E. coli, select ampicillin-resistant ransformants,
and confirm presence and orientation of desired gene.
4) Linearize constructs with appropriate restriction enzymes to
generate His+Muts recombinant strain.
5) Transform and select for His+transformants.
6) Screen His+transformants for His+Muts strains
7) Confirm integration of your gene in His+Muts strain by PCR.
8) Grow recombinants in 100-200 ml of buffered glycerol medium 
(BMGY) to an OD600= 2-6.
9) Harvest cells and resuspend to an OD600of 10 with methanol 
medium (BMMY) and place in 250 ml flask.
10) Incubate at 300C with shaking and take samples for analysis at
0, 24, 48, 72, 96, 120, and 144 hours.
11) Analyze medium for protein via PAGE/Coomassie Blue staining,
western blot, activity, ELISA, or immunoprecipitation.
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overnight.  This culture was then used to inoculate several liters of BMG.  The cultures 
were grown for 48 hours until the OD reached approximately 20.  The cells were spun 
down, resuspended in the same volu  of BMM, and grown for 4 to 5 days with 
vigorous shaking.  Cells were fed methanol to a concentration of 1% every 24 hours.  For 
rVCP~2,3, BMG media was inoculated with an overnight culture and grown at 30oC with 
vigorous shaking until an OD of approximately 6 had been attained.  The pellet was then 
harvested by centrifugation, resuspended in BMM media (40% of the total BMG volume) 
and grown for 5 days with daily addition of methanol to a concentration of 0.5%. 
Purification of rVCP~3,4 has been described previously (Wiles et al., 1997).  For 
purification of rVCP~1,2, media was concentrated down to a small volume using a 
combination of a Millipore Prep/Scale-TFF cartridge (3 kDa molecular size cut-off) and 
Amicon stirred-cell (with 3 kDa molecular size cut-off).  The sample was exchanged into 
50 mM Tris-HCl (pH 9.0) using a Pharmacia PD-10 column and loaded onto a Pharmacia 
Mono-Q column, equilibrated in the same buffer.  The protein was then eluted with a 
NaCl gradient of 0 to 100% over twenty minu es.  Fractions containing rVCP~1,2 were 
collected and concentrated using Amicon stirred-cell ultrafiltration and then loaded onto 
a Brownlee Aquapore C4 reverse-pha  column and the protein eluted with an 
acetonitrile gradient.  Fractions containing pure rVCP~1,2 were collected and 
lyophilized.  For purification of rVCP~2,3, media was concentrated to approximately 50 
ml using an Amicon concentrator (3 kDa cut-off) before being centrifuged at 20,000 x g 
for 1 hour and the pellet discarded.  The sample was exchanged into 5 mM sodium 
acetate (pH 4.0) using a PD-10 column and applied to a Mono-S cation exchange column 
(Amersham Pharmacia, Uppsala, Sweden), equilibrated in the same buffer.  Protein was 
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eluted with a NaCl gradient and fractions corresponding to ure rVCP~2,3 were pooled 
and lyophilized.  For purification of rVCP~1-4, media was concentrated to a small 
volume by the same means as rVCP~1,2.  The protein was exchanged into 20 mM 



















Growth and Affinity Purification 
BMGY –versus- BMMY: 
 The various rVCP yeast clones described previously were stored in 10% glycerol 
and frozen to –80oC.  When growth is desired, the frozen stock was plated on minimal 
methanol histidine media (MMH) for selecting and maintaining a pure culture of the 
clone.  Optimal growth on MMH was achieved through incubation at 30oC for several 
weeks.  A single colony was then used for inoculation of starter culture. 
 Using sterile technique, a single colony was removed from the MMH plate and 
inoculated into 1 ml buffered minimal-complex glycerol medium (BMGY).  One liter of 
BMGY consists of: 750 ml peptide base (30 g YEP in one liter H2O, autoclaved), 100 ml 
10X glycerol (100 ml glycerol in 900 ml H2O, autoclaved), 100 ml phosphate buffer pH 
6.0 (~132 ml 1 M K2HPO4 and ~868 1 M KH2PO4, autoclaved), 50 ml yeast nitrogen 
base (1.7 g YNB in 100 ml H2O, sterile filtered), and 2 ml 500X biotin (sterile filtered).  
The 1 ml starter culture was grown at 30oC overnight.  The starter culture was then used 
to inoculate the remaining 999 ml BMGY in a large 4 L Erlenmeyer flask, the mouth 
covered with cheesecloth.  The culture was then incubated at 30oC wi h vigorous shaking 
(200 rpm) for 2-3 days.  The cells were then removed by swing ucket centrifugation 
(3,000 rpm) for 30 min using 250 ml polypropylene bottles.  Being careful to prevent 
contamination, the cells were then resuspended in 500 ml (50% of the total BMGY 
volume) buffered minimal-complex methanol medium (BMMY).  BMMY consists f: 
250 ml peptide base (30 g YEP in one liter H2O, autoclaved), 500 ml autoclaved H2O, 
100 ml 20% methanol (200 ml methanol in 800 ml H2O, autoclaved), 100 ml phosphate 
buffer pH 6.0 (~132 ml 1 M K2HPO4 and ~868 1 M KH2PO4, autoclaved), 50 ml yeast 
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nitrogen base (1.7 g YNB in 100 ml H2O, sterile filtered), and 2 ml 500X biotin (sterile 
filtered).  The culture was then incubated at 30 oC with vigorous shaking (200 rpm) for 2 
days.  Additional methanol was added to a final concentration of 2% (10 ml) after the 
first day.  After two days of incubation, the cells were then removed by high-speed 
centrifugation (12,000 rpm) for 45 min using 250 ml polycarbonate bottles.  The media 
was then carefully decanted and passed through a 0.22 mm bottle-top filter.  The media 
was then concentrated using an Amicon stirred-cell with 10 kDa molecular weight cut-off
membrane to ~50 ml.   
  
Affinity Purification and Endotoxin Removal: 
Recombinant VCP (rVCP = rVCP~1-4) was purified from the concentrated 
BMMY media by using heparin HiTRAP (Pharmacia) affinity chromatography.  BMMY 
was first pumped at a rate of 1 ml/min through a sterile filter (0.22 mm syringe filter) into 
a series of five heparin HiTRAP columns run in tandem.  The unbound material was 
collected and the column was washed with 50 ml sterile H2O.  A NaCl 30 ml step 
gradient ranging from 250 mM to 550 mM, increasing in 50 mM increments, was then 
applied to the column to elute the bound protein.  Finally, the column was washed with 
50 ml 2 M NaCl to remove any remaining proteins.  The fractions were then visualized 
by SDS-PAGE and coomassie blue staining, see figure 7.  The fractions containing rVCP 
were then pooled, the protein concentration was estimated using a Bio-Rad protein assay 
kit, and the protein's activity est mated using the hemolysis assay (Kotwal and Moss, 










Figure 7.  Heparin purification of rVCP (rVCP~1-4).  Coomassie blue stained SDS-
PAGE gel shows fractions following heparin affinity chromatography.  Fractions shown 
are from a NaCl elution step gradient ranging from 250 mM to 550 mM (by 50 mM 






















































Heparin Purification of rVCP
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method.  This procedure can be used for purification of rVCP~1-4, rVCP~1,2, rVCP~3,4, 
and rVCP~2,3,4, but cannot be used to purify rVCP~2,3. 
rVCP~2,3 was purified most effectively by affinity chromatography using 
HiTRAP ANX (high sub) sepharose fast flow (Pharmacia).  ANX sepharose is a weak 
anion exchanger, similar to DEAE, with a high degree of cross-linking.  This allows for 
better purification of rVCP~2,3 and higher yields.  Similar methodology was used for 
chromatographic purification of rVCP~2,3 as compared to the other rVCP clones, with 
the exception of the step gradient.  A NaCl step gradient ranging from 50 mM to 350 
mM, increasing in 50 mM increments, was applied to the column to elute the bound 
protein.  Visualization and characterization of the protein was the same as above. 
If contamination of the yeast culture does not occur, samples of rVCP will contain 
only trace amounts of endotoxin and do not need further purification.  However, if 
contamination occurs, and endotoxin is present (BioWhittaker Limulus Amebocyte 
Lysate endotoxin detection assay), endotoxin removal can be carried out as follows.  
Twenty milliliters of endotoxin removal gel, polymyxin B sepharose, was seeded into a 
30 ml all-purpose HPLC column, washed with endotoxin free water, and activated using 
the appropriate activation buffer.  Keeping in mind that the matrix has an endotoxin 
binding capacity of 5,000 EU/ml, the appropriate amount of rVCP was then passed 
through the column at a 0.5 ml/min flow rate.  The column was then rinsed with a column 
volume of endotoxin free water and a NaCl gradient (H2O to 1 M) was used to elute the 
rVCP that was nonspecifically bound.  Fraction collection was continually monitored at 
280 nm, and two rVCP peaks are visible; the first peak was rVCP which flowed directly 
through the matrix, and the second was rVCP which had a nonspecific interaction with 
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the matrix and was eluted with low NaCl, see figure 8.  Fractions were then visualized by 
SDS-PAGE and coomassie blue staining, the fractions were pooled, and the protein 
concentration estimated using a Bio-Rad protein assay kit.  Finally, the final 
concentration of endotoxin was estimated using the BioWhittaker Limulus Amebocyte 
Lysate endotoxin detection assay and compared with the original estimate to determine 



























Figure 8.  Endotoxin removal using Polymyxin B HPLC.  A representative graph of 
the 280 nm scan and fractions following endotoxin removal of rVCP using Polymixin B 
chromatography is shown.  The 280 nm scan is shown in blue, the NaCl gradient shown 
in red, and peaks one and two are labeled. rVCP elutes from the column as two peaks 










Peak 1 Peak 2











Figure 9.  Endotoxin removal of rVCP.  The concentration of endotoxin in a sample of 
rVCP is shown before and after each step of purification.  Heparin affinity 
chromatography was performed as described in the "Growth and Affinity Purification" 
section of chapter 2, protein concentrations were estimated using the Bio-Rad protein 
assay kit, and endotoxin was estimated using the BioW ittaker Limulus Amebocyte 
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Assays and Characterization 
Hemolysis Assay and Activity Units: 
The hemolysis assay was developed to test the activity of VCP quickly and easily 
using a microtiter plate reader (Kotwal and Moss, 1988).  At the heart of the assay is the 
sensitized sheep red blood cell (sSRBC) (Diamedix).  In the presence of serum, the 
classical complement pathway will be activated on the surface of the erythrocyte, 
resulting in its lysis.  In the presence of VCP, however, the complement pathway 
activation will be inhibited and the erythrocyte will not be lysed.  The assay was 
performed in 0.65 ml general-purpose polypropylene Eppendorf tubes on ice, see figure 
10 for diagram.  First, half of the sSRBC buffer (1.5 ml) was removed to obtain the 
correct concentration for the assay (OD of 5.0 @ 405 nm).  The VCP sample was then 
serially diluted in 20 ml of the buffer.  Next, 30 ml of diluted serum (~1:70) was added 
(must be able to only lyse 95% of the sSRBCs).  Finally, 150 ml of sSRBCs was added to 
each tube to give a final volume of 200 ml. A positive control was made by adding no 
VCP, and a negative control was made by adding no serum.  The tubes are incubated for 
one hour at 37oC, and then centrifuged at 7,000 rpm for 20 seconds.  Directly after 
centrifugation, 150 ml of the supernatant was then pipetted into a 96 well flat-bottomed 
microtiter plate.  The plate was then read at 405 nm,nd the activity units are derived 
from the percent lysis inhibition which was calculated using the formula {[(O.D. sample 
– O.D. negative control)/(O.D. positive control – O.D. negative control) X 100] – 1 0}.   
Specific activity for VCP can be determind usi g the hemolysis assay.  Specific 
activity units are defined as the quantity of VCP required to inhibit hemolysis to 50% in 








Figure 10.  Hemolysis assay.  Illustrated are the procedures used to perform the 
hemolysis assay to measure the activity of VCP.  After serially diluting the sample of 
VCP, enough serum is added to lyse 95% of the sSRBSs.  Lastly, the sSRBCs are added 
and the tubes are incubated at 37 oC for 1 h.  After incubation, the tubes are centrifuged 
for 20 sec and the supernatant pipetted into a 96 well flat-bottomed microtiter plate.  Th  
absorbance is read at 405 nm using a microtiter plate reader (ELX800 BIO-TEK 
Instruments, Inc.) and the activity of the sample is calculated, as indicated in the "Assay 
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appropriate dilution (producing 50% lysis inhibition) is multiplied by the total volume of 
the sample.  In most cases, one activity unit equates to approximately 0.25-0.50 g of 
VCP. 
 
Protein Estimation Assay: 
Accurate estimation of the amount of purified rVCP and rVCP fragments can be 
done quickly and easily using the Blue Bio-Rad protein assay.  Bovine serum albumin 
was used as a standard for accurate concentration estimates.  A microtiter plate reader 
was used for this assay, which reduces the quantity of protein required (5 ml) to do the
estimation.  This was far superior to the Red Bio-Rad protein assay, which uses a 













VCP Production for NMR, X-Ray Crystallography, and Antibodies 
Labeling for NMR: 
In order to obtain an NMR structure of VCP, all amino acids of the protein must 
be labeled with N15 non-radioactive isotope.  Typically, the best way to achieve this is by 
growing the yeast in the presence of N15 labeled ammonium sulfate.  Due to the great 
expense of this labeled compound, optimal growth nd labeling conditions were first 
established using unlabeled ammonium sulfate.  Yeast were first grown under normal 
conditions in 500 ml BMGY, as described above.  After removing the medium by 
centrifugation, the yeast were starved for 6 hours in ammonium sulfate media.  This 
media consisted of the following: 2.5 g ammonium sulfate, 225 ml sterile H2O, and 25 ml 
10X glycerol.  This medium is designed to replace the unlabeled amino acid reserves in 
the yeast with what would normally be N15 la led amino acids, from the ammonium 
sulfate.  As a control, the same experiment was done without ammonium sulfate, to test 
the turnover of the amino acid reserves, see figure 11A.  Finally, the yeast were growth 
for 3 days, with daily addition of methanol (to a finalconcentration of 2%), in 
ammonium sulfate methanol medium.  This media consisted of the following:  2.5 g 
ammonium sulfate, 225 ml sterile H2O, and 25 ml of 10% methanol.  After removing the 
yeast by high-speed centrifugation, the media was filtered and the protein was purified by 
heparin affinity chromatography, see figure 11B.  Yeast grown without ammonium 
sulfate produced only a small amount of protein (no nitrogen source), indicating that the 
vast majority of rVCP produced by yeast growing in the presence of ammonium sulfate 
was the result of this compound being present.  The fractions containing rVCP were then 








Figure 11.  Heparin affinity chromatography of ammonium sulfate rVCP.  In order to 
determine the amount of rVCP that can be produced, for use in NMR, by growing the
Pichia pastoris yeast clone in minimal media, yeast were grown by two methods, with 
and without ammonium sulfate.  A)  rVCP produced after heparin chromatography 
following growth in minimal media containing no ammonium sulfate.  B)  rVCP 
produced after heparin chromatography following growth in minimal media containing 
ammonium sulfate.  In both cases, rVCP was purified using a NaCl elution step gradient 
ranging from 100 mM to 500 mM (increasing increments of 50 mM).  The starting 








































































greater than 95% pure rVCP can be made using 5 g of ammonium sulfate.  Due to the 
great cost required, N15 labeled ammonium sulfate was never used. 
 
Large Scale Purification for X-Ray Crystallography: 
In order to produce large quantities of highly purified rVCP for X-ray 
crystallography, the above procedure was scald up to 2 liters.  After heparin purification 
was repeated a second time, the purity of rVCP was found to be approximately 98%, see 
figure 12.  The protein concentration was estimated to be approximately 12.5 mg, and the 
activity units estimated to be approximately 5 x 105.  The sample was then sent for 
crystallization as 10% glycerol at 4oC.  Crystals were produced and the structure of rVCP 
was obtained, discussed in chapters 3-5. 
 
Anti-VCP Production, Purification, and Characterization: 
In order to obtain antibodies to rVCP, for use in immunohistochemisty and 
Western blot analysis, purified protein was mailed to Washington Biotec (Baltimore, 
Maryland) for immunization of a chicken and a rabbit.  Both the rabbit and chicken 
received three immunizations.  In order to obtain antibodies to linearized epitopes on 
rVCP to be used for Western blotting, the second immunization given to the rabbit was of 
denatured rVCP.  After running several milligrams of rVCP on SDS-PAGE with 
reducing agent, the protein was purified by gel extraction.  Immunization of the chicken 
and purification of IgY from hen eggs was done by Washington Biotech, Inc.  Due to the 
high concentration of non-specific antibodies in the samples, further purification of anti-









Figure 12.  Purity of rVCP used in X-Ray crystallography.  Various amounts of 
purified rVCP are shown by SDS-PAGE and Coomassie blue staining.  Also shown is the 
total volume, number of milligrams, and total activity units of the sample.  This sample 
contained 10% glycerol (total volume) and was sent to Dr. Krishna Murthy for 
crystallization studies, which ultimately resulted in the crystal structure of rVCP, 
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protein immobilization kit.  Using this kit, 20 mg of purified rVCP was covalently 
immobilized to 2 ml activated sepharose beads for use in chromatography.  Using this 
column, rVCP specific antibod es could be purified from the immunoglobulin samples.  
After passing 5 ml of purified IgY through the column, a NaCl step gradient was used to 
elute the bound antibodies, see figure 13A.  As can be seen, different strengths of 
antibody affinity are evident.  Only the higher NaCl fractions were then pooled and 
concentrated.  Similar techniques were used in an attempt to purify rabbit anti-rVCP IgG, 
but were unsuccessful due to very low concentrations of specific antibodies.  The low 
concentration of specific IgG antibodies against VCP found in the immunized rabbit sera 
was most likely the result of VCP being only mildly immunogenic in mammals.  This is 
due to the great structural similarity between VCP and the mammalian complement 
regulatory proteins.  
To better characterize the affinity-purified anti-rVCP IgY, a Biacore X instrument 
(University of Western Cape, Cape Town, SA), utilizing surface plasmon resonance 
technology, was employed.  With rVCP covalently immobilized to a CM-5 sensor chip, 
10 mM anti-rVCP IgY was injected.  As can be seen in figure 13B, strong binding 
occurs.  To test the specificity of this antibody, 10 mM pre-immune (non-affinity 
purified) IgY was injected.  Figure 13C shows that no binding was evident, indicating 
that binding antibodies arose after immunization.  Finally, anti-rVCP was pre-incubated 
with 50 nM rVCP before injecting.  As can be seen in figure 13D, the binding to the chip 
(with rVCP immobilized) was completely abolished, compared to that seen in figure 13B.  
The results obtained in these experiments demonstrated the specificity of the anti-rVCP 





Figure 13.  Purification and characterization of anti-rVCP IgY.  IgY anti-rVCP was 
obtained from Washington Biotech through multiple i munization of a single chicken.  
A)  rVCP affinity purification of ant-rVCP IgY using an rVCP column, made by 
immobilizing rVCP to a Pierce Amino-Link Plus column.  Anti-rVCP IgY was eluted 
using a NaCl step gradient ranging from 50 mM to 2 M.  IgY with various affinities can 
be seen eluting from the column at different NaCl concentrations.  Only the higher 
affinity antibodies were pooled and concentrated for use in immunohistochemistry and 
Biocore studies.  B)  With rVCP immobilized to a CM5 Biacore sensor chip, 10 nM of 
anti-rVCP IgY was injected and binding was observed.  The kinetics of this binding are 
very strong, as indicated by the extended disassociation time.  C)  With rVCP 
immobilized to a CM5 Biacore sensor chip, 10 nM of pre-immune IgY was injected and 
binding was monitored.  No binding was observed, indicating that no anti-rVCP IgY was 
present.  D)  With rVCP immobilized to a CM5 Biacore sensor chip, 10 nM of anti-rVCP 
IgY and 50 nM rVCP was mixed together, injected, and binding was monitored.  Agai , 































































































































































































HEPARIN BINDING ACTIVITY OF VCP 
 
Introduction to Heparin Binding 
This chapter contains material adapted from the following publications and manuscript: 
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, 
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J. 
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on 
poxvirus complement control proteins serve as putative heparin binding sites and 
contribute to inhibition of molecular interactions with human endothelial cells: a 
novel mechanism for evasion of host defense.  J. Virol. Jun. 74(12):5659-66, 2000 
[Cover of J. Virol. Oct. 74(20), 2000].   
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata 
C.M., and Kotwal G.J.  Crystal structure of a complement control protein that 
regulates both pathways of complement activation and binds heparan sulfate 
proteoglycans. Cell. Jan. 26, 104:301-1 , 2001.  
Smith S.A., Arjunwadkar S., Krishnasamy G., Judge K., Murthy K.H., Pugh D.R., and 
Kotwal G.J.  Mapping of regions within the vaccinia irus complement control 
protein involved in binding to key complement components and heparin using surface 
plasmon resonance.  Submitted to Virology, 2002. 
The most recently identified property of the multifunctional VCP is its ability to 
bind heparin.  It has been shown in previous studies, as well as this one, to exhibit 
lysozyme-like heparin binding activity.  Because of this activity, VCP can be taken up by 
mast cells and possibly persist in the tissue for extended periods of time, helping to 
preserve the viral habitat (Kotwal et al., 1998b).  In vivo studies have indicated that 
FITC-labeled VCP injected intravenously becomes localized along the endothelium.  It 
has also been shown to reduce chemotactic migration of leukocytes in the presence and 
absence of the chemokine MIP-1a (Reynolds et al., 2000).  This suggests that VCP can 
bind to heparin-l ke (heparan sulfate proteoglycans, see figure 14) molecules lining the 
surface of endothelial cells, blocking chemokine binding and thereby blocking the 
chemotactic signal.   
It is clear that the ability to bind polyanions, such as heparin, is crucial for the 
function of many immune-regulating proteins.  Factor H (fH), for example, binds to the 
polyanion sialic acid on the surface of mammalian cells, preventing activation of the 
alternative pathway (Meri and Pangburn, 1994).  Like VCP, fH is made up of SCRs, 
three of which have been shown to have heparin binding abilities (Blackmore t al., 
1998).  It is postulated that these heparin-binding domains are responsible for binding 
sialic acid, thereby preventing alternative pathway activation.  The heparin binding 
regions of many other proteins exhibiting heparin binding activity have been mapped 
(Cardin and Weintraub, 1989; Cardin et al., 1991; Marino et al., 1999; Sendak and 
Bensadoun, 1998; Wong et al., 1995; DuBose and Haugland, 1993).  VCP, fH, and C4b-
BP are the only complement control proteins found to p ssess this ability (B om et al., 
1999; Blackmore et al., 1998).  In most cases (including ours), binding is the result of 
dense regions of positively charged amino acids.  These arginine and/or lysine rich 
regions vary in sequence and length among heparin binding proteins.  Interestingly, the 
heparin binding sequences used by VCP and its homologues are short and relatively 
conserved. 
We have attempted to further characterize the biological significance of VCP's 
ability to bind heparin.  Using flow cytometry, the amount of specific antibody binding to 







Figure 14.  Heparan sulfate proteoglycans.  Heparan sulfate proteoglycan structure is 
illustrated, along with their location and the monomers that make up the large 
polysaccharide chains.  Heparan sulfate proteoglycans are present on many cell surfaces.  
The main body, or peptide core, possesses a short intercellular domain, membrane 
anchoring region, and extracellular peptide core to which the polysaccharide, 
glycosaminoglycan, chains are attached.  Heparan sulfate proteoglycans are named by the 
number of sulfate groups per disaccharide unit of the glycosaminoglycan chain; for 
example, heparan monosulfate contains one sulfate group per disaccharide unit.  Also 
shown are the monomers that can make up the glycosaminoglycan chain.  Depending on 
the degree of sulfation, heparan sulfate proteoglycans may have varying degrees of 







Cell Surface: Molecular Size:
•Hepatocytes HS 10k avg.
•Endothelial cells HS 25k avg.
•Fibroblasts HS 25k avg.
•Epithelial cells HS 25k avg.






































found that VCP was able to inhibit antibody binding to MHC class I molecules on human 
endothelial cells.  This suggests that VCP can interfere with molecular interactions with 
infected cells and could prevent antibody-dependent cell-mediated cytotoxicity (ADCC) 
as well as other cytotoxic cell interactions with target cells.  The ability of VCP to bind 
heparin-like molecules suggests that it plays many roles and therefore may have a variety 
of applications.  It is for these reasons that we have been interested in obtaining a better 
understanding of the molecular basis for the VCP-heparin interaction.  Through 
examination of several recombinant VCP fragments, it has now been determined that the 
percentage of positively charged amino acids, overall charge, and the number of putative 
heparin binding sites, are all important factors governing the heparin binding ability of 
rVCP.  In addition, the heparin binding ability of rVCP and the various truncated rVCP 
molecules was tested using surface plasmon resonance (SPR) binding analysis (Biacore 
X ®) with heparin immobilized to the sensor chip.  Positive binding was determined by 
subtraction of ligand channel readings from the readings of the control channel, and each 
experiment was repeated several times to confirm results.  Next, in order to test whether 
the putative heparin binding site, K/R-X-K/R, was actually involved in this interaction, 
synthetic peptides (tri-peptides) were designed to resemble the putative heparin binding 
sites present on rVCP, and competition assays were performed.  The presence of this 
synthetic heparin binding site resulted in a stronger binding between rVCP and heparin, 
which was beli ved to result from the bridging of the protein's central net negative 
charge.  With the results of these assays in hand, attempts were then made to purify 
rVCP~2,3 using this technique.  Finally, due to the extreme cost of heparin 
chromatography, dextran sulfate chromatography was also investigated.  As a result of 
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the similar high degree of sulfation, rVCP was found to bind very effectively to sulfated 
dextran beads. 
Utilizing the data collected in the above experiments, an NMR model of rVCP 
was created and the positions of the heparin binding sites highlighted.  Two areas, located 
at each end of the protein, were identified as being involved in binding.  In addition, with 
the X-ray crystal structure in hand, an accurate model of the electrostatic field 
distribution across rVCP could be predicted and illustrated.  Finally, spatial homology 















Materials and Methods 
Flow Microfluorimetric Analysis: 
 Ratchapin Srisatjaluk and David Reynolds, Department of Microbiology and 
Immunology, aided in all experiments involving flow microfluorimetric analysis.  Human 
umbilical cord vascular endothelial cells (HUVECs) were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD) at passage thirteen.  Monolayer cultures 
were maintained using F12K Ham’s media supplemented with 10% fetal bovine serum, 
30 mg/ml endothelial cell growth supplement (Sigma), and 100 mg/ml heparin (Sigma), at 
37oC in humidified aircontaining 5% CO2.  Cells were cultured to approximately 80% 
confluency in 75 cm2 vented flasks coated with 1.5% gelatin in phosphate buffered 
saline.  Cells were trypsinized (0.25% trypsin, 1 mM EDTA, Sigma), and 4 x 105 cells/ml 
were placed in a 6-well flat-bottom culture plates (3.5 cm diameter, Falcon, Lincoln Park, 
NJ), coated with 1.5% gelatin, and incubated for 24 h in F12K media without growth 
factor (Lian et al., 1996).  In order to determine the ability of rVCP, rVCP~3,4, and HBP 
to bind HUVECs, duplicate wells (2 ml each) were trypsinized and rinsed with FTA 
hemagglutination buffer (Becton Dickinson) and stained for 30 min on ice with either 20 
mg of FITC-labeled rVCP, 30 mg of FITC-labeled rVCP~3,4, or 30 mg of FITC-labeled 
HBP.  For analysis of antibody interaction with cell surface class I HLA-ABC molecules, 
triplicate wells (2 ml each) were trypsinized and rinsed with FTA hemagglutination 
buffer and stained for 30 min on ice with 0.25 mg of phycoerythrin-conjugated mouse 
antihuman HLA- BC mAb (Caltag, Burlingame, CA), or a mouse IgG2a mAb (an 
isotype-match negative control) in the presence or absence of 2 or 5 mg VCP– 90-98% 
pure from natural infection.  After incubation, cells were rinsed three times in FTA 
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buffer, and then fixed in Hank’s balanced salt solution (HBSS) containing 2% 
paraformaldehyde.  B fore staining, cell cultures were assessed for viability by trypan 
blue dye exclusion, and the cells were found to be >95% viable.  The percentage of 
positively stained cells was determined using a flow cytometer (Becton Dickinson 
FACScan, San Jose, CA) equipped with a single 15-mW argon laser tuned to 488 nm, 
technical assistance and use of the FACS facilities was provided by Dr. Sam Welhausen 
of the J. Graham Brown Cancer Center.  Forward and 90o angle light scatter, integrated 
log phycoerythrin and FITC fluorescence signals were collected and analyzed.  
Variability between duplicate samples was less than 10%.  To compensate for any 
background fluorescence, the control threshold was set less than 1% binding of control 
mAbs.  Data were acquired from analysis of >3000 events.  A single homogenous cell 
population was indicated as detected by forward and 90o light scatter. 
 
Heparin Binding Ability: 
In order to establish a basis for comparing heparin binding ability, 10 mg each of
bovine serum albumin (BSA), heparin binding protein (HBP)[described earlier 
(Flodgaard et al., 1991)], lysozyme, and MIP-1 a were pooled, dissolved in 1 ml of 
ultapure water, and passed through a 1 ml HiTRAP heparin column and the unbound 
material collected.  The bound proteins were rinsed with 1 ml of ultrapure water and then 
eluted with increasing sodium chloride concentrations ranging from 250 mM up to 4.0 M.  
Next, 20 mg of purified rVCP~1,2, rVCP~2,3, rVCP~3,4, rVCP or 10 mg f wild type 
VCP (from VV infection of cell culture) were each dissolved in 1 ml of ultrapure water 
and passed through separate 1 ml HiTRAP heparin columns and the unbound materials 
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collected.  After washing the column with 1 ml of ultrapure water, the proteins were 
eluted with sodium chloride concentrations ranging from 250 mM to 2.5 M.  The 
fractions were then separated using SDS-PAGE and silver stained.  Densitometric 
readings were taken using the AlphaImager 2000 software system.  Finally, 0.5 ml of the 
fraction containing the protein was concentrated by ultrafiltration and its activity tested 
using the hemolysis assay. 
 
Sequencing of the VCP Homologue in MPV: 
Sequencing was done by Alexei Totmenin, from the Department of Molecular 
Biology of Genomes, State Research Center of Virology and Biotechnology Koltsovo, 
Novosibirsk Region, Russia, as described p eviously (Shchelkunov et al., 1998). 
 
Biacore Instrumentation: 
Instruction and use of the Biacore X ® facilities was provided by David Pugh and 
Jasper Rees from the Department of Biochemistry, University of Western Cape, Cape 
Town, South Africa.  Carboxylated dextran sensor chip CM5 was chosen for amine 
coupling.  Chip was docked and primed in a Biacore X ® nstrument.  Hepes-buffered 
saline (HBS) (Biacore, Biagrade) was used as the running buffer throughout the study.  
Standard amine coupling was used to immobilize heparin to the sensor chip – see figu e 
15 for amine coupling procedure.  First, channel one was selected with a flow rate of 10 
ml/min.  The surface of the sensor chip was then activated by injecting 35 ml of a freshly 
prepared 1:1 mixture of N-hydroxysuccinimide (NHS) to N-ethyl-N'-









Figure 15.  Standard amine coupling procedure for Biacore instrument.  The 
carboxylated dextran sensor chip (CM5) was chosen for amine coupling.  Chip was 
docked and primed in a Biacore X ® instrument.  The surface of the sensor chip was then 
activated by injecting a freshly prepared 1:1 mixture of N-hydroxysuccinimide (NHS) to 
N-ethyl-N'-(dimethylaminopropyl)-carbodiimine (EDC).  Directly following surface 
activation, a mixture of streptavidin (the ligand) (1 mg/ml) and coupling buffer 3 (0.1 M 
glycine pH 4.8) was injected.  The surface was then deactivated (unreacted groups were 



































of a mixture of 5 ml streptavidin (1 mg/ml) and 95 ml coupling buffer 3 (0.1 M glycine pH 
4.8) was injected.  The surface was then deactivated (unreacted groups were blocked) by 
injecting 20 ml ethanolamine HCl (1M, pH 8.5).  Surface regeneration was frequently 
achieved by injecting 10 ml of Biacore regeneration solutions 1, 2, or 3.  In order to arrive 
at satisfactory regeneration in studies testing heparin binding of rVCP, 1-10 ml injections 
of 50-70 mM NaOH were used.  If regeneration was not adequate after the first injection, 
more than one injection was tried.  Care was taken not to damage ligand on chip surface.  
BiaEvaluation 3.0 software was used to evaluate all dat  collected.  For comparison, data 
is presented by displaying both ligand channel and control channel for all binding studies.   
In order to test the interaction between heparin and rVCP, heparin was 
immobilized to a CM5 sensor chip in the following manner.  Using standard amine 
coupling, streptavidin (Sigma) was immobilized to channel one of the sensor chip.  Next, 
heparin-albumin-biotin (Sigma) was passed over the streptavidin, resulting in binding of 
this heparin coated albumin molecule (albumin with heparin and biotin covalently bound) 
to the sensor chip.  Finally, the interaction between rVCP and heparin could be measured.  
The interaction of various fragments of rVCP with heparin was also tested. 
 
Tri-peptide Studies: 
 To test the hypothesis that synthetic peptides resembling the putative heparin 
binding sites could interfere with binding of rVCP to heparin by competitive inhibition, 
three tri-peptides were purchased from Bio-Synthesis Incorporated.  The KRR tri-pep ide 
was synthesized to act as the competitive inhibitor and both negatively charged (DID) 
and neutral (GSS) tri-peptides were used as a control.  In the presence and absence of 
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various concentrations (300 mg – 3 mg) of each tri-peptide, heparin chromatography of 
rVCP was performed.  The tri-peptide was suspended in water in the presence of 300 mg 
rVCP.  This starting material was then passed through a 1 ml HiTRAP heparin column 
and the unbinding material was collected.  The column was then washed and the protein 
was eluted with a NaCl step gradient ranging from 100 mM to 500 mM.  The fractions 
were then visualized using SDS-PAGE and coomassie blue staining.  The rVCP 
containing fractions were then compared between tri-peptides in order to determine the 
effect that they had on the heparin binding ability of rVCP.   
 
Model of rVCP: 
The structure of the two unknown VCP modules (VCP SCR 1 and VCP SCR 2) 
were modeled by homology with the four known VCP module structures: VCP SCR 3, 
VCP SCR 4, fH SCR 15 and fH SCR 16, using the program MODELLER (Sali and 
Blundell, 1993).  Five models of each module were created.  The model which was 
closest to the average structure was used in the construction of the rVCP~1-4 mod l.  
Construction of the rVCP~1-4 was undertaken using the molecular visualization package, 
InsightII (Msi Inc. San Diego, Ca).  This was achieved by simply bonding the two 
modeled VCP structures to the NMR derived structure of the rVCP~3,4 module pair 
(Wiles et al., 1997).  No attempt was made to accurately model the junctions between 
modules 1 and 2 and modules 2 and 3.  Rather, torsion angles in the two residues linking 





 Dr. Krishna Murthy from the Center for Biophysical Science and Engineering, 
University of Alabama at Birmingham performed the X-ray crystallography of rVCP.  
Two crystal forms, form I and form II, of rVCP expressed in yeast were grown.  Both 
were obtained using a protein concentration of 5-12 mg/ml in 20 mM TRIS, pH 7.5 (form 
I) and 8.3 (form II), 100 mM NaCl.  Form I crystals were grown using 10% PEG 6000 
and form II crystals using 8-12% PEG 8000 in hanging drop vapor diffusion experiments 
















Specific Antibody Blocking to HUVECs: 
In order to determine the biological consequences of heparin binding by VCP, we 
tested whether VCP was able to block functional molecular interactions with human 
umbilical cord vascular endothelial cells (HUVECs).  First, the ability of FITC-labeled 
rVCP to bind heparin was tested by chromatography.  As can be seen in figure 16, the 
heparin binding ability of rVCP is diminished due to labeling.  However, approximately 
~25% of the labeled material retains functional heparin binding ability.  The ability of 
rVCP, rVCP~3,4, and HBP to bind the surface of HUVECs was then tested using flow 
cytometric analysis.  As shown in figure 17A and B, all three proteins possess the ability 
to bind strongly to HUVECs.  A 3.0, 2.9, and 5.4 fold increase in mean fluorescent 
intensity (MFI) over the control was observed when 20 mg FITC-labeled rVCP, 30 mg
FITC labeled rVCP~3,4, or 30 mg FITC labeled HBP (respectively) was added to the 
suspension of HUVECs.  Next, using flow cytometric analysis of HUVECs treated with 
mouse monoclonal antibodies to human MHC class I molecules – in the presence and 
absence of VCP – VCP was shown to be capable of modulating antibody binding in a 
dose-dependent manner.  As shown in figure 17C, addition of 5 ml (2 mg) of VCP to 
antibody treated HUVECs, reduced antibody binding from 91.5% down to 7 .4%.  An 
additional 15 ml (5 mg total) of VCP reduced antibody binding from 91.5% to 61.0% - 













Figure 16.  Heparin binding of FITC-labeled rVCP.  Heparin purification of rVCP 
labeled with FITC.  Most of the FITC rVCP sample passed through the HiTRAP heparin 
column with out binding.  Only ~25% of the sample bound heparin with the same affinity 
as the unlabeled protein, see figure 7 for comparison.  This observation may be due to 







































































Figure 17.  Representative histograms showing that VCP is able to reduce mouse 
antihuman HLA class I antibody binding to HUVECs.  The results of flow 
microflourimetric analysis are as follows: A1) No treatment control A2) Binding of 
FITC-labeled rVCP to HUVECs B1) No treatment control B2) Binding of FITC-labeled 
rVCP SCR (3,4) to HUVECs B3) Binding of FITC-labeled HBP to HUVECs C1) 
Nonspecific mouse monoclonal antibody (isotype-matched mouse IgG2a mAb) binding 
to HUVECs cells (negative control) C2) Mouse monoclonal antihuman HLA-ABC 
antibody binding to HUVECs (positive control) C3) Mouse monoclonal antihuman HLA-
ABC antibody binding to HUVECs in the presence of 5 ml (2 mg) of VCP C4) Mouse 




























A1 FITC -VCP (20 mg)
93.44 MFI
A2
FITC -3,4 (30 mg)
73.19 MFI





Heparin Binding of rVCP and rVCP Fragments: 
 To calibrate the HiTRAP heparin column, several proteins having different 
binding affinities for heparin were passed through the column and eluted with increasing 
sodium chloride concentrations.  SDS-PAGE analysis of the eluted fractions containing 
these proteins of various heparin-bindi g activities can be seen in figure 18.  Analysis 
suggests that bovine serum albumin (BSA) does not bind heparin, since it is present only 
in the unbound and wash fractions.  Lysozyme and MIP-1 , which bound heparin with 
moderate and equal affinity, were contained within the 500 mM and 750 mM sodium 
chloride fractions.  HBP, showing the highest affinity for heparin, was eluted by a sodium 
chloride concentration of 2.0 M. 
In order to better characterize the heparin binding ability of the VCP molecule, 
VCP, recombinant VCP, and various recombinant segments of VCP were passed through 
HiTRAP heparin columns and analyzed using SDS-PAGE, shown in figure 19.  The 
results suggest that the full-l ngth natural and recombinant proteins bind heparin with 
close to or equal affinity as lsozyme and MIP-1 a; both VCP and rVCP were 
concentrated primarily in the 500 mM and 750 mM sodium chloride fractions.  PAGE 
analysis of the various recombinant VCP segments revealed data that are even more 
interesting.  Recombinant rVCP~1,2 and rVCP~3,4 bound heparin with the same strength 
as the full-length protein, eluting once again at 500 mM and 750 mM.  In contrast, 
recombinant rVCP~2,3 did not bind heparin at all and was found primarily in the 
unbound and wash fractions.  The activity of the purified proteins was then tested using 
the hemolysis assay.  The results indicate that only the full-length protein inhibits lysis of 










Figure 18.  PAGE analysis of the heparin binding activity of BSA, HBP, lysozyme, 
and MIP-1 alpha.  In order to calibrate the HiTRAP heparin column, various proteins 
(BSA, HBP, lysozyme, and MIP-1a) with differing affinities for heparin were passed 
through the column and eluted with sodium chloride concentrations ranging from 250 
mM to 4.0 M.  M = molecular weight marker, S.M. = starting material, Unb. = unbound 

























































Figure 19.  PAGE analysis of the heparin binding activity of VCP and rVCPs.  VCP 
and various rVCPs were passed through separate HiTRAP heparin columns and eluted 
with sodium chloride concentrations ranging from 250 mM to 2.5 M.  The fractions were 
collected, run on SDS PAGE, silver stained, and the band densities measured.  The 
results are shown as follows: A) recombinant rVCP SCR (1,2) B) recombinant rVCP 
SCR (2,3) C) recombinant rVCP SCR (3,4) D) recombinant rVCP E) VCP from the 
natural infection process.  For gels A-E, M = molecular weight marker, S.M. = starting 
material, Unb. = unbound fraction, W = wash, VCP = VCP from natural infection. F) 









segments showed no inhibition of lysis, suggesting that the whole protein is needed to 
block complement activation.  The naturally truncated VCP homologue produced by 
monkeypox virus (MPV)(shown in figures 20 and 21), which lacks almost the entire 
fourth SCR, has been shown to inhibit hemolysis of sensitized sheep red blood cells.  
Thus, this indicates that it is blocking the classical pathway of complement activation. 
 
Conserved K/R-X-K/R Sites: 
To more precisely identify the molecular basis behind the VCP-heparin 
interaction, the amino acid sequences were analyzed using the MacVector software 
system.  Putative heparin binding sites (K/R-X-K/R) were first identified – shown in 
figure 20 along with the sequence alignment of different poxvirus VCP homologues – 
and predicted to be located on the surface of the protein.  The amino acid sequences were 
then scanned to determine the total number of positive amino acids (K+R), the percentage 
made up of these positively charged amino acids (% K+R), and the overall pI of the 
protein – the results are summarized in figure 21.  All of the proteins shown to bind 
heparin had an overall pI of greater than 7.0, and more importantly, were made up of 
greater than 9% positively charged amino acids.  The results also suggest that SCR 1 and 
SCR 4 contribute the most to this interaction.  Although the results show there is no 
simple answer to how VCP binds heparin, it is clear that the overall positive charge, 
number of putative binding sites, and the percentage of positive amino acids making up 










Figure 20.  Sequence alignment including termini of rVCP constructs and putative 
heparin binding sites.  Multiple alignment of the four short consensus repeats (SCR) 
from orthopoxviruses VAC-COP (vaccinia virus, Copenhagen strain), VAC-WR 
(vaccinia virus, western reserve strain), CPV-GRI (cowpox virus, Russian isolate from 
human patient), CPV- BRI (cowpox virus, Brighton strain), VAR-BSH (variola virus, 
Bangladesh strain), VAR-IND (variola major virus, Indian strain), VAR-GAR (variola 
minor virus, alastrim Garcia strain), and MPV-ZAI (monkeypox virus, isolated from a 
human patient from Zaire in 1996).  The putative heparin binding sites (K/R-X-K/R) are 
marked with solid bars, arrows indicate the termini of the rVCP constructs, and the 







VAC- COP C3L     C CTIPSRPINMKFKNSVETDANANYNIGDTIEYLCLPGYRKQKMGPIYAKCTGTGWTLFNQCI
VAC- WR  C21L    . . ................................ . ............... . .......... . .
CPV- GRI C17L    . . P......T....GT. -- . -- SH.......... . ............... . .......... . .
CPV- BRI IMP     . . ...............G................ . ............... . .......... . .
VAR- BSH D15L    . . ................................ . ............... . .......... . .
VAR- IND D12L    . . .........T...................... . ............... . .......... . .
VAR- GAR B18L    . . ................................ . ............... . .......... . .
MPV- ZAI D15L    Y . .................... -- .......... . ............... . .......... . .
VAC- COP C3L     KRRCPSPRDIDNGQLDIGGVDFGSSITYSCNSGYHLIGESKSYCELGSTGSMVWNPEAPICE
VAC- WR  C21L    ... . ......................... . ............. . ................ . .
CPV- GRI C17L    ... . ......................... . ............. . ................ . .
CPV- BRI IMP     ..K . ..........I.....E........ . ....Q........ . ...Y............ . .
VAR- BSH D15L    ... . .........H............... . ....Y....Y... . K...........K... . .
VAR- IND D12L    ... . .........H............... . ....Y....Y... . K...........K... . .
VAR- GAR B18L    ... . .........H............... . ....Y....Y... . K...........K... . .
MPV- ZAI D15L    ... . ......................... . ............. . ................ . .
VAC- COP C3L     SVK CQSPPSISNGRHNGYEDFYTDGSVVTYSCNSGYSLIGNSGVLCSGGEWSDPPTCQ
VAC- WR  C21L    ... . ........................... . ............. . .......... . .
CPV- GRI C17L    ... . ........................... . ............. . .......... . .
CPV- BRI IMP     ... . P....VT.................... . ...........IV . .......... . .
VAR- BSH D15L    ... . .L............N............ . ............. . ......N... . .
VAR- IND D12L    ... . .L............N............ . ............. . ......N... . .
VAR- GAR B18L    ... . .L............N............ . ............. . ......N... . .
MPV- ZAI D15L    ... . ..................I...I.... . ............M . ......N... . .
VAC- COP C3L     IVK CPHPTISNGYLSSGFKRSYSYNDNVDFKCKYGYKLSGSSSSTCSPGNTWKPELPKCVR
VAC- WR  C21L    ... . ........................... . ............. . ............ . ..
CPV- GRI C17L    ... . ........................... . ............. . ......Q..... . ..
CPV- BRI IMP     ... . ...S.T.............H....... . RH........... . ......Q..... . ..
VAR- BSH D15L    ... . .....L....................T . ............. . ......Q..... . ..
VAR- IND D12L    ... . .....L....................T . ............. . ......Q..... . ..
VAR- GAR B18L    ... . .Y...L....................T . ............. . ......Q..... . ..


















Figure 21.  Structure-function summary table of VCP, VCP homologues, and 
rVCPs.  VCP/IMP/SPICE, MPV homologue of VCP, recombinant VCP, and four 
overlapping recombinant segments of VCP with 2 or 3 SCRs are shown along with their 
ability to inhibit hemolysis of sensitiz d sheep red blood cells and/or bind heparin.  Also 
listed are the number of positively charged amino acids (K+R) found in the protein, 
percentage of positively charged amino acids (% K+R) making up the protein, pI of the 









Short Consensus Repeats (SCR)
---C--P--------------------YF-C---C--------C---G-W----A/P-C-
rVCP SCR (1,2) + 12 9.60 7.00 3
rVCP SCR (3,4) + 11 9.24 9.08 1
rVCP SCR (2,3) 7 5.83 4.41 1








+ +VCP/IMP/SPICE 23 9.43 8.80 4
MPV  Homolog of VCP + N/D 16 8.00 7.22 3
rVCP + + 23 9.43 8.80 4
9
5
Biacore Heparin Binding: 
To map the heparin binding site(s) on VCP using SPR, heparin was immobilized 
to a CM5 sensor chip and rVCP, or rVCP fragments, was injected and their ability to bind 
measured.  As shown in figure 22, both rVCP and rVCP~3,4 bound strongly to the 
immobilized heparin.  Surprisingly, rVCP~1,2, although the protein was purified using 
heparin affinity chromatography, did not show the ability to interact with heparin 
immobilized to the sensor chip.  The chromatography data suggests that two sites on 
rVCP, that are highly homologous to the well-characterized heparin binding site of 
fibroblast growth factor protein, may be involved in heparin binding.  The two sites are 
located at the junction between CCP modules 1 and 2 (KRR), and at the far end of 
module 4 (KQK).  These sites were first identified when mutant proteins rVCP~1,2 and 
rVCP~3,4 were shown to bind and be purified using heparin affinity chromatography.  
The second heparin b nding site found at the junction of CCP modules 1 and 2 may 
possess a much weaker affinity, and without the presence of the remaining half of the 
protein is unable to bind heparin using SPR.  This region may therefore double as a 




 Small tri-peptides were ordered from Bio-Synthesis Incorporated (Lewisville, 
Texis) to determine whether the heparin binding of rVCP could be inhibited in the 
presence of a high concentration of putative, K/R-X-K/R, binding sites.  The putative 










Figure 22.  Heparin binding of rVCP fragments.  The ligand and control channel 
responses are shown for the binding between rVCP, or rVCP fragments, and heparin 
immobilized to the sensor chip.  Control channel response represents only bulk effects; 
no protein is immobilized.  All proteins were tested at different concentrations to confirm 






























































































GSS (neutral), were each tested in various concentrations to see what effect they would 
have in rVCP's ability to bind heparin.  As can be see in figure 23, rVCP binding to 
heparin was actually enhanced with increasing concentrations of the KRR tri-pep ide.  
This effect was also seen, though to a lesser extent at higher concentrations, with the DID 
and GSS tri-peptides – see figures 24 and 25.  These results suggested that the KRR tri-
peptide might bridge the central negatively charged region of rVCP, and thus increase its 
interaction with heparin by increasing its positive electrostatic field.  If this hypothesis 
were true, rVCP~2,3 (normally unable to bind heparin due to strong negative charge), in 
the presence of high concentrations of KRR, would bind heparin.  As can be seen in 
figure 26, this was not the case.  rVCP~2,3 did not bind heparin even in the presence of 
high concentrations of the KRR tri-peptide. 
 
Dextran Sulfate Affinity Chromatography: 
 As an alternative to heparin chromatography, in an attempt to reduce expense and 
increase binding capacity, dextran sulfate matrix was purchased from Sigma.  Using a 
disposable 20 ml Bio-Rad column, 20 ml of sulfated dextran matrix was seeded and 
rinsed with water.  Figure 27 shows the results obtained using a NaCl step gradient to 
elute rVCP.  rVCP was found to bind dextran sulfate with a higher affinity (500 mM 
elution) than heparin (400 mM elution).  In addition, its binding capacity seemed to be 
greater than that observed for heparin matrices.  Unfortunately, however, the dextran 











Figure 23.  Heparin binding of rVCP in presence of KRR tri-peptide.  Heparin 
affinity chromatography was performed on rVCP in the presence of varying amounts of 
the positively charged tri-peptide KRR.  rVCP was eluted from the column using a NaCl 
gradient ranging from 100 mM to 2 M.  rVCP eluted in the 300 mM NaCl fraction in the 
absence of KRR, but eluted as high as 500 mM in the presence of large concentrations of 
KRR.  It is not known why the KRR tri-peptide was stained while the DID and GSS tri-














































































Figure 24.  Heparin binding of rVCP in presence of DID tri-peptide.  Heparin affinity 
chromatography was performed on rVCP in the presence of varying amounts of the 
negatively charged tri-peptide DID.  rVCP was eluted from the column using a NaCl 
gradient rangin from 100 mM to 2 M.  rVCP eluted in the 300 mM NaCl fraction in the 
absence of DID, and eluted as high as 450 mM in the presence of large concentrations of 
DID.  Although DID resulted in rVCP having an increased affinity for heparin, this 
affinity was significantly lower at higher concentrations of tri-peptide than that observed 












































































Figure 25.  Heparin binding of rVCP in presence of GSS tri-peptide.  Heparin affinity 
chromatography was performed on rVCP in the presence of varying amounts of the 
neutrally charged tri-peptide GSS.  rVCP was eluted from the column using a NaCl 
gradient ranging from 100 mM to 2 M.  rVCP eluted in the 300 mM NaCl fraction in the 
absence of GSS, and eluted as high as 450 mM in the presence of large concentrations of 
GSS.  Although GSS resulted in rVCP having an increased affinity for heparin, this 
affinity was also significantly lower than that observed in the presence of the KRR tri-









































































Figure 26.  Heparin purification of rVCP~1,2, rVCP~2,3 (using KRR), rVCP~2,3,4.  
Purification of rVCP~1,2, rVCP~2,3, and rVCP~2,3,4 using heparin affinity 
chromatography.  rVCP~1,2 and rVCP~2,3,4 are easily purified by this method due to 
their strong affinity for heparin, however, rVCP~2,3 does not show this affinity and must 
be purified by other means.  Attempts were made to use the tri-peptide KRR to purify 
rVCP~2,3 by heparin affinity chromatography, but failed.  Proteins were eluted using a 


















































































































































Figure 27.  Dextran sulfate chromatography of rVCP.  Do to the similarity between 
dextran sulfate and heparan sulfate, attempts were made to purify rVCP by dextran 
sulfate chromatography.  rVCP was eluted using a NaCl step gradient ranging from 300 
mM to 1 M.  Interestingly, rVCP eluted from the dextran column at a significantly higher 
NaCl concentration (500 mM as compared to 350–400 mM) than seen using heparin 
chromatography.  This indicates that rVCP possesses a higher affinity toward dextran 
sulfate than heparin.  This may be due to the greater degree of sulfation present on the 




















































Dextran Sulfate Purification of rVCP
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NMR Modeled Structure: 
In order to better visualize the positioning of heparin binding sites in the VCP 
molecule, a model was developed using four known VCP module structures: VCP SCR 
3, VCP SCR 4, factor H (fH) SCR 15 and fH SCR 16 – see figure 28.  As can be seen in 
this model, heparin binding exists primarily at the ends – SCRs one and four.  The middle 
of the molecule therefore does not contribute any to the binding (hence rVCP~2,3 
showed no ability to bind). 
 
Electrostatic Charge Distribution: 
Using the X-ray crystal structure of rVCP, the electrostatic field distribution was 
predicted.  An extreme positively charged field over the fourth domain is very evident.  
In addition, concentration of basic residues [Lys (K) and Arg (R) residues] at the junction 
of modules 1 and 2 makes a second highly positively charged patch – see figure 29.  Most 
of the residues with carboxylic acid side chains are clustered in modules 2 and 3 with 
those two modules carrying a net negative charge.   
 
X-Ray Crystal Structure Homology: 
Other than VCP, only the serum complement regulatory proteins C4b-BP and fH 
have heparin binding activity.  Binding sites for heparin on CCP modules 1 and 2 on the 
a chain of C4b-BP (Blom et al., 1999; Hessing et al., 1990) and on CCP modules 7, 20 
and 13 for fH (Blackmore t al., 1998; Sharma and Pangburn, 1996) have been identified.  
The above experimental results suggest the possible presence of two heparin binding sites 










Figure 28.  VCP model showing the heparin binding sites.  Front (A) and back (B) 
views of the modeled structure of VCP SCR (1-4) showing the heparin binding sites 
(differentially colored).  In order to differentiate the extents of the individual modules, 
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Figure 29.  Electrostatic attributes of VCP.  Domain 1 is at the top and domain 4 at the 
bottom in all panels.  a-d) Electrostatic potential mapped on to the molecular surface of 
molecule A of form I crystals.  Dark blue represents 10.2 electrons per Å and red 
represents –4.3 electrons per Å.  e) Representation of the ±2kT contour of the potential 
field around the molecule calculated and displayed by GRASP using program defaults for 
all parameters, a-carbon trace is shown in yellow.  f) Expanded views of the two positiv  
patches between domains 1 and 2 (top) and domain 4 (bottom).  The top half of the panel 
is in approximately the same orientation as panel a; the bottom panel represents a view as 
seen from the bottom of panel a looking up at module 4.  K and R residues contributing 












The structure of VCP confirms that there are two spatially distinct putative 
heparin binding sites in the molecule.  rVCP, in the crystal structures, appears to be a 
long molecule with large positively charged domains at its two ends; a large patch of 
positive charge is located at the tip of domain 4 and a second positive patch straddles 
domains 1 and 2.  Negatively charged groups on heparin and positively charged groups 
on proteins dominate heparin-protein interactions.  Heparin binding sequence motifs in 
proteins consisting of suitably spaced K and R residues have been proposed (Margalit et 
al., 1993) and such motifs have been identified in VCP.  Structures of acidic (DiGabriele 
et al., 1998; Schlessinger et al., 2000) and basic (Faham et al., 1996) fibroblast growth 
factors (FGFs) complexed with heparin have offered insights into details of binding of 
heparin by proteins.  Modeling of heparin binding to rVCP employing FGF as a template 
and using Insight II (Biosym-Technologies, 2000) shows that a carbon atoms of K 
residues, 214, 216, 220 and 241, in a flexible region of module 4, can be superimposed 
on corresponding basic residues, K113, R119, R112 and K128 in acidic FGF (DiGabriele 
et al., 1998; Schlessinger et al., 2000).  All the ligands in module 4 are either end 
residues of b strands or are in flexible loops between strands – see figure 30.  Similarly, 
residues K64, R65 and R66 in module 1 and the linker connecting modules 1 and 2 can 
be superimposed on residues K122, K118 and R119 of FGF.  These two putative heparin 
binding regions are separated by about 80 Å.  Figure 30 shows a stereo view of the model 
for the site at the tip of module 4.  It is significant that the model for rVCP interactions 
with heparin resembles that in the FGFs closely, an unrelated protein, indicating heparin-








Figure 30.  Stereo view of interaction of VCP with Heparin.  An Ca trace of residues 
213-242 of VCP is shown in orange.  Carbohydrate is shown with carbons colored gray, 
oxygen, red, nitrogen blue and sulfur yellow.  Sidechains of the four basic residues of 
acidic and basic FGF and VCP that were superimposed are shown in d, magenta and 
cyan respectively.  VCP sidechains are labeled.  The figure was composed using a rigid 
body transformation of VCP mainchain on to the basic FGF heparin binding segment. 
The sidechains of the K residues in VCP have been rotated to point towards the heparin 
fragment.  The side chain of K 214 is beyond hydrogen bonding distance from heparin as 
currently modeled.  Mainchain movements of 1-2 Å will be required to bring its 












The ability of VCP to bind heparan sulfate proteoglycan molecules adds a new 
dimension to its role in modulating the host immune response.  In previous studies, the 
ability of VCP to bind heparin was found to permit uptake by mast cells – possibly 
allowing for tissue persistnce over an extended time.  In addition, earlier studies have 
shown that binding to heparin-like molecules on the surface of endothelial cells can block 
chemokine adherence, resulting in reduced chemotactic signaling.  The next step was to 
determine if VCP, bound to the endothelial cell surface, could interfere with antibody 
binding.  In this study, flow cytometry was used to demonstrate that VCP is able to bind 
the surface of endothelial cells, interfering with antibody binding.  More importantly, this 
study demonstrates that addition of VCP significantly decreases the amount of antibody 
able to attach to HUVECs in a dose-dependent manner.  It is postulated that VCP, 
binding to heparin-like molecules on the surface of endothelial cells, prevents antibody 
adherence.  This binding may therefore block antibody attachment through steric 
interference, and block both molecular and cellular interactions - which are dependent on 
target cell adhesion molecules binding to cytotoxic cells.  Furthermore, this novel 
mechanism can enable virus-infected cells or the antigen presenting cell from destruction 
by host defense mechanism.  Interestingly, it was estimated that the amount of VCP 
required for inhibition of roughly 5 x 105 cells is approximately the same as that 
produced by 2 x 105 infected cells, and therefore each infected cell can protect itself and 
one or two surrounding cells.  Thus, VCP enables orthopoxviruses, all of which encode 
homologues of VCP, to evade the immune system by multiple mechanisms, e.g. by 
blocking complement pathways, blocking antibody-depen ent cytotoxic cell activity 
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(ADCC) or by interfering with attachment of cytotoxic T cells to virus infected cells.  
This observation is further strengthened by recent studies by Al-Mohanna et a. (2001), 
who showed that rVCP was able to block interactions between pig aortic endothelial cells 
(PAECs) and naïve neutrophils and NK cells, preventing cell killing (Al-Moha na et al., 
2001).  In addition, cell culture studies demonstrate that VCP blocks complement-
mediated killing of PAECs by human serum, in a dose-dependent manner. 
Due to the apparent importance heparin binding has in many of the biological 
activities exhibited by VCP, we became interested in better characterizing the molecular 
reasons for this interaction.  Recombinant segments of VCP - each representing two of 
the four SCRs - were generated by genetic engineering vaccinia virus DNA, encoding 
VCP, into the Pichia pastoris expression system.  The ability of these recombinant 
segments to bind heparin was then tested.  It was determined that recombinant proteins 
rVCP~1,2 and rVCP~3,4 retained the same binding affinity as the full-length native 
protein.  While recombinant protein rVCP~2,3 retained no heparin binding ability at all.  
In order to explain this, the amino acid sequences of the recombinant protein segments 
were more closely examined.  It was determined that the number, and more importantly, 
the percentage of positively charged amino acids making up the protein contributed 
greatly to its ability to interact with heparin.  In addition, the overall charge and number 
of putative binding sites (K/R-X-K/R) making up the protein, appears to play a role in 
heparin binding.  For the most part, the ability of VCP to bind heparin lies in its first and 
fourth SCR.  These two sh rt consensus repeats possess within them the highest 
percentage of positive amino acids, the greatest number of putative binding sites, and 
have a very strong overall positive charge (data not shown). 
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Using SPR, Biacore binding analysis, the ability of rVCP and rVCP fragments 
was tested in order to confirm the locations of the heparin binding sites.  The two sites are 
located at the junction between CCP modules 1 and 2, and at the far end of module 4.  
These sites were first identified in the above experiments where mutant proteins 
rVCP~1,2 and rVCP~3,4 are found to bind and be purified using heparin affinity 
chromatography.  With heparin immobilized to the sensor chip, rVCP and the various 
mutant rVCP truncations were injected and their interaction measured.  rVCP nd 
rVCP~3,4 was found to bind strongly to the immobilized heparin.  Surprisingly, 
rVCP~1,2 did not show the ability to interact with heparin immobilized to the sensor 
chip.  The second heparin binding site found at the junction of CCP modules 1 and 2, 
may possess a much weaker affinity and without the presence of the remaining half of the 
protein is unable to bind heparin using SPR.  It is now believed that this region may 
double as a heparin/C3b-C4b binding site, binding weakly to heparin only in the absence 
of complement. 
In order to better visualize the positioning of heparin binding sites in the VCP 
molecule, a model was developed using four known VCP module structures: VCP SCR 
3, VCP SCR 4, factor H (fH) SCR 15 and fH SCR 16.  As can be seen in thi  model, 
heparin binding exists primarily at the ends – SCRs one and four.  The middle of the 
molecule therefore does not contribute any to the binding (hence rVCP~2,3 showed no 
ability to bind).  This model was confirmed when the crystal structure w s resolved.  
Using the crystal structure, an accurate assessment of charge distribution could be used to 
authenticate the heparin binding site locations.  Indeed, strong positive charge can be 
seen surrounding the locations of the heparin binding sites at the junction between CCP 
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modules 1 and 2, and at the far end of module 4.  In addition, using spatial modeling, 
both of these regions showed a considerable degree of homology with the heparin 
binding site of acidic and basic fibroblast growth factor (FGF) protein.  The small heparin 
binding sequence of FGF is often used to define heparin binding sites on other proteins.  
Due to the very close alignment of critical basic amino acid residues on rVCP with FGF, 
it is almost certain that these two putative heparin sites are responsible for VCP's ability 
to interact with heparin.   
Using synthetic tri-peptides to mimic the short conserved sequences (K/R-X-K/R) 
suspected to be involved in the heparin binding of rVCP, competition analysis was 
performed.  The ability of rVCP to bind heparin was actually enhanced in the presence of 
increasing concentrations of the predicted heparin binding site sequence.  This did not 
prove that these sequences were not involved in heparin binding, although it suggested 
that the sequences were not this size.  Previously published heparin binding sites are 
much longer than three amino acids and containing spacer regions to spatially position 
the basic amino acids in alignment with the negatively charged heparin.  All of the above 
data suggests that the K/R-X-K/R binding motif is, in fact, part of the heparin binding 
sites of rVCP, but is not the entire site required for the interaction.  It is now believed that 
the heparin binding site at the junction between CCP modules 1 and 2 does consist of 
amino acids K64, R65, and R66, (and possibly R40, K41, and K43) but does however 
involve the linker region between CCP 1 and 2 as well.  Likewise, a series of K residues, 
214, 216, 220 and 241, which also incorporates a K/R-X-K/R binding motif, makes up 








Figure 31.  Residues involved in binding heparin in VCP.  Spatial relationship of two 
heparin binding sites on VCP.  Residues K64, R65, and R66 (cyan) between modules 1 
and 2 are believed to be involved in weak heparin binding in the absence of complement, 
image A.  In the presence of complement, these basic residues are thought to double as a 
ligand for C3b/C4b, image B.  Residues K214, K216, K220, and K241 (cyan) at the C-
terminus of VCP are thought to bind heparin strongly, contributing significantly to VCP's 
heparin binding abilities.  Heparin hexasaccharide (carbon, white; oxygen, red; nitrogen, 
blue; and sulfur, yellow) is modeled in A and B, with the four lysine residues which 










The importance of heparin binding to the function of soluble complement control 
proteins is becoming more evident.  Studies of factor H (fH) show that heparin binding is 
very important in distinguishing activator surfaces from host cell surfaces (Pangb rn et 
al., 2000).  In addition, both C3b decay acceleration and co-factor activities of fH are 
enhanced in the presence of heparin (Meri and Pangburn, 1994).  This may add strength 
to the hypotheses that VCP binds heparan sulfate on the surface of vaccinia virus infected 
host cells to protect the cell from complement activation, cell lysis, and thus preserves the 
viral habitat. 
In summary, by examining the heparin-binding ability of VCP, we have gained a 
better understanding of the molecular basis by which this interaction occurs.  In addition, 
the data presented here further enhances our understanding of this truly unique, yet 
compact, multifunctional viral protein.  It resembles in structure and function giant 
complex human complement regulatory proteins human C4b binding protein (C4b-BP) 
and the complement receptor 1 (CR1), respectively.  Not only is VCP a miniature version 
of these large molecules, it has retained all the complement modulating functions, and as 
we have described here, added a number of additional functions to its repertoire due to its 
ability to bind heparin-like molecules.  This better understanding may some day help in 
the exploitation of VCP’s possible therapeutic properties in the treatment of 
inflammatory conditions such as Alzheimer’s Disease (Daly and Kotwal, 1998), CNS 











COMPLEMENT BINDING ACTIVITY OF VCP 
 
Introduction to Complement Binding 
This chapter contains material adapted from the following publications and manuscript: 
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, 
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J. 
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on 
poxvirus complement control proteins serve as putative heparin binding sites and 
contribute to inhibition of molecular interactions with human endothelial cells: a 
novel mechanism for evasion of host defense.  J. Virol. Jun. 74(12):5659-66, 2000 
[Cover of J. Virol. Oct. 74(20), 2000].   
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata 
C.M., and Kotwal G.J.  Crystal structure of a complement control protein that 
regulates both pathways of complement activation and binds heparan sulfate 
proteoglycans. Cell. Jan. 26, 104:301- 1, 2001.  
Smith S.A., Arjunwadkar S., Krishnasamy G., Judge K., Murthy K.H., Pugh D.R., and 
Kotwal G.J.  Mapping of regions within the vaccinia virus complement control 
protein involved in binding to key complement components and heparin using surface 
plasmon resonance.  Submitted to Virology, 2002. 
In order to modulate the inflammatory response mounted by the host, many 
poxviruses encode proteins that mimic components of the complement and chemokine 
systems (Kotwal, 2000).  Our lab has been interested in the many properties of the 
vaccinia virus complement control protein (VCP).  Functionally, VCP is very similar to 
factor H (fH), membrane cofactor protein (MCP), decay-acceler ting factor (DAF), and 
complement receptor one (CR1).  Structurally, it is composed of four complement control 
protein (CCP) modules, also known as short consensus repeats (SCR) or Sushi domains, 
making it along with homologous proteins members of the complement control protein or 
regulators of complement activation (RCA) family – see f gure 32 (Kotwal and Moss, 
1988).  VCP has been shown to inhibit the classical and alternative pathways of 
complement activation, through its ability to bind C3b and act as a cofactor for factor I 
cleavage, preventing the formation of the alternative pathway C3 and classical pathway 
C5 convertase (McKenzie et al., 1992; Kotwal et al., 1990; Sahu et al., 1998).  VCP is 
also able to bind C4b, allowing it to block early steps in the classical pathway of 
complement activation – see figure 33.  By blocking complement activation at multiple 
sites, VCP down-regulates C3a, C4a, and C5a proinflammatory chemotactic factors, 
resulting in reduced cellular influx and inflammation.  Experimental support for this 
comes from in vivo experiments using BALB/c mice injected in the footpad with cowpox 
virus (CPV) expressing or lacking the VCP homologue in CPV, termed the inflammation 
modulatory protein (IMP) (Miller et al., 1997).  A significantly greater influx of 
inflammatory cells into the tissue was observed when the footpad was infected with CPV 
lacking IMP as compared to that found in IMP expressing CPV.  Another experiment, 
using BALB/c congenically matched C5-sufficient and C5-deficient mice injected in the 
footpad with CPV, showed that C5-deficient mice exhibited a significantly greater 
swelling response that persisted longer and also showed signs of hemorrhage, edema, and 
ulceration (Miller et al., 1995).  In addition, the presence of IMP drastically diminished 
the inflammatory response elicited by CPV (Kotwalet al., 1998a; Howard et al., 1998). 
As mentioned in chapter 1, the origin of vaccinia virus remains unknown.  Since 
VCP is secreted from the infected host cell in order to establish a suitable habitat for viral 








Figure 32.  Several members of the complement control protein (CCP) family.  
Illustrated are the cartoon structures of VCP, C4b-BP, and CR1.  These are examples of 
proteins that belong to the family of SCR containing proteins, also known as the CCP 
family.  These proteins are made of repeating units, SCRs, which have a common, 
relatively conserved sequence, which results in two disulfide bonds and a characteristic 
sushi structure.  The size of VCP, and the MPV homologue, is compared to that of C4b-
BP, which it shares the highest degree of sequence homology, and CR1, which it shares 





























Figure 33.  Complement cascade and points of VCP inhibition.  Illustrated are the two 
main pathways of complement activation, the classical pathway, initiated by antibody 
fixation, and the alternative pathway, initiated by an activator surface.  VCP possesses the 
ability to block both pathways of complement activation by binding C3b and C4b 
(depicted by red Xs), resulting in their cleavage and inactivation by factor I.  This 
prevents the formation of the classical and alternative pathway C3 convertase, ultimately 
blocking activation at an early step.  In addition, VCP blocks the formation of the C5 
convertase in the classical pathway.  By blocking multiple steps of complement 
activation, VCP is also able to prevent the release of proinflammatory chemotactic 






























































that VCP's affinity and/or activity for binding and inhibiting complement activation may 
be stronger for one animal species as compared to another.  The animal species th t 
vaccinia virus most commonly infects would be most susceptible to the complement 
inhibiting action of VCP.  To initially test this hypothesis, the activity of VCP and rVCP 
was tested against various animal sera, including: pig, dog, rabbit, rat, human, horse, and 
baboon.  Interestingly, VCP and rVCP possessed different activities against many of 
these sera. 
To determine whether full-length rVCP is needed for hemolysis inhibition, factor 
I cofactor activity, or if one or more of the rVCP constructs retains thi activity, each of 
the constructs purified and described in chapter 3 were tested in the hemolysis assay.  In 
addition, V.N. Loparev, from the Poxvirus Section, Viral Exanthems and Herpesvirus 
Branch, Division of Viral and Rickettsial Diseases, National Center for diseases, Centers 
for Disease Control and Prevention, Atlanta, GA, used the hemolysis assay to test the 
activity of the monkeypox homologue of VCP.  This VCP homologue is naturally 
truncated at its C-terminus, missing 75% of the fourth CCP module (figures 20 and 21). 
In order to determine whether full-l ngth rVCP is required to bind complement, 
various rVCP constructs were created using the Pichia pastoris expression system and 
subjected to plasmon resonance binding analysis (Biacore X ®) with C3b.  With C3b 
immobilized to the sensor chip, recombinant VCP or truncated rVCP molecules, 
consisting of CCP modules 1 and 2 (rVCP~1,2), 2 and 3 (rVCP~2,3), 3 and 4 
(rVCP~3,4), and 2-4 (rVCP~2,3,4), were injected to determine whether they possessed 
the ability to bind C3b.  In addition, with rVCP immobilized to a CM5 sensor chip, 
methylamine treated C3 or C4 (C3-MA, C4-MA) was injected and binding was observed.  
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In all cases, positive binding was determined by subtraction of ligand channel readings 
from the readings of the control channel (nothing immobilized).  Each experiment was 
repeated several times to confirm results.  
The ability of rVCP to perform both of its functions simultaneously, binding 
complement and heparin, was tested using a modified he lysis assay.  This modified 
assay tests the ability of rVCP to inhibit hemolysis of sheep red cells in the presence of 
various concentrations of heparin or heparan sulfate.  The results of these preliminary 
experiments suggest that rVCP is in fact able to bind complement while remaining bound 
to heparin by the C-terminus.  To conclusively demonstrate this ability, Shrihari 
Arjunwadkar, from the Division of Medical Virology, University of Cape Town, Cape 
Town, South Africa, used plasmon resonance binding analysis (Biacore X ®).  With 
heparin immobilized to the sensor chip (described in chapter 3), rVCP was injected and 
binding to heparin was observed.  Shortly after injection of rVCP stopped, without 
regeneration, methylamine treated C3 or C4 (C3-MA, C4-MA) was injected to test for 
binding to rVCP.  As a control, C3-MA and C4-MA were injected in the absence of 
rVCP, to test whether they possessed the ability to interact with heparin (data not shown).  
The results suggest that C3-MA and C4-MA do interact with heparin, but only slightly.  
The interaction was very small in comparison to that seen in the presence of rVCP.  Each 
experiment was repeated three times to confirm the results and positive binding was 
observed by channel subtraction. 
Using the results obtained by the above experiments, results obtained in chapter 3, 
and homology found between rVCP and other complement control proteins, a model of 
the putative heparin and/or complement binding residues was created.  These putative 
132 
binding domains were visualized using the X-ray crystal structure of rVCP.  The residues 
involved in complement binding were predicted using rVCP's homology with the well-
characterized MCP.  A recent study subjected MCP to extensive alanine-scanning 
mutagenesis and epitope maping, which revealed the residues involved in cofactor 
activity and involved in binding C3b and/or C4b (Liszewski et al., 2000).  The homology 
between VCP and MCP is so great that these residues could very confidently be projected 
















Materials and Methods 
Hemolysis Assay: 
 The hemolysis assay was performed as described in chapter 2 with a few 
modifications.  Serial dilutions of rVCP were mixed with various amounts of heparan 
sulfate (HS) (Sigma) before addition of serum and sSRBCs.  In assays usi g heparin 
sepharose, 10 ml of slurry, made from 1ml heparin sepharose (Pharmacia) and 1 ml water, 
were added to a series of rVCP dilutions and incubated for 30 min on ice.  After the 
incubation, the samples were centrifuged and the supernatants tested for hemoly is 
activity.  The heparin sepharose beads were then washed with buffer before serum and 
sensitized sheep red blood cells were added.  After the assay was performed, reaction 
supernatants and the pelleted heparin sepharose beads were analyzed by SDS-PAGE for 
the presence of rVCP.  Supernatants were concentrated and the heparin beads 
resuspended in 600 mM NaCl, to strip off rVCP, and concentrated.  In all cases, both 
positive and negative controls received the same amount of heparin/heparan as all of t  
samples, in order to compensate for lysis inhibition caused by the heparin/heparan.
 
Preparation of rVCP and rVCP Truncations: 
 The cloning of VCP and fragments rVCP~1,2; rVCP~2,3; rVCP 3,4; rVCP~2,3,4 
in the Pichia pastoris yeast expression system (Invitrogen) was described in chapter 2.  
rVCP; rVCP~1,2; rVCP~3,4; rVCP~2,3,4 were all purified from media using heparin 
(Pharmacia) affinity chromatography, described in chapter 2.  rVCP~2,3 was purified by 
ion exchange chromatography using a 1 ml DEAE HiTrap fast flow (Pharmacia) column.  
All proteins were visualized by SDS-PAGE (4-12% gel) with coomassie blue staining.   
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Complement Component Purification: 
 Initial purification of C3 and C4 was performed by Gunasekaran Krishnasamy, 
from the Center fo Biophysical Science and Engineering, University of Alabama at 
Birmingham, AL.  Three milliliter of inhibitor solution containing 330 mM KH2PO4 (pH 
7.3), 66 mM EDTA, 66 mM benzamidine-HCl and 1 g of Lysine (free base) was added to 
the 20 ml of blood plasm .  The resultant treated plasma was added to polyethylene 
glycol 4000 D (PEG4K) for precipitation.  The final concentration of PEG in the solution 
was 5%.  After removing the precipitate, the plasma solution was further made 21% 
PEG4K.  The solution was stirred in cold room at 4oC for about 2 hrs.  The precipitate 
formed was dissolved in 7 ml of DEAE starting buffer [3 mM KH2PO4 (pH 7.3), 6.5 mM 
EDTA, 6.5 mM benzamidine-HCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 40 mM 
EACA and 30 mM NaCl].  The sample was applied on a 100 ml DEAE column, and after 
washing with two column volumes of starting buffer, a gradient was developed from 30 
mM to 150 mM NaCl. Those fractions containing C3 were dialyzed against a buffer 
containing 25 mM Tris (pH 7.8), 50 mM EACA, 2 mM EDTA, 2 mM benzamidine-HCl 
and 50 mM NaCl.  The dialyzed sample was applied on a 5 ml Blue Sepharose column 
and eluted with a gradient of 50-500 mM NaCl (Gresham et al., 1986).  
To produce C3b, purified C3 was further purified by perfusion chromatography 
using BioCAD 20HQ column – see figure 34.  C3b was prepared by limited trypsin 
digestion of C3 with sequencing grade trypsin (Roche).  C3 was incubated with 5% 
trypsin (w/w) for 2 min at 37 oC, before adding 5% (w/w) soybean trypsin inhibitor 
(SBTI) (Sigma) to stop the reaction.  C3 and C3b were visualiz d by SDS-PAGE (4-12% 








Figure 34.  C3 Purification using BioCAD 20HQ Column.  Purification of C3 was 
achieved using BioCAD 20HQ ion exchange chromatography.  The top panel shows the 
first passage, with a large amount of unbound material.  The absorbance is shown in red 
and the NaCl gradient shown in blue.  As can be seen in this panel, the C3 peak appeared 
half way through the NaCl gradient (SDS-PAGE analysis of this peak is shown in figure 
39), indicating strong binding.  The bottom panel shows a rerun of the unbinding material 
from the top panel, showing that all of the initial unbound material passed through the 



















































































































































To isolate C4, 5 mM PMSF, 5 mM EDTA and 2.7 mM iodoacetamide were added 
to 20 ml of plasma and the pH was adjusted to 7.4.  After 5% PEG precipitation, the 
resultant supernatant was made 26% PEG.  The precipitate obtained was dissolved and 
diluted to a conductivity of 2.9 mS in 20 mM phosphate buffer (pH 7.0) with 5 mM 
EDTA, 5 mM PMSF and 10 mM NaCl.  The sample was applied to a DEAE-cellulose 
(DE-52 cellulose) column and eluted with the same buffer.  The eluted fractions 
containing C4 were applied to a DE-52 cellulose column a second time and eluted with a 
gradient of 30-2 0 mM NaCl (Reboul et al., 1979; Press and Gagnon, 1981).
The purified C3 and C4 were dialyzed against 20 mM KHPO4, 2 mM EDTA, 
100 mM NaCl, 20 mM EACA (pH 7.5).  The C3 or C4 was treated with 20 mM, 50 mM 
and 100 mM methylamine in steps for a eri d of 3 hrs at 4°C (Tack et al., 1980).  Then, 
the solution was allowed to stand in the same temperature for about 10 hrs.  The resultant 
methylamine-treated C3 or C4 was dialyzed against 20 mM KH2PO4, 2 mM EDTA and 
100 mM NaCl (pH 7.5) and concentrated. 
 
Primary and Secondary Antibody Binding Analysis: 
 The binding between a mono-specific anti-rVCP IgY 1o antibody (Washington 
Biotec, described in chapter 2) and rVCP was visualized using BiaEvaluation 3.0 
software system.  With rVCP amine coupled to a CM5 sensor chip, 40 ml of 10 nM 
purified mono-specific IgY was diluted in HBS, and injected with a flow rate of 10 
ml/min at 25oC.  The wash was delayed for 600 seconds.  The binding between a 2o anti-
chicken IgG (Vector Laboratories) and the 1o mono-specific anti-rVCP IgY was 
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visualized by the same method.  The 1o antibody was immobilized and the 2o antibody 
was used as the analyte. 
 
Simultaneous Heparin and Complement Binding: 
Hemolysis assays were performed as described in chapter 2, with a few 
modifications.  Serial dilutions of rVCP were mixed with various amounts of heparan 
sulfate (HS) (Sigma) before addition of serum and sensitized sheep red blood cells.  In 
assays using heparin sepharose, 10 ml of slurry, made from 1ml heparin sepharose 
(Pharmacia) and 1 ml water, was added to a series of rVCP dilutions and incubated for 30 
min on ice.  After the incubation, the samples were centrifuged and the supernatants 
tested for hemolysis activity.  The heparin sepharose beads were then washed with buffer 
before serum and sSRBCs were added.  After the assay was performed, reaction 
supernatants and the pelleted heparin sepharose beads were analyzed by SDS-PAGE for 
the presence of rVCP.  Supernatants were concentrated and the heparin beads 
resuspended in 600 mM NaCl, to strip off rVCP, and concentrated.  In all cases, both 
positive and negative controls received the same amount of heparin/heparan as all of the 
samples, in order to compensate for lysis inhibition caused by the heparin/heparan.
 
X-Ray Crystallography: 
 The procedures for the X-ray crystallography are described in chapter 3.  
Homology with MCP was obtained using a BLAST search and through comparison with 




Hemolysis Assay of Various Animal Sera: 
 The ability to block the activity of complement in various animal species was 
tested using the hemolysis assay.  The outcomes of experiments using VCP and rVCP are 
presented in figure 35.  VCP was found to behave very similarly to rVCP with most 
animal sera tested – see figure 36.  For rat sera, the results very strongly suggest that VCP 
has the greatest degree of activity against rat sera.  Melanie Scott, from the Department of 
Microbiology and Immunology, University of Louisville, obtained very similar results 
using mouse sera (personal communication).  In addition, VCP clearly possess s very 
limited activity against rabbit sera.  Most importantly, however, is the moderate activity 
that VCP exhibits against human sera.  This activity was also found to be identical in 
baboon (data not shown).  Therefore, VCP was found to have very strong activity against 
rat, moderate activity against human, and little activity against rabbit sera. 
 
Hemolysis Assay of rVCP Constructs: 
The activity of the purified recombinant protein constructs was tested using the 
hemolysis assay.  The results indicate that only the full-length protein inhibits lysis of 
sSRBCs - anywhere from 60 to 90% inhibition.  The rVCP segments showed no 
inhibition of lysis, suggesting that the whole protein is needed to block complement 
activation.  Although, the naturally runcated VCP homologue produced by monkeypox 
virus (MPV) (shown in figure 37), which lacks almost the entire fourth SCR (figures 20 
and 21), has been shown to inhibit hemolysis of sSRBCs.  This indicates that it is 







Figure 35.  Hemolysis assay of various animal sera. The ability of VCP and rVCP to 
block the activation of complement in various animal sera was tested.  A)  Silver- ained 
SDS-PAGE gel showing the concentration of VCP and rVCP used in the experiment. B)  
The ability of VCP, produced by the natural infection of mammalian cells, to inhibit the 
activation of complement in dog, horse, human, pig, rabbit, and rat sera was tested.  The 
results clearly indicate that VCP possesses the greatest activity against rat ser  (and pig) 
and the lowest activity against rabbit sera.  C)  The ability of rVCP, produced by the 
Pichia pastoris yeast expression system, to inhibit the activation of complement in dog, 
horse, human, pig, rabbit, and rat sera was tested.  Again, he results clearly indicate that 
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Figure 36.  Hemolysis assay of rat sera using VCP and rVCP. The activity of VCP 
and rVCP against complement activation using rat sera is shown – data taken from figure 
35.  The concentration of VCP and rVCP were estimated to be the same and the activity 
exhibited against rat serum complement is shown to also be the same.  This demonstrates 
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Figure 37.  Structure-function summary table of VCP, VCP homologues, and 
rVCPs.  VCP/IMP/SPICE, MPV homologue of VCP, recombinant VCP, and four 
recombinant segments of VCP are shown along with whether they are able to inhibit 
hemolysis of sSRBCs, bind C3b using SPR, or bind heparin using chromatography or 
SPR.  Also listed is the number of putative heparin binding sites found on the surface of 













Short Consensus Repeats (SCR)
---C--P--------------------YF-C---C--------C---G-W----A/P-C-
rVCP SCR (1,2) + 3
rVCP SCR (3,4) + 1
rVCP SCR (2,3) 1









MPV  Homolog of VCP + N/D 3


















Biacore Complement Binding: 
As a control to determine whether the Biacore instrument was functioning 
properly, rVCP was immobilized on a CM5 sensor chip by standard amine coupling.  10 
nM of purified mono-specific chicken anti-rVCP IgY, primary antibody, was injected 
across the surface of the sensor chip and very strong binding was observed, see figure 
38A.  In addition, this primary anti-rVCP antibody was immobilized to a CM5 sensor 
chip by standard amine coupling procedures.  10 nM of biotinylated goat anti-chicken 
IgG (Vector Laboratories), secondary antibody, was passed across the immobilized anti-
VCP antibody and extremely strong binding was observed, see figure 38B.   
To better understand the binding of rVCP to C3b, C3 was subjected to incomplete 
trypsin digestion, followed by amine coupling to a CM5 sensor chip.  Using 
recombinantly expressed rVCP and fragments of rVCP, the location for C3b binding on 
rVCP was mapped – see figure 39 for the protein reagents.  Interestingly, none of the 
recombinant proteins, representing nearly all combinations of two and three CCP 
modules found in rVCP, had the ability to bind.  As can be seen in figure 40, rVCP is the 
only protein found to bind C3b immobilized to the sensor chip.  By comparing the ligand 
channel response to the control channel response, it is very clear that all segments of 
rVCP are unable to bind the immobilized C3b.  In all cases, the analyte was injected at 
different concentrations to confirm the results.  The amplitude of binding was found to be 
low due to the incomplete cleavage of C3 to C3b, resulting in less immobilized C3b on 
the surface of the sensor chip.  In addition, the best line fitting was obtained using the 
heterologous ligand model, due to a mixed population of C3 and C3b (dat  not shown).  










Figure 38.  Control 1o and 2o antibody binding.  A)  Analysis of anti-VCP IgY (1o 
antibody) binding to VCP.  Subtracted ligand channel and control channel is shown.  B)  
Analysis of anti-chicken IgG (2o antibody) binding to anti-VCP IgY 1o antibody.  


















































1 5 0 0
2 3 0 0
3 1 0 0



















































































Figure 39.  Coomassie blue stained SDS-PAGE of C3, C3b, and rVCP constructs.  A) 
(1) Purified C3a and b chains before trypsinization. (2) C3b after trypsinization.  Note 
that incomplete trypsinization resulted in approximately 80% of the C3 being converted 
into C3b, leading to a mixed ligand.  B)  Purified rVCP and rVCP fragments 
(approximately 20 mg) are shown as: (1) rVCP; (2) rVCP~1,2; (3) rVCP~2,3; (4) 
































Figure 40.  C3b binding of rVCP fragments.  The ligand and control channel responses 
are shown for the binding between rVCP, or rVCP fragments, and C3b immobilized to 
the sensor chip.  Control channel response represents only bulk effects; no protein is 
immobilized.  All proteins were tested at different concentrations and with multiple C3b 




































































































































































































much stronger ability to interact with C3b.  This ability of rVCP to bind, at least weakly, 
to C3 is in agreement with data obtained earlier (Sahu et al., 1998).  In addition, the 
ability of rVCP to bind methylamine treated C3 or C4 (C3-MA, C4-MA) was tested.  
With rVCP immobilized to the sensor chip, 80 nM C3-MA or 80 nM C4-MA was 
injected and binding was recorded.  As can be seen in figure 41, rVCP binds strongly to 
both C3-MA and C4-MA.  This demonstrates the ability of rVCP to bind the activated 
forms of the third and fourth components of the complement system.  Taken together, 
these results suggest that VCP is the smallest unit required for binding C3b and 
facilitating factor I cofactor function, thus blocking activation of complement.
 
Simultaneous Heparin and Complement Binding: 
Since rVCP is an extended molecule, and given the probable location of a heparin 
binding site at the extreme C-terminal end and putative regions involved in binding 
complement spread throughout the remainder of this extended molecule, it might be 
expected that C3b/C4b interactions and heparin binding are not mutually exclusive.  
Participation of common residues in heparin binding and complement inhibition in rVCP 
is not supported by the observation that rVCP is able to inhibit hemolysis of sSRBCs and 
bind heparin simultaneously (figure 42 and 43).  Addition of varying amounts of soluble 
heparin (figure 42) or heparan sulfate to a hemolysis assay containing rVCP had no effect 
on the protein’s ability to inhibit hemolysis (figure 43a).  The hemolysis inhibition seen 
in the cases when only heparin or heparan sulfate is present in high concentrations is 
likely due to its slight ability to bind C3/C4, thus inhibiting hemolysis on its own.  A 










Figure 41.  rVCP binding to activated C3 and C4.  rVCP was immobilized to a CM5 
sensor chip.  A)  80 nM C3-MA was injected and binding was observed.  B)  80 nM C4-
MA was injected and binding was observed.  In both cases, the results are shown as the 






















































































































































































































































Figure 42.  Simultaneous heparin biding and hemolysis inhibition by rVCP.  Results 
of hemolysis assays performed on serially diluted samples of rVCP each containing 0.01, 
0.03, 0.05 Units of soluble heparin (filled squares, filled triangles and open circles, 
respectively) are compared to the sample without heparin (control, shown as filled 
diamonds). The degree of hemolysis inhibition caused by heparin alone is shown as 







































rVCP + 0.01 Units Heparin 
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Figure 43.  Simultaneous heparan sulfate binding and hemolysis inhibition by rVCP. 
a)  Results of hemolysis assays performed on serially diluted samples of rVCP each 
containing 0.01, 0.1, 1.0 mg of soluble heparan sulfate with an average molecular weight 
of 7,500 (filled circles, open triangles and open circles, respectively) are compared to the 
sample without heparan sulfate (control, shown as filled squares). The degree of 
hemolysis inhibition caused by heparan sulfate alone is shown as asterisks.  b)  The 
results of a hemolysis assay performed on rVCP bound to heparin sepharose beads are 
compared to the sample without heparin sepharose (control shown as squares). The 
results of a hemolysis assay performed on material that did not bind to the heparin 
sepharose beads (supernatant) are shown as triangles.  c)  Coomassie blue stained SDS-
PAGE shows (1) 3.0mg of rVCP, (2) rVCP that was bound to the heparin sepharose beads 
after the hemolysis assay shown above, and (3) rVCP that was contained within the 
supernatants after the hemolysis assay shown above.  The material in lane 3 probably 
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hemolysis assay, revealed that rVCP can still inhibit complement activation while 
remaining bound to insoluble heparin, although to a much lesser extent (figure 43b).  The 
reaction mixture was further examined after the assay was performed in order to 
determine whether rVCP inhibits hemolysis while bound to heparin, or is pulled off by 
C3 and C4 during the reaction.  Figure 43c clearly demonstrates that the hemolysis-
inhibiting activity could be attributed to rVCP that remained bound to the heparin 
sepharose beads and was not detached from the beads in the process.  
To confirm the above results using SPR technology, heparin was immobilized to a 
CM5 sensor chip, 80 nM of rVCP was injected, and binding was observed.  Shortly after 
the injection of rVCP stopped, 100 nM of C3-MA or C4-MA was injected to test if 
binding to rVCP could occur.  As can be seen in figure 44, rVCP is able to bind 
complement while remaining bound to heparin immobilized to the sensor chip.  These 
results demonstrate the ability of rVCP to perform both functions at once.  With both C3-
MA and C4-MA, strong binding was observed, indicating that rVCP is able to 
simultaneously bind both heparin, via its C-terminus, and complement, using the rest of 
its exposed surface.  Using the data obtained in the above experiments, along with 
sequence homology data described below, a model for heparin binding and complement 
component binding was developed and shown in figure 45.
 
X-Ray Crystal Structure Homology: 
Putative sites on rVCP, which are suspected to interact with C3b/C4b, are 
suggested by comparison with other complement control proteins for which extensive 






Figure 44.  Simultaneous binding to heparin and complement by rVCP.  A)  Analysis 
of rVCP binding to heparin, followed by binding of methylated C3 to rVCP.  Results are 
represented by subtraction of the ligand channel and the control channel.  The experiment 
was repeated to confirm results.  B)  Analysis of rVCP binding to heparin, followed by 
binding of methylated C4 to rVCP.  Results are represented by subtraction of the ligand 













































































Figure 45.  Model for simultaneous heparin and complement binding.  Spatial 
relation of C3b/C4b binding and heparin binding in rVCP is shown.  The positive patch 
between modules 1 and 2 is shown with contributing basic residues labeled.  Side chains 
of residues of putative importance for C3b and C4b binding by rVCP are shown as 
spheres on a a-carbon trace (light blue) of rVCP.  Color-coding is the same as in figure 
46A.  Heparin hexasacchride (carbon, brown; oxygen, red; nitrogen, blue and sulfur, 
yellow) derived from the complex with acidic FGF is also shown below with the four 










mutagenesis and epitope mapping of MCP is one of the most comprehensive (Liszewski 
et al., 2000).  An alanine-scan of MCP from residues 94-103 (figure 46) proves to be 
particularly useful.  The mutations Y97A, Y98A, L99A and E103A each abolished 
cofactor activity for C4b but not binding of C4b, while N94A, E95A, G96A and E102A 
decreased both C4b binding and cofactor activity, and C3b binding was affected only by 
E102A.  The equivalent residues in VCP, also 94-103, are close in sequence (figure 46) 
and lie in module 2 near the interface with module 3.  Thus, by homology with the rVCP 
structure, it is likely that residues 94, 95, 8, 102 and 103 of MCP are involved directly, 
and N94, E95 and E102 directly contact C4b.  It is reasonable to propose that N94, H98 
and E102 (figures 45 and 46, red) play a similar role in rVCP.  The same study 
(Liszewski et al., 2000) determined that residues in the region 191-196 of MCP were 
very important for C3b-binding.  Substitutions of K193, R195 and F196 by alanine 
interfered with both C3b-binding and cofactor activity for C3b.  In VCP, the equivalent 
region is 184-189 and lies at the C-t rminus of module 3 with K186 and H189 exposed.  
Since K193 and F196 of MCP contact C3b, it is reasonable to propose that K186 and 
H189 of VCP (figures 45 and 46, magenta) play a similar role.  Finally, in MCP, residues 
in the region 206-212, G207A, F208A, K210A, K211A and F212A are involved in C3b-
binding since the mutations each significantly reduce affinity for C3b, but not C4b, F208 
and K210 (figure 45, yellow) are likely to be contact points for C3b.  In rVCP these 
residues lie within the sequence 199-205 of module 4 with F201 and R203 exposed at the 
surface.  Although it is not unreasonable to invoke F201 and R203 (figures 45 and 46, 
yellow) as C3b-binding residues in rVCP, most of this module, including residues 208 
166 



























Figure 46.  Putative C3/C4 binding residues in rVCP.  A)  Alignment of the sequences 
of rVCP and MCP in regions identified as potential C3b/C4b binding sites are shown.  
The three sets of residues in MCP shown to decrease C4b binding (red), C3b binding 
(magenta and yellow) when mutated.  rVCP residues in the three positions corresponding 
to those in MCP, which appear to be accessible for complement binding, are also shown 
in matching colors.  B) Putative C3b and C4b binding regions of VCP are shown in 
alignment with a well-characterized C3b/C4b binding site on human MCP CCP 1 (shown 
outlined), along with other complement regulating proteins from different species.  Noted 
in red are important residues, shown to be necessary for C3b binding by MCP.  Colored 
green are highly conserved cysteine residues.  The locations of each site are shown for 
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Proposed C4b binding domain of human MCP (outlined) is compared with similar sequences of other complement 





Results obtained by testing VCP's ability to inhibit the activation of complement, 
using various animal sera, demonstrate a significant difference in specificity.  VCP was 
found to have very limited activity against rabbit complement, possessing 250 fold less 
activity than it has against rat sera (and possibly pig).  It was also shown to possess 
moderate activity against human and baboon (data not shown) sera, having 4 to8 fold 
less activity than against rat sera.  Clearly, VCP shows the greatest activity against rat 
complement.  This study does not suggest the reason for this significant difference in 
specificity.  VCP may have a greater affinity for rat C3b/C4b, or its cofactor activity may 
be enhanced.  The mechanism by which VCP blocks the activation of rat complement 
greater than human complement can be investigated further in the future by using Biacore 
(SPR) binding analysis.  The affinity and kinetics of VCP with human or rat C3b/C4b can 
be studied to help answer this question.  The idea that VCP may be specific for rat, 
suggesting that a rat/rodent host coevolved with vaccinia virus, is further strengthened by 
studies done by Ariella Rosengard, University of Pennsylvania, on the variola virus 
homologue of VCP she termed SPICE, for smallpox inhibitor of complement enzymes.  
These studies suggest that the variola virus homologue inhibits complement activation of 
human sera fourfold more effectively than VCP.  This suggests that SPICE is more 
specific for human complement due to it coevolving in a human host.  This hypothesis is 
quite interesting considering that the difference between VCP and SPICE is only twelve 
residues. 
In an attempt to map the location of C3b/C4b binding and cofactor activity on 
rVCP, various truncated proteins consisting of nearly all combinations of 2 and 3 CCP 
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module fragments [CCP modules 1 and 2 (rVCP~1,2), 2 and 3 (rVCP~2,3), 3 and 4 
(rVCP~3,4), and 2-4 (rVCP~2,3,4)] were tested in the hemolysis assa .  The results 
suggest that only full-length rVCP is able to inhibit complement activation in the 
hemolysis assay.  To confirm these results using surface plasmon resonance (SPR), the 
recombinant truncated versions of rVCP were used to map the regions involved in C3b 
binding.  Only full-length rVCP was able to bind C3b.  These results help to confirm 
previous data showing that none of the mutant proteins were able to inhibit complement-
mediated lysis of sSRBCs in the hemolysis assay.  The results of both studies suggest that 
VCP is the smallest functional unit, and, therefore, most of the exposed surface is 
required for binding complement, cofactor activity, and ultimately blocking complement 
activation.  This was also suggested by previously published studie  using truncated 
membrane bound versions of rVCP (Rosengard et al., 1999).  With the origin of VCP in 
mind, it is easy to understand why this protein is the smallest functional unit.  The size of 
the vaccinia virus genome, though it is quite large for a virus, is very limited in size.  
VCP was most likely pirated from the host, possibly as C4b-BP or MCP, and reduced to 
its minimal functional unit to conserve valuable genomic space.  VCP does not represent 
the smallest CCP known to bind C3b, only the smallest CCP able to bind C3b and inhibit 
complement activation.  Surface plasmon resonance studies of fH have shown that a two 
CCP module fragment, SCR 19-20, was able to bind C3b (Jokiranta et al., 2001).  
Although this small fragment was able to bind both C3b and C3d, it does not retain 
cofactor or decay accelerating activity (personal communication).  The notion that a two 
CCP module fragment of fH is required to bind portions of C3, while all four CCPs of 
VCP are required, suggests that differing mechanisms of action are involved.  The idea 
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that VCP and fH may have different mechanisms of action to inhibit complement 
activation has been suggested by previous data (Sahu et al., 1998). 
In order to investigate the hypothesis that VCP may inhibit complement activation 
while remaining bound to heparin/heparan sulfate, several experiments were employed.  
Various concentrations of heparan sulfate was added to a serially diluted sample of rVCP 
and then tested using the hemolysis assay.  The ability of rVCP to inhibit complement 
activation was unchanged.  This experiment was repeated using various concentrations of 
heparin with the same results.  In order to be sure that rVCP was binding and remaining 
bound to heparin while being tested in the hemolysis assay, heparin sepharose beads were 
also used.  rVCP bound to heparin sepharose beads was tested in various concentrations 
in the hemolysis assay.  The results obtained by all experiments suggest that VCP is able 
to inhibit complement activation while remaining bound to heparin/heparan sulfate.  
These results were later confirmed using SPR analysis.  With rVCP immobilized to the 
sensor chip, C3-MA or C4-MA was injected and binding between the proteins was 
confirmed.  Next, with heparin immobilized to the sensor chip, rVCP was injected and 
allowed to bind before C3-MA or C4-MA was injected.  Clear binding was observed 
between rVCP bound to heparin on the surface of the sensor chip and both C3-MA and 
C4-MA.  These experiments imply that the protein, in addition to its ability to strongly 
inhibit complement activation while in soluble form, may also inhibit complement while 
bound to heparan sulfate proteoglycans lining the endothelial cell layer.  rVCP would 
therefore be able to protect the infected host cell, and neighboring cells, from not only 
host complement attack, but also antibody binding and cell death caused by NK cells.  
The ability of rVCP to perform both functions at once has significant implications in our 
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understanding of viral habitat formation.  VCP may act in two states, the cell bound state, 
where it utilizes heparan sulfate to tether itself to the cell surface, and the soluble state, 
where it is free to diffuse into the surrounding local tissue.  Therefore, VCP acting in the 
cell bound state may not only be involved in protecting the infected cell from the 
molecular and cellular interactions of the immune system, but also cell surface activation 
of complement.  In addition, the soluble form of VCP may be able to diffuse locally, 
blocking complement activation in the surrounding tissue, and preventing the release of 
chemoattractant compounds.  All together, the two states of VCP may create a habitat 
better suited for local spread of viral progeny and growth. 
 With the X-ray crystal structure of rVCP in hand (see chapter 5), the data 
obtained in the above experiments, as well as homology studies with other well 
characterized complement regulatory proteins, was used to map the locations of the 
complement binding regions and project them onto the structure of rVCP.  MCP, whose 
residues involved in C3b/C4b binding are well mapped, aligns very closely with rVCP.  
Therefore, it was used to accurately predict the residues on rVCP involved in C3b/C4b 
binding without requiring alanine-sca ning mutagenisis of VCP.  Taken together, the 
above experiments and homology data suggest that most, if not all, of the surface of 
rVCP is needed to bind C3b/C4b, as well as cofactor activity for their cleavage by factor 
I.  VCP, made up of 4 CCP modules, would represent the smallest functional unit 
required for binding and inhibiting complement activation.  This knowledge could be 
important in the bioengineering of new therapeutic proteins capable of blocking 









VCP STRUCTURE AND STABILITY 
 
Introduction to CCP Structure 
This chapter contains material adapted from the following publication and manuscript: 
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata 
C.M., and Kotwal G.J.  Crystal structure of a complement control protein that 
regulates both pathways of complement activation and binds heparan sulfate 
proteoglycans. Cell. Jan. 26, 104:301-11, 2001. 
Smith S.A., Krishnasamy G., Murthy K.H., Cooper A., Bromek K., Barlow P.N., and 
Kotwal G.J.  Vaccinia virus complement control protein is monomeric, and retains 
structural and functional integrity after exposure to adverse conditions.  Bio him. 
Biophys. Acta., In press, 2002. 
As previously mentioned in chapter 4, VCP exhibits sequence and functional 
similarity to the mammalian complement regulators, such as, factor H (fH), membrane 
cofactor protein (MCP), decay-a celerating factor (DAF), complement receptor type one 
(CR1), and complement 4b binding protein (C4b-BP).  VCP is most similar in terms of 
sequence to the N-terminus of the a-chain of C4b-BP, sharing 24, 33, 35 and 29 identical 
or conservatively replaced residues, out of about 60, in modules 1, 2, 3 and 4, 
respectively (figure 32).  VCP is the smallest, only 244 amino acids, and least complex of 
the complement control proteins, with no glycosylation or transmembrane domains, 
making it an excellent candidate for structural analysis.  Structures of fragments of MCP 
with, two out of four CCP modules (Casasnovas et al., 1999) and fH with, one (Barlow et 
al., 1991; Barlow et al., 1992) or two (Barlow et al., 1993) out of 20 CCP modules have 
been published.  The NMR structures of two pairs of modules of rVCP, modules 3 and 4 
(rVCP~3,4) (Wiles et al., 1997) or 2 and 3 (rVCP~2,3) (Henderson et al., 2001), have 
also been published.  None of these fragments shows complement inhibition activity or 
factor I cofactor activity.  The structure of b2-glycoprotein I (b2-GPI or apolipoprotein-
H), a molecule with four CCP modules, has been reported, however, b2-GPI is not a 
complement inhibitor (Bouma et al., 1999; Schwarzenbacher et al., 1999).  Thus, to date 
there has been no three-dim nsional structure available of a protein or protein fragment 
that is able to regulate complement activation.  
In all published structures of CCP modules, each folds into a compact 6-8 
stranded b-structure that has a conformation similar to that originally observed in the 
structure of fH16 (Barlow et al., 1991).  Between each module are "linkers  of varying 
lengths, which connect one module to another.  The relative orientations of neighboring 
modules seem to differ from one module-pair to another quite significantly and in a 
manner that is not predictable from differences in primary sequences (Barlow et al., 
1993; Casasnovas et al., 1999; Henderson et al., 2001; Gaboriaud et al., 2000).  Despite 
this, bi-modular orientation preferences have been used in building structures containing 
three or more CCPs.  Such models have been used to fulfill the need to provide a three-
dimensional context for functional and mutational studies of RCA proteins.  Examples 
include models for the structures of rVCP and MCP (Liszewski et al., 2000).  Similarly, 
homology modeling has been used to develop C3dg-binding bi-modular fragments of 
CR2 based on those identified on fH (Molina et al., 1995; Nagar et al., 1998; Prodinger et 
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al., 1998).  However, without the structure of a functional stretch of CCP modules, such 
models are only speculative. 
The crystal structure of rVCP that is fully active both in complement inhibition 
and in binding heparin (in soluble form) was resolved in two different crystal forms by 
Dr. Krishna Murthy from the Center for Biophysical Science and Engineering, University 
of Alabama at Birmingham.  This structure, for the first time, offers a picture of the three-
dimensional positioning of all the CCP domains necessary for a well-characterized 
complement inhibitory activity.  Unlike studies of CCP protein fragments, this structure 
is not susceptible to the criticism that deletion of modules might alter orientations at 
inter-modular junctions.  The high level of sequence similarity between VCP and the 
mammalian RCAs, as well as complement receptor type 2 (CR2) means that the rVCP 
structure will provide the richest and most reliable source of information yet.  This 
information may be invaluable for modeling ther functional stretches of three to four 
CCPs using homology, or for the design and interpretation of mutagenesis experiments 
aimed at understanding the structural basis of complement control.  The structure of a 
fully active, complete four-d main rVCP presented here will significantly contribute to 
our understanding of viral and mammalian complement regulatory proteins, and 
ultimately many complement- diated diseases. 
Knowledge of the oligomerization state of VCP and its stability are crucial for 
understanding the durability of the evasion of host response mediated by VCP.  
Understanding the stability of VCP is also important for administration, shipping, 
storage, and dosage purposes.  rVCP has now been shown, using gel filtration, to be a 
monomeric protein in solution.  In order to test its thermal stability, the protein was 
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examined by NMR over a range of temperatures and analyzed by differential scanning 
calorimetry.  These studies demonstrate that the 3D structure of rVCP is robust and able 
to tolerate extreme temperatures.  It was very important, however, to assess the extent to 
which functional activity is able to withstand high temperatures.  Therefore, rVCP was 
subjected to a variety of harsh conditions, after which the specific activity was measured 
to determine whether the protein had retained its functional conformation.  These 
included exposure to multiple freeze-thawing events and strong acids.  rVCP was found 
to be functionally stable after exposure to severe conditions, remaining active ven after 
boiling.  The shelf-life of rVCP was also investigated and the protein was found to retain 














Materials and Methods 
Production and Purification of rVCP: 
 Samples of rVCP were produced using the Pichia pastoris yeast expression 
system (Invitrogen) and purified to greater than 95% using heparin affinity 
chromatography (Pharmacia), described in chapter 2).
 
X-Ray Crystal Structure of rVCP: 
 The procedures for X-ray crystallography are describ d in chapter 3.  
 
Shelf-life: 
 Aliquots of 50 ml of rVCP (2.75 mg/ml) were placed in 0.65 ml microcentrifuge 
tubes and stored at room temperature.  At various time points, 2 ml (5.5 mg) samples were 
tested for complement inhibition in the hemolysis assay.  The experiment was performed 
on aliquots of a single rVCP sample. 
 
Freeze-thawing Sensitivity: 
 A 0.5 ml sample of rVCP (2.75 mg/ml) was repeatedly frozen to –20oC for 30 min 
and then rapidly thawed to room temperature.  After various numbers of freeze-thaw 
events, 8 ml was removed, serially diluted, and its activity tested in the hemolysis assay.  






 Aliquots of 50 ml of rVCP (2.75 mg/ml) were placed in 0.65 ml microcentrifuge 
tubes and incubated in a heat block at various temperatures for 30 min.  After incubation, 
4 ml (11 mg) was taken from the sample and tested in the hemolysis assay.  The 
experiment was performed on aliquots of a single rVCP sample. 
 
pH Sensitivity: 
 Several 100 ml aliquots of rVCP (3.0 mg/ml) were sealed in dialysis tubing and 
placed into flasks containing 150 ml of water adjusted to various pHs.  After vigorous 
stirring for 30 min, the dialysis tubing containing the sample of rVCP was removed and 
placed into a beaker with 800 ml of water, to equilibrate the sample to a neutral pH.  
After vigorous stirring for 1 h, the sample was removed from the dialysis tubing and 4 ml 
(12 mg) was then tested by hemolysis assay.  Several sentinel samples were removed 
early from the dialysis tubing and tested using litmus paper to ensure that the desired pH 
was achieved.  The experiment was performed on aliquots of a single rVCP sample. 
 
Hemolysis Assay: 
The hemolysis assay was performed as described in chapter 2.
 
Gel Filtration: 
 A 50 x 0.7 cm glass column was packed with 19 ml Superdex 75 (Pharmacia) and 
equilibrated with either water or 100 mM NaCl.  Using blue dextran (Sigma), the column 
exclusion volume was determined.  The positions of various gel filtration standards (4 mg 
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each) (Sigma) were then determined individually by collecting numerous 100 ml 
fractions, visualized by SDS-PAGE stained with coomassie blue, and quantitated by 
densitometry (AlphaImager 2000 software system).  The position of rVCP (4 mg) was 
then determined, using the same procedure as the markers, and the densitometric readings 
superimposed with those of the markers.  The whole process was performed in water and 
in 100 mM NaCl to prevent unwanted interactions with the column. 
 
Nuclear Magnetic Resonance (NMR): 
NMR measurements were performed by Paul Barlow from the Edinburgh Center 
for Protein Technology, University of Edinburgh, Edinburgh, UK, on a Varian (Palo Alto, 
CA, U.S.A.) Inova NMR spectrometer operating at 600 MHz (proton frequency) ina 5 
mm triple-resonance pulsed field gradient probe.  The 1H spectra were acquired using a 
pulse sequence with pulse field gradient water suppression using 0.3 mM sample (Hwang 
and Shaka, 1998).  Each of the spectra was acquired for 40 min at a range of temperatures 
from 37°C to 53°C; an additional spectrum was measured at 37°C after the sample had 
been heated to 90°C, as in the calorimetry measurement.  Data were acquired, processed 
and plotted using VNMR (Varian VNMR 6.1, Varian Associates, Inc.). 
 
Differential Scanning Calorimetry (DSC): 
DSC studies were conducted by Paul Barlow from the Edinburgh Center for 
Protein Technology, University of Edinburgh, Edinburgh, UK, on a VP-DSC differential 
scanning calorimeter (Microcal, Northampton, MA, U.S.A.) with the assistance of 
Margaret Nutley (University of Glasgow, Glasgow, Scotland, U.K.).  The cell volume 
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was 1.5 ml, the rate of heating was 1°C per min, and excess pressure was kept equal to 80 
bar (1 bar = 105 Pa).  Samples were equilibrated at 10°C and then heated to 90°C.  The 
partial molar heat capacity and melting curve were analyzed using standard procedures 
(Privalov and Potekhin, 1986).  The collected data were processed using the software 
ORIGIN.2 (Microcal).  The protein concentration was 0.016 mM (0.46 mg/ml; molecular 
mass 28.6 x 103 g/mol) as determined by measurements of absorbance at 280 nm 

















X-Ray Crystal Structure of rVCP: 
In both the crystal forms of rVCP that were analyzed, the molecule has an 
elongated structure with no intramolecular contacts between non-sequential modules – 
see figure 47.  Packing of the two molecules (A and B) in the asymmetric unit of form I 
crystals (pH 7.5) is head-to-tail, with CCP module 4 of each molecule making contacts 
with module 1 of the other.  In form II crystals (pH 8.3) the three molecules (A, B and C) 
in the asymmetric unit associate such that modules 3 and 4 of B interact with modules 1 
and 2 of both A and C.  Packing interactions within the asymmetric units of the two 
crystal forms do not show evidence of specific oligomerization of rVCP m lecules. 
All five crystallographically independent molecules in the two structures are 
highly similar in structure as reflected in root mean square (rms) deviations between Ca 
atoms in the b-strands of molecule A and those of B, C, D and E being 0.28, 0.67, 6  
and 0.69 Å, respectively – figure 48.  At the module level, the originally observed 6 b-
strand topology is closely resembled by all CCP modules of both copies of rVCP within 
the asymmetric unit of form I crystals (Barlow et al., 1991; Barlow et al., 1992; Barlow 
et al., 1993).  Module 1 is remarkable for its prominent "hypervariable" loop of 10 
residues, K14-A23, compared to 2, 4 and 5 residues in modules 2, 3 and 4, respectively, 
projecting from rVCP near the N-terminal tip of the molecule.  Also noteworthy in 
module 1 is an unusual insertion, Q42, K43, that forms a prominent b-bulge close to the 
interface with module 2.  In addition, module 2 has a 5 residue insertion, L109-S114, that 










Figure 47.  Packing in form I and form II crystals.  A)  The three molecules in the 
asymmetric unit of form II crystals are shown with the domains color-coded as in panel 
B.  Molecules A, B and C are labeled.  Side chains of residues making polar interactions 
at intermolecular interfaces are shown.  B)  The two molecules in the asymmetric unit of 
form I crystals are shown.  Domains 1-4 are colored red, blue, magenta and cyan 
respectively.  Side chains of residues that form polar interactions at the two ends of the 



















Figure 48.  Five independent molecules are similar.  a)  Stereo pair of superposed Ca 
traces of all five crystallographically independent molecules in the two crystal forms are 
shown.  Molecule A in form I crystals is colored red, molecule B blue, and molecul s C, 
D and E in form II crystals are colored magenta, cyan and yellow respectively.  CCP 
domains are labeled mod1- od4.  b) A Ca trace of molecule A from Form I crystals is 
shown in magenta in the same orientation as in panel a.  Every 10th Ca has been colored 










VCP is a Monomer in Solution: 
In order to shed light on how VCP functions in vivo to maintain a habitat 
favorable to the virus, experiments were performed to determine whether it exists as a 
monomer or an oligomer in solution.  Initial gel filtration experiments did not 
immediately determine whether rVCP was a monomer or multimer.  As can be seen in 
figure 49a, one large peak and one small peak (possibly due to non-specific attachment to 
column matrix) can be seen in the rVCP densitometric profile.  The presence of two 
distinct peaks is even more evident for the hemolysis activity of the fractions – igure 
49b.  However, when gel filtration was performed on marker proteins with and without 
NaCl, rVCP was found to exist solely as a monomer in solution - see figure 50a and b.  In 
both cases, rVCP emerged from the column in approximately the same fractions as 
carbonic anhydrase, a 29 kDa molecular weight marker protein.  No sign of rVCP was 
found in the 60 or 90 kDa range, where it may have emerged if it had been a dimer or 
trimer. 
 
Shelf-life and Freeze-thawing Tolerance: 
In order to test the shelf-lif  of rVCP, several 50 ml aliquots (2.75 mg/ml) of rVCP 
(in 18 MW ultrapure water) were allowed to sit at room temperature for various periods 
of time prior to assay of hemolysis inhibiting activity.  As shown in figure 51b, rVCP 
continued to remain fully active after 30 days, the longest time pint tes ed. This 
demonstrates that rVCP in solution has a long shelf- ife. In addition, rVCP was tested to 
determine its ability to resist irreversible denaturation caused by multiple freeze-thawing 









Figure 49.  Gel filtration chromatography of rVCP.  A) Gel filtration fractions 
containing rVCP (fractions 67-103) are visualized by SDS-PAGE and coomassie blue 
staining.  Densitometry shows the existence of at least two peaks.  Gel filtration 
chromatography was performed in water.  B)  Each fraction was tested for hemolysis 
inhibiting activity in the hemolysis assay.  Due to the sensitivity of this assay, the peaks 













































































































































































































































Figure 50.  Gel filtration chromatography of rVCP and marker proteins.  a)  
Overlaid densitometric results of gel filtrations conducted on rVCP and marker proteins 
ranging from 200 kDa to 12.4 kDa.  Column and samples were equilibrated in water.  
The second rVCP peak observed in figure 49 does not appear on this plot (smaller than 
12 kDa) and is most likely an artifact.  b)  Overlaid desitometric results of gel filtrations 
conducted on rVCP and marker proteins ranging from 66 kDa to 12.4 kDa.  Column and 
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Figure 51.  rVCP tolerance to extreme temperature and shelf-life.  a)  Hemolysis 
inhibiting activity of 11 mg rVCP taken from samples that were incubated for 30 min at 
temperatures ranging from 37 to 115oC.  b)  Hemolysis inhibiting activity of 5.5 mg rVCP 
taken from samples that were incubated at room temperature (~25oC) for 6 h, 1 h, 24 h, 







































5.5   g rVCPm
b)
rVCP Tolerence to Temperature












37 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115















11   g rVCPm
a)










Figure 52.  rVCP tolerance to freeze-thawing and pH.  a)  Hemolysis inhibiting 
activity of serially diluted rVCP (2.75 mg/ml) that has been freeze-thawed 2, 5, 10, 25, or 
50 times.  Also shown is serially diluted rVCP (2.75 mg/ml) that was lyophilized and 
resuspended to the original concentration.  b)  Hemolysis inhibiting activity of 12 mg 
rVCP taken from samples that were adjusted to a wide range of pH for 30 min, and 
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shows that rVCP is completely tolerant to freeze- hawing, maintaining complete activity 
after fifty events.  A slight enhancement in activity appears when rVCP was tested after 
fifty freeze-thawing events.  This is most likely due to evaporation taking place over the 
course of the experiment.  As also shown in figure 52a, rVCP was found to be completely 
tolerant to lyophilization.  The ability of this novel immunomodulating protein to tolerate 
freeze-thawing, lyophilization, and long periods of time at room temperature, will prove 
very valuable for shipping and storage purposes.
 
Temperature and pH Tolerance: 
To assess the extent to which functional activity is to withstand high 
temperatures, 50 ml samples of protein in water (2.75 mg/ml) were incubated at various 
temperatures for 30 minutes prior to testing of their activity (at 37oC) using the hemolysis 
assay.  As can be seen in figure 51a, rVCP retains most of its activity after exposure to 
temperatures up to the boiling point of water.  At 100oC only a slight white precipitate 
was evident.  At 110oC, however, most of the protein was irreversibly denatured and was 
seen to form a white precipitate.  It may be possible that sample dilution during assaying 
allowed for a small amount of aggregated protein to re-diss lve and regain functional 
activity.  Nonetheless, the results of these experiments reveal the high structural and 
functional stability of rVCP. 
To assess the ability of rVCP to tolerate extremes in pH, 100 ml aliquots of 
protein were sealed in dialysis tubing and the pH of the sample changed.  After returning 
the pH of the sample to near neutrality, the hemolysis inhibiting activity of the protein 
was tested, see figure 52b.  Recombinant VCP was able to withstand exposure to a pH 
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well below zero, at which point the dialysis tubing was destroyed (>5.0N HCl).  rVCP, 
however, was not quite as stable under basic conditions, becoming irreversibly denatured 
and forming a heavy white precipitate at pH 12.5.  The extreme acid stability of rVCP 
may be very important for administration purposes.  Since rVCP should easily be able to 
tolerate the acidity of the stomach, oral administration of this complement inhibitor may 
be possible. 
 
Nuclear Magnetic Resonance (NMR) and Differential Scanning Calorimetry (DSC) 
Studies: 
The thermal stability of rVCP was studied using differential scanning calorimetry.  
Figure 53a shows the calorimetric profile, which can be fitted with three, two-state, fully
reversible transitions.  That the curve may be fitted in this way implies that van't Hoff and 
calorimetric enthalpies are equal; attempts at fitting without this restraint produced an 
order of magnitude difference between the enthalpies, which could not be explained by 
any reasonable transitio  model (Privalov and Potekhin, 1986).  The three fitted 
transitions are characterized by midpoint temperature, Tm = 58.3 ± 0.07°C with enthalpy, 
DH, = 71.0 ± 0.7 kCal mol-1, Tm = 62.68 ± 0.09°C with DH = 84.2 ± 0.6 kCal mol-1 and 
Tm = 68.46 ± 0.10°C with DH = 62.4e ± 7.1 kCal mol-1.  As the protein consists of four 
modules it is possible that more transitions could be invoked, however these three were 
sufficient to represent the experimental profile.  We are therefore unable to assign 
discrete transitions to individual modules.  The calorimetry indicates that the thermal 
unfolding is to a large extent reversible as may be judged from the fitting but also from 










Figure 53.  Differential scanning calorimetry profiles.  A) The experimental data points 
after baseline subtraction are shown as black dots.  Solid thin line indicates reconstructed 
profile using three fitted transitions represented as dotted lines.  B) The experimental data 






































Temperature  / 
o
C

































enthalpy it is consistent with most of the protein molecules refolding and just a small 
proportion of the population not reaching the lowest energy state.  The current results 
may be compared with previous data reported for rVCP~2,3, i.e. a protein fragment 
containing just the two central modules of VCP (Kirkitadze t al., 1999).  The 
calorimetric profile of rVCP~2,3 showed a Tm = 57°C and DH = 86 kCal mol-1.  The 
curve for rVCP~2,3 had a distinct shoulder and could not be fitted to one or more two-
state reversible transitions. 
To further explore structural properties of this protein during heating and cooling, 
a series of 1D 1H NMR spectra was acquired over a range of temperatures.  These show 
that no significant changes appear between the physiological temperature of 37°C and the 
elevated temperature of 53°C (the maximum that could safely be achieved in the NMR 
probe) - compare figure 54a and b.  In contrast, NMR data obtained previously on 
rVCP~2,3 showed that module 2 melted in the range 45-55°C, although module 3 was 
more stable.  The NMR data for rVCP~2,3 were consistent with its calorimetric profile.  
Clearly, module 2 is more stable in the context of full-length rVCP than in the 2,3 
fragment.  To investigate the structural properties of the protein after the reversible 
unfolding step, a spectrum at 37°C after heating to 90°C was acquired.  The full 1H 
spectrum is shown as an inset in figure 54c.  All of the spectral lines in the methyl region 
of the 1H NMR spectrum, which are sensitive to 3D structural integrity of the protein, are 













Figure 54.  NMR spectroscopy.  a) and b) 1H NMR spectra of VCP at 37°C and 53°C 
respectively.  c) Overlaid methyl regions of 1H NMR spectra of VCP as quired before, 
and after heating to 90°C showing evidence of folded protein.  Inset shows entire 1H 














As suggested by the root mean square (rms) d viations between Ca atoms in the 
b-strands shown in figure 48, the relative orientations of each of the four modules of 
rVCP are remarkably similar among all five molecules in the two crystal forms (2 in I 
and 3 in II) despite their being crystallographically independent.  This suggests that this 
conformation is strongly preferred of rVCP in solution under the conditions used to grow 
the crystals, and that packing interactions are not responsible for the conformation 
observed.  The "tilt" angles (i.e. the rotation required to align the z-axis of the inertia 
tensor of each module with its neighbor) between the long axes of the modules are 600, 
630 and 990 at the 1-2, 2-3 and 3-4 module junctions, respectively.  However, the tilts 
between adjacent pairs of modules are in almost diametrically opposite directions, so that 
module 3 is tilted by only 10° relative to module 1 and module 4 is tilted by 36° relative 
to module 2, forming a "W" appearance.  Thus, the molecule has an extended and 
approximately linear part consisting of modules 1-3, then a kink between modules 1-3 
and module 4.  Interactions at the 1-2 interface in rVCP are between mostly hydrophilic 
residues, those at the 2-3 interface are mixed, and those at the 3-4 in erface are 
predominantly hydrophobic.   
Figure 55a superimposes the structures of VCP and MCP 1,2 (Casasnovas et al., 
1999).  The arrangement of the N-terminal modules of MCP differs from that found in 
rVCP, providing another example of the significant variation in inter-m dular 
orientations among this famly of proteins.  Knowing the crystal structure of rVCP, 
comparisons between the structure of intact rVCP and the solution structures of rVCP 








Figure 55.  Diverse orientations of modules in CCP containing proteins.   The four 
modules of rVCP are shown in red and labeled.  a)  The first CCP module of MCP (gold) 
is superimposed over module 1 of rVCP using the b sheet residues in each to calculate 
the transformation.  Similarly, module 2 of the solution structure of rVCP~2,3 (rose) is 
superimposed over that of VCP2 and module 3 of the solution structure of VCP3,4 
(purple) superimposed over module 3 of rVCP.  b)  The first CCP module of rVCP is 
superimposed over module 1 of b2GPI (light blue).  Modules 1-4 in each are labeled.  Not 











between modules 3 and 4 of the NMR structure of rVCP~3,4 (tilt = 67°, twist = 81°, and 
skew = 7°) are comparable to those seen in the crystal structure (tilt = 99°, twist = 74° 
and skew = -20°) (Wiles et al., 1997).  The 2-3 intermodular angles within the NMR 
structure of rVCP~2,3, however, are dissimilar to those in the crystal structure of intact 
rVCP.  Moreover, approximately 281 Å2 of surface is buried between modules 2 and 3 in 
the crystal form, while the junction between these two modules is not extensive in the 
NMR rVCP~2,3 fragment (Kirkitadze t al., 1999).  In addition, NMR indicates that this 
pair is very flexible (Henderson et al., 2001).  It is noticeable, however, that there are 
significant differences in the structure of module 2 between intact and truncated forms of 
rVCP, while modules 3 and 4 show only small insignificant differences.  The notable 
differences observed in module 2 may be the result of the lack of module 1, which could 
destabilize module 2 in rVCP~2,3, and hence the 2,3 junction.  For example, the L109-
S114 insertion in module 2 is a mobile loop in rVCP~2,3 but has moved by some 15 Å in 
the crystal structure and contacts the Q42, K43 insertion of module 1.  Modules 2 and 3 
might also stabilize each other, which could explain the smaller differences between the 
arrangement of modules 2 and 4 in intact rVCP compared to the rVCP~3,4 fragment.  It 
is clear from these comparisons that the structure of rVCP reported here, the first of an 
intact complement control protein, represents a significant advance over previous 
structural studies based on fragments.  This structure's validity does not rely on the 
assumption that CCP modules are structurally independent of the remainder of the 
protein.  Therefore, this structure may be considered the most reliable basis yet for the 
design of mutagenesis experiments and homology modeling exercises. 
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Previous data suggested that VCP might function as an oligomer in order to 
increase its stability and life in solution (Ko wal et al., 1990).  Furthermore, dimeric and 
trimeric structures are observed in crystals.  Current results suggest that rVCP may be 
found as a monomer in its soluble state, where it is able to diffuse throughout the area of 
viral infection, binding and destroying complement in the local surrounding tissue.  rVCP 
also exists in the cell bound state, where it remains bound to heparan sulfate found on the 
infected cell, and neighboring cells' surfaces.  In this state, rVCP is able to prevent 
complement-mediated cell lysis, as well as chemotactic migration of monocytes, NK 
cells and neutrophil-mediated cell killing, and antibody attachment.  It is not known if 
rVCP oligomerizes at the cell surface.  Additional gel filtration experiments are needed to 
determine whether rVCP can oligomerize in the presence of low molecular-weight 
heparin. 
The ability of rVCP to resist irreversible denaturation in extremes of heat and pH 
can be attributed to its unusual architecture.  The protein is composed of four modules 
arranged in an extended head-to-tail fashion.  Each module has an elongated shape and is 
composed of extended regions of peptide running approximately parallel and antiparallel 
with the long axis, with loops and turns formed at either end of the module.  The main 
chain makes a total of five passes up and down the module such that the N-terminus is at 
one end of the long axis and the C-terminus is at the other. The extended regions are 
connected by networks of hydrogen-bonds (H-bonds) and over much of their length 
form b-strands that lie in antiparallel double or triple-stranded b-sheets – see figure 56a.  
In addition to interstrand H-bonds, two disulphide bonds within each module provide 









Figure 56.  Extensive H-bonding within VCP structure contributes to its stability.  a)  
Ca trace (shown in red) of the VCP molecule crystal forms I and II (13)with main-chain 
H-bonds (shown in white).  b)  Residues 10Å around the center of each module interface 
are shown with H-bonds (shown in red).  The main-ch i  hydrogen bonds were shown in 
white (b1) module 1 – module 2 interface (b2) module 2 – module 3 interface (b3) 

























conserved C residues - the first C that is also the first residue of the CCP consensus 
sequence is bonded to the third C, while the second C is bonded to the fourth C that is the 
last residue of the consensus sequence – se  figure 57 for disulphide bonding pattern.  
The two disulphides lie as far apart as possible within the structure and form the lower 
and upper boundaries of the hydrophobic core.  It is likely these disulphides survive 
elevated temperatures and their presence probably explains the reversibility of 
denaturation.  The core almost entirely buries the side-chain of the invariant W residue 
and contains a number of highly conserved aromatic and L, I and V side-chains.  Thus, 
each module consists of a compact hydrophobic core, bounded by two disulphides and 
wrapped in b-sheet.  In the crystal structure (and in the average NMR structures), the 
CCP modules of rVCP are arranged such that the eight disulphides form a twisted ladder 
with roughly parallel and evenly spaced rungs.   
From the crystal structure, we know that within rVCP, modules 1 and 2, and 
(particularly) modules 3 and 4, touch against one another.  The 1-2 junction within the 
crystal structure exhibits many intermodular H-bonds and this could explain why module 
2 is more stable (higher Tm) when module 1 is preent (comparing the calorimetric 
profiles obtained for rVCP and for rVCP~2,3) – see figure 56b.  A similar effect is seen 
amongst the CCP modules of CR1 (Kirkitadze t al., 1999).  In the 3-4 junction, as seen 
in both X-ray and NMR (Henderson et al., 2001) structures, modules make mainly 
hydrophobic contacts with one another and these two modules are tilted to create a 
significant interaction area.  Module 3 may be more stable in full length rVCP than in 
rVCP~2,3 but it is also possible that the melting of module 3 accounts for the first 










Figure 57.  Disulphide bonding pattern within CCP modules of VCP.  Sequence of 
the four CCP modules of VCP, following signal sequence cleavage, is shown.  Invariant 
W residue is shown in blue.  The highly conserved C residues are shown in red.  
Disulphide bonding between CCP 1 (C21-C70 and C54-C81) CCP 2 (C86-C126 and 
C112-C143) CCP 3 (C148-190 and C176-201) CCP 4 (C206-248 and C234-261) are 
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(57°C) of rVCP~2,3.  The 2-3 junction itself is the smallest one and NMR studies 
indicate that this is a point of flexibility within the protein.  Thus it is likely that module 2 
derives little or no stabilization from module 3 and this would account for its poor 
thermal stability in rVCP~2,3.  A previous analysis of NMR relaxation times (Henderson 
et al., 2001) showed the backbone of module 3 to be more flexible than module 2 – 
despite module 3 undergoing melting at a higher temperature – so it is possible that some 
of the stability of CCPs also derives from "give" in the structure tha  allows for local 
motion without denaturation. 
Overall, VCP is a protein that, unusually, combines three properties.  First, it is 
relatively small in terms of number of amino acid residues (and therefore is an 
economically encoded protein in terms of the limited size of the viral genome).  Second, 
its highly elongated shape creates a large surface area that is available for binding to C3b, 
C4b and proteoglycans.  Lastly, as shown in the current study, it is both stable and robust, 
able to tolerate a range of adverse circumstances. 
The consensus sequence that defines CCP modules is found several thousand 
times in the database (normally in tandem with other CCPs – solitary CCPs are rare).  In 
comparison to other module-types, there is an unusual degree of variation in the spacing 
between the four consensus C residues, and in sequence apart from the consensus 
residues themselves.  This indicates that the CCP module consensus sequence provides a 
highly versatile framework, tolerant of many insertions, deletions an  substitutions, and it 
is consistent with the observations recorded here showing the CCP scaffold to be robust.  
Knowledge obtained from this study may be valuable in understanding the stability of 
other CCPs.  It would also be interesting to know if other non-CCP members of this large 
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SCR containing family of proteins also possess the unusual ability to retain functional 
activity after being subjected to extreme physical conditions.  The question of whether 
VCP is stable having been answered, th next question is why?  One of the hallmarks of 
the complement components is their heat stability up to 56°C.  Our study indicates that 
rVCP is at least as stable as the complement components.  It is therefore possible that 
their co-existence over an extensiv  evolutionary period has resulted in this comparable 
stability.  The importance of the disulfide bonds, for both stability and specific activity, is 
currently being investigated. 
Due to the many extraordinary activities exhibited by this protein, its u e as a 
novel immunomodulating agent is currently being investigated for treatment of many 
complement-mediated diseases.  Determining the stability of rVCP was crucial for 
shipping, storage, administration, and dosage purposes as well as future protein-
engineering efforts.  rVCP has therapeutic potential as a means of ameliorating the 
complement-mediated damage associated with many medical conditions.  The findings 
presented in this study may be important for future use of VCP in the treatment of many 
complement mediated diseases, such as: Alzheimer's disease, restonosis, systemic lupus 














PHARMACOKINETICS OF VCP 
 
Introduction 
This chapter contains material adapted from the following manuscript: 
Anderson J.B., Smith S.A., Wijk R.V., Chien S., and Kotwal G.J.  Vaccinia virus 
complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat 
heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding 
and complement pathway activation.  Submitted to Transpl. Immunol., 2002. 
 Simply stated, pharmacokinetics is the study of the process by which a drug is 
absorbed, distributed, metabolized, and eliminated by the body.  Many routes of drug 
administration exist, including intravenous, oral, buccal, sublingual, rectal, intramuscular, 
transdermal, subcutaneous, inhalational, and topical.  Ultimately, the goal of any 
pharmacokinetic study is to develop a means to maintain a steady-s te concentration of 
the drug with rate of elimination equal to rate of administration, and the dosing rate must 
equal the clearance rate times the desired plasma concentration (Carso  and Jones, 1979).  
Until recently, the use of proteins as potential therapeutic agents had not received much 
attention.  However, due to the recent advances in protein purification and recombinant 
DNA techniques, pharmacokinetic studies of proteins are becoming much more common.  
The most common, by far, mode of administration used in these studies is intravenous.  
Unfortunately, proteins are often cleared from the blood very rapidly.  This occurs most 
commonly via glomerular filtration in the kidneys, and the protein is excreted in the 
urine.  The tendency for a protein to be eliminated from circulation by glomerular 
filtration depends mainly on two factors,the size of the protein and its electrostatic 
charge.  Small proteins, less than 40 kDa, are often removed very rapidly.  Likewise, the 
glomerular barrier also discriminates according to a protein's charge (Brenner et al., 
1978).  Negative charge seems to have the effect of reducing clearance of a protein via 
filtration.  Therefore, in order to increase the half-life of a therapeutic protein in the 
blood, one must increase its size and/or negative charge.  Many strategies have been 
developed to accomplish this, including: addition of polyethylene glycol (PEG) chains 
(PEGylation), covalent cross-linking, immunoglobulin domain fusion, and covalent 
fusion with albumin. 
Most of the therapeutic studies that have been published in the area of CCPs 
involve the use of soluble complement receptor one (sCR1).  sCR1 has been studied for 
its therapeutic use in, among other things, graft rejection, arthritis, allergic 
encephalomyelitis, and antigen-induced bronchoconstriction (Pratt et al., 1997; Mizuno et
al., 2000; Piddlesden et al., 1994; Regal et al., 1993).  These studies used different 
dosages and different routes of delivery.  Early studies indicated that the effective 
intraperitoneal dose, as determined by the serum CH50, was 20 mg/kg/day (Piddlesden et 
al., 1994).  In addition, the plasma sCR1 concentration was found to remain relatively 
constant from day to day.  These results indicate that this dosage would result in a 
complement CH50 hemolytic activity below 5 for at least 6 days.  For the transplantation 
studies using sCR1, an intravenous dosage of 25 mg/kg/day was used throughout the 
experimental time course (P att et al., 1996).  Studies testing the ability of sCR1 to 
reduce the severity of experimentally induced arthritis found that, in addition to a direct 
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intraarticular dose, an intravenous dose of 15 mg/kg/12h was very effective (Goodfellow 
et al., 2000).  Taken together, it would seem that the half-life of sCR1 is relatively long; 
glomerular filtration of sCR1, therefore, would appear to be low.  This is most likely due 
to the protein's size; possessing 20 SCRs (60-70 amino acids each), it is much too large to 
be easily excreted in the urine.   
Several other CCPs have been used as therapeutic agents.  Soluble versions of 
CD59 (sCD59), DAF (sDAF), and MCP (sMCP) have been investigated for use in 
treatment of complement- diated disease.  In addition, various chimeric fusion proteins 
have been created in an attempt to lengthen the serum half-life of a complement 
inhibiting protein.  One such experiment used a chimeric protein created by fusing the 
active domains of MCP with a recombinant soluble form of the im unoglobulin 
receptor, FcgRII (Lanteri et al., 2000).  Results indicated that this chimera possessed a 
much greater serum half-life than either of its components acting alone.  Moreover, when 
less than 0.5 mg of the protein was injected intravenously, it was found to block 
hyperacute rejection in a mouse (wt) to mouse (Gal o/o) heterotopic xenograft model. 
Until this time, there has been no data determining the pharmacokinetics of VCP 
in vivo.  Knowing the size and the charge of VCP, one might predict that it would very 
easily be filtered by the kidneys, eliminated rapidly from the blood, and excreted in the 
urine.  Initial in vivo experiments utilized FITC-labeled VCP injected intravenously to 
attempt to determine its localization.  As expected, VCP was found to localize along the 
endothelium, near to the site of injection, most likely binding to heparan sulfate present 
on the endothelial cell surfaces.  However, the results of this experiment did not 
demonstrate the intense staining that was anticipated.  The cause of this was later 
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revealed when FITC rVCP was found to bind heparin much less effectively than 
unlabeled rVCP – see figure 16.  It seems clear that the label or the labeling process 
results in a dramatic reduction in VCP's ability to bind strongly to heparin, possibly by 
masking the binding sites or preventing proper folding and alignment of the sites.  Using 
unlabeled rVCP and staining with anti-rVCP and labeled secondary antibodies solved this 
problem.   
Single bolus injection studies were then conducted on live anesthetized rats.  
Various dosages and delivery locations were attempted while the pharmacokinetics was 
monitored by periodic collection of serum, for CH50 analysis, and urine, for CH50 and 
SDS-PAGE analysis.  In addition, to understand how delivery could be optimized for use 
in long-term experiments, multiple or continuous injection strategies would be required.  
Therefore, various multiple and continuous intravenous dosages were attempted while 
serum was periodically collected for CH50 analysis.  Finally, in an attempt to increase the 
serum half-life of rVCP, various strategies of protein modification were attempted.  
Efforts were made to covalently oligomerize rVCP, and to covalently link it to albumin, 
thus, in each case making the protein larger and less likely to be eliminated by glomerular 
filtration.  Unfortunately, both attempts failed, either resulting in an inactive modified 







Materials and Methods 
Single Injection Strategies: 
 Pharmacokinetic studies were done with the surgical help of Jaime Anderson.  In 
order to insure that the desired quantity of rVCP was entering the bloodstream, rVCP was 
injected directly into the jugular vein of anesthetized rats (anesthetized using 55 mg/kg, 
I.P., sodium pentobarbital).  A small incision wa  made in the neck of each rat, and the 
dose of rVCP was injected directly into the jugular vein making sure no leakage resulted.  
The small lesion was then closed with superglue and the animal was allowed to awaken.  
Blood was taken before the injectio  and periodically afterwards by cutting off the 
extreme tip (2 mm) of the tail using a fresh scalpel blade.  After the experiment was 
complete, the rats made a full recovery and were used in other unrelated experiments. 
 
Multiple and Continuous Injection S rategies: 
 Several methods were attempted in order to administer rVCP over an extended 
time period.  The first was to use an external syringe pump and inject rVCP into the 
jugular vein while the rat remained anesthetized.  This method, using a Harvard 
Apparatus 22 syringe pump, was not practical due to the length of time the rat needed to 
be anesthetized.  The second method that was attempted used an implantable rodent 
pump.  This Harvard Apparatus implantable infusion pump was powered by an elastomer 
spring and delivered a constant rate of drug delivery.  The pump was implanted 
subcutaneously in the rat's back, with the line running subcutaneously to the jugular vein.  
Although the pump allowed the rats to awaken while being studied, because this pump 
supplied a steady flow rate of only 0.12 ml/day, it was also unpractical.  In order to 
220 
deliver the amount of rVCP needed to maintain the desired level in the blood, the protein 
concentration was much too high and resulted in a clogged line.  Finally, an intermittent
strategy of administration was attempted.  A small I.V. port was superglued externally to 
the back of the rat, while the line ran subcutaneously to the jugular vein.  With the rat 
awake, any amount of rVCP could very easily be injected as often as e ired.  This 
strategy was most effective, but required continuous attention.   
 
CH50 Hemolytic Activity Assay: 
 To determine the complement activity of a serum sample, the complement 
hemolytic activity at 50% (CH50) assay was employed.  This assay greatly re embles the 
hemolysis assay, however it tests the serum complement activity as opposed to testing the 
ability of a protein to inhibit serum complement.  Both assays use sSRBCs to accurately 
quantify complement activity, or the inhibition thereof.  The CH50 assay determines the 
serum complement activity by identifying the quantity of a given serum needed to lyse 
50% of the sSRBCs in the assay.  Therefore, serially diluted serum samples were 
incubated with a known concentration of sSRBCs, and the % lyses was determined by 
comparing the sample to a positive control, usually water lysed sSRBCs. 
 
Detection of rVCP in Urine: 
 Urine samples were collected by a 25 G urinary catheter before and after rVCP 
injection.  All samples were then concentrated and dialyzed aga nst water to the same 
final volume.  First, the urine sample was centrifuged at 10,000 rpm, in order to pellet 
contaminating bacteria and epithelial cells.  Next, each sample was filtered through a 0.2 
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mm syringe filter.  The samples were then placed in separate centricon concentrators and 
centrifuged at 7,000 rpm at 4oC.  After the samples were concentrated to the same 
volume (~100 ml), they were dialyzed by addition of 2 ml sterile water.  Finally, the urine 
samples were analyzed by hemolysis assa  and visualized by SDS-PAGE and Coomassie 
blue staining. 
 
Oligomerization and Modification of rVCP: 
 In order to couple rVCP to BSA or to itself, standard amine coupling procedures 
were used.  To couple rVCP to BSA, 5 mg of BSA was suspended in 5 ml activation
buffer: 100 mM MES, 500 mM NaCl, pH 6.0.  Next, 2 mg of N-ethyl-N'-
(dimethylaminopropyl)-carbodiimine (EDC) and 3 mg of N-hydroxysuccinimide (NHS) 
were added to the solution.  The solution was then allowed to incubate at room 
temperature for 15 min.  In order to quench the EDC, 7 ml of b-mercaptoethanol was 
added to the mixture.  Finally, 4 mg of rVCP was added to the solution and allowed to 
incubate at room temperature for 2 hours.  After the incubation period, 0.4 g of 
hydroxylamine was added to rform the uncoupled carboxyl groups on the BSA.  The 
mixture was then concentrated and dialyzed to eliminate all remaining chemicals.  The 








Single Bolus Injection Studies: 
 In order to determine the half-life of rVCP in the serum of rats, various routes of 
admission and dosage strategies were investigated.  Starting with a relatively high dose of 
3 mg (0.5 ml total bolus), preliminary intravenous (I.V.) and intraperitoneal (I.P.) 
injections were attempted while the serum CH50 was monitored.  As can be seem in 
figure 58a, clear complement depletion is observed by 15 min following I.V. injection of 
rVCP.  This activity rapidly starts to decrease and the serum complement approaches 
normal levels.  This decrease (lack of complement activity) is not observed when rVCP is 
injected into the peritoneum of the rat – see figure 58b.  Only a very small amount of the 
protein makes it to the serum and is detected.  The inability of rVCP to enter the blood 
from the tissue was also observed when a rat was injected subcutaneously with a large 24 
mg/kg bolus.  Very little serum complement depletion is observed by the CH50 of this 
rat.  The results of the above experiments determined that rVCP must be injected 
intravenously to work most effectively.  Therefore, in order to establish the most 
effective I.V. dose, rats were injected with various bolus amounts of rVCP.  The averaged 
results (2 rats each) of a single dose of 3 mg/kg, 6 mg/kg, or 12 mg/kg are shown in 
figure 59.  A clear difference can be seen between the slopes of the CH50s for the various 
doses.  Thus, the rate of clearance can be effectively predicted from this data.  See the 
appendix for figures showing additional preliminary results of single animal studies. 
 The ability of rVCP to deplete serum complement was also investigated in 
baboons.  Due to the extreme size of this animal, large quantities of the protein must be 










Figure 58.  CH50 following I.V. and I.P. injection of 3 mg rVCP.  A)  Complement 
depletion in rat injected intravenously with 3 mg rVCP.  Serum complement activity at 
15 min, 30 min, and 60 min is shown.  Significant depletion of complement activity can 
be observed.  B)  Complement depletion in rat injected intraperitoneally with 3 mg rVCP.  
Serum complement activity at 15 min, 30 min, 60 min, and 12 hours is shown.  No 
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Figure 59.  Serum CH50 of I.V. injected rVCP at 3, 6 and 12 mg/kg.  Two rats in each 
group were administered either 3, 6 or 12 mg/kg IV of rVCP and the serum was collected 
at 15 minutes intervals and assayed for CH50 as compared to serum control prior to 
rVCP administration.  The pharmacokinetics of rVCP in rats can be accurately deduced 






























only a few experimental animals and by comparing their data with that obtained in the rat 
studies.  The first baboon in the study (University of Cape Town, Cape Town, SA) was 
injected intravenously with 45 mg rVCP bolus and the serum and urine were collected for 
analysis.  Due to the extreme size and the small amount of rVCP that was injected (~3 
mg/kg), no complement activity depletion was observed at any time point, even 15 min.  
The size of the I.V. dose was then increased to 9 mg/kg in hopes of seeing even a slight 
decrease in CH50.  Baboon 479 (15.8 kg) showed a slight drop in serum CH50 at the 15 
min time point.  The CH50 was reduced to 37 (37% lysis using the pre-treatment s rum 
dilution that resulted in 50% lysis) by 15 min, but returned to normal by the ext time 
point, 30 min.  An additional baboon was injected with the same dose, 9 mg/kg, but was 
injected using an I.V. drip.  Baboon 397 (17.1 kg) received rVCP over 15 minutes in an 
I.V. drip, as opposed to baboon 479 who got a single bolus.  As can be een in figure 60, 
the serum CH50 of baboon 397 was much higher than that observed in baboon 479 at the 
5 min time point.  Baboon 397 had a CH50 of 30, while baboon 479 had a CH50 of only 
5, after 5 min.  This does not suggest that the single bolus injection strategy of 
administration was more effective in depletion of serum complement activity, because the 
drip was not completed until the 15 min time point.  More animals would have to be 
tested in order to confirm these results.  However, the data obtained by these experiments 
may be sufficient for determining the approximate clearance rate of rVCP in the baboon.  













Figure 60.  Baboon 479 and 397 CH50 following 9 mg/kg I.V. rVCP.  Serum samples 
taken from baboon 397, which received rVCP in an I.V. drip, and 479, which received 
rVCP as a bolus, were tested for complement activity with the CH50 assay.  The CH50 
was tested at time 0 and 5 min following completion of the injection.  The v rticle lines 






































Multiple and Continuous Injection Studies: 
To further exploit rVCP's therapeutic potential, it would have to be administered 
over an extended period of time.  Therefore, preliminary attempts were made to inject 
rVCP I.V. continuously or intermittently for an extended time.  The initial experiments 
were attempted using an external syringe pump.  With the rat sedated, rVCP was pumped 
into the jugular vein at a continuous controlled rate, 16 mg/kg/hr was injected and blood 
samples were taken 15, 30, and 60 min.  This method worked well, controlling the 
complement activity by maintaining the CH50 below 10.  Next, an implantable pump was 
used in order to allow the rat to awaken.  With the pump implanted subcutaneously in the 
back of the rat, the small injection line was sutured to the jugular vein.  The type of pump 
used had a fixed rate of drug administration.  With the injection rate of the pump in mind, 
rVCP was added to the pump such that a steady concentration of rVCP would be present 
in the blood.  First, rVCP was added to the pump such that a continuous dose of 3 
mg/kg/hr would be given, following an initial bolus of 6 mg/kg.  Complement activity 
was initially depleted but very slowly increased over the 6-h ur time course.  Although 
the CH50 never returned to normal levels, this demonstrates that an insufficient amount 
of rVCP was being injected.  Therefore, a higher dose was attempted, trying a 
concentration of rVCP high enough to deliver 6 mg/kg/hr.  Unfortunately, this 
concentration was too high and resulted in a clogged pump line.  Thus, less rVCPwas 
detected in the serum and resulted in a more rapid return of complement activity, as 
detected by the increase in CH50 to near normal levels.  Because of these experiments, 
the continuous method of injection, via an implantable pump, has been set aside.  A 
different strategy for long-term delivery had to be worked out in order to administer large 
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amounts of rVCP continuously.  See the appendix for figures showing preliminary results 
of single animal studies. 
To deliver rVCP over extended periods of time without the aid of an implantable 
pump, a catheter technique was developed.  A small I.V. catheter port was fixed to the 
back of the rat by superglue, and a small injection line was run subcutaneously and 
sutured to the jugular vein.  After an initial 6 mg/kg bolus was given, 2 mg/kg was 
injected through the I.V. catheter every 20 min to sustain a concentration of 6 mg/kg/hr.  
The complement activity was depleted to below a CH50 of 5 after 15 min and was held to 
the same level at 6 hours.  This strategy of long-term injection works well, however, it is 
very time consuming and not very practical.  See the appendix for figures showing 
preliminary results of single animal studies. 
 
Presence of rVCP in Urine: 
 In order to investigate the mannor by which rVCP is cleared from the blood, 
various urine samples were taken and studied.  Early animal experiments were conducted 
using rVCP that was unknowingly contaminated with endotoxin, approximately 30,000 
EU/ml.  Urine samples obtained from the animals injected intrav nously with this rVCP 
revealed extremely high levels of the protein excreted into the urine.  As can be seen in 
figure 61a, large concentrations of rVCP can be seen in two samples taken from rats 
injected with rVCP (endotoxin contaminated), but cannot e see  in the sample taken 
before injection.  In addition, figure 61a shows urine samples taken (taken over several 
hours following injection) from rats and a baboon that received rVCP that was endotoxin 







Figure 61.  Presence of rVCP in urine.  A)  SDS-PAGE analysis of rat urine and a 
baboon urine samples taken before and after administration of rVCP, contaminated with 
endotoxin (lanes 1-4), or endotoxin free (lanes 5-8). rVCP marker can be seen in lanes 1 
and 5.  Lane 2 represents urine before rVCP was injected while lanes 3 and 4 represent 
urine samples taken over 2 hours from two different rats following rVCP administration.  
Again, lane 6 represents urine before rVCP was injected while lane 7 represents urine 
taken for 2 hours following rVCP administration.  Lane 8 shows a baboon urine sample 
following rVCP administration.  B)  Hemolysis inhibiting activity of rat urine samples 
taken before and after (for 2 hours) rVCP injection.  Also shown is the hemolysis 
inhibiting activity of baboon urine after injection of rVCP.  As can be seen, a significant 
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sample.  Finally, the rat and baboon sample were tested for hemolysis inhibiting activity.  
Figure 61b shows that rat urine after rVCP (endotoxin free) was injected showed a 
significantly greater degree of hemolysis inhibiting activity.  This can only be attributed 
to a small amount of active rVCP being present in the urine sample.  The baboon urine 
sample showed no sign of rVCP by SDS-PAGE analysis or hemolysis assay. 
 
Attempts to Oligomerize and Modify rVCP: 
 Due to the rapid rate at which rVCP is eliminated from the blood, most likely 
through glomerular filtration, attempts were made to extend the proteins half-lif by 
modification or multimerization of rVCP.  Using standard amine coupling procedures, 
rVCP was covalently conjugated to bovine serum albumin (BSA).  As can be seen in 
figure 62, rVCP coupled to BSA was purified away from uncoupled rVCP and uncoupled 
BSA by heparin affinity purification.  Coupled rVCP-BSA bound heparin with less 
affinity than rVCP alone, allowing for complete separation from the unconjugated 
protein.  Unfortunately, when rVCP-BSA was tested for hemolysis inhibiting activity it 
was found to be inactivated.  Next, rVCP was coupled to itself by standard amine 
coupling procedures.  As can be seen in figure 62, only a slight degree of dimerization 
took place.  Not enough rVCP dimers were created to purify away from the uncoupled 
rVCP.  Therefore, dimers of rVCP could not be tested for their ability to inhibit 
hemolysis in the hemolysis assay or if they could ffectively increase the half-life of 











Figure 62.  Modification of rVCP using standard amine coupling.  Heparin 
purification following the coupling of rVCP to BSA and rVCP to itself is shown by SDS-
PAGE analysis.  Following rVCP coupling to BSA, heparin chromatography provides a 
way to purify out rVCP-BSA from both uncoupled rVCP and BSA.  This is due to rVCP-
BSA having a lesser affinity for heparin than rVCP.  However, rVCP coupled to itself 
can not be purified away from rVCP by this method.  Thus, heparin chromatography is 













































































































 Initial experiments employed single bolus doses of rVCP delivered by various 
routes to try to determine the best dosage and location of delivery.  It was determined that 
the intravenous (I.V.) route of injection was the most effective.  Intraperitoneal and 
subcutaneous injection strategies were attempted with poor results.  It is possible that the 
strong affinity that VCP possesses for heparin and heparan sulfate contributes to hese 
findings.  When rVCP is injected into these locations, it may bind to heparan sulfate 
proteoglycans on the surface of cells or to heparin containing mast cells.  This could 
effectively prevent rVCP from entering the blood, even at a slow rate.  Although nothing 
is known about what happens following rVCP binding to heparan sulfate on the surface 
of cells, studies are underway using electron microscopy.  If the protein is internalized, 
and possibly degraded, it would result in the effect seen in the abov  experiments, where 
it is injected into the tissue and does not affect serum complement.  
 Using single bolus, continuous, and intermittent strategies of I.V. injection, the 
rate at which rVCP leaves the blood can be calculated relatively accurately.  Using the 
data presented in figure 59, for example, when 3 mg/kg is injected, the CH50 returns to 
around 20 at 30 min post injection.  When 12 mg/kg is injected, it takes twice the amount 
of time before the CH50 reaches 20.  Therefore, it takes 4 times the amount of rVCP to 
double the time the protein effectively depletes serum complement activity.  This data 
tells us a lot about the pharmacokinetics of rVCP.  Obviously, rVCP is being eliminated 
from the blood at a very fast rate.  By studying figure 59, it seems that half of the protein 
activity is eliminated, CH50 of 25, somewhere between 6 and 12 mg/kg, closer to 6 
mg/kg.  Using this data one would predict that rVCP is eliminated from the blood at a 
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rate of approximately 8 mg/kg/hr.  Thus, rVCP would need to be administered 
continuously to be effective in sustaining a low serum CH50.   
The studies where rVCP was injected I.V. continuously or intermittently also give 
us clues about the elimination rate of rVCP.  Preliminary data shows that while the CH50 
is immediately reduced by the 6 mg/kg bolus, it continues to rise despite a continuous 
infusion of 3 mg/kg rVCP.  This demonstrates that 3 mg/kg is not sufficient for 
controlling complement levels in the blood.  The study using a continuous infusion of 16 
mg/kg I.V. showed extremely reduced complement activity sustained for up to an hour.  
This dose was most likely "overkill" because of what was found when 6 mg/kg was 
injected intermittently following a 6 mg/kg bolus.  Priliminary data shows that the serum 
CH50 was not only depleted at the early 15 min time point, but also at the latest time 
point of 6 hours.  This study indicates that in order to maintain a CH50 below 5, one 
needs to continuously inject 6 mg/kg rVCP intravenously.  This supports the conclusin  
drawn by the bolus dose experiments, that rVCP is eliminated from the blood at a very 
high rate, somewhere between 6 and 12 mg/kg/hr.  It also seems likely that the level of 
complement activity in the blood slowly decreases over time as rVCP is continuously 
administered.  Therefore, it is quite possible that lower levels of rVCP would be needed 
at later time points and the dosage could be dropped.   
The initial data collected from baboons injected intravenously with large bolus 
doses of rVCP shows thate protein is clearly not as effective as in rodents.  This data 
supports conclusions drawn in chapter 4, hypothesizing that rVCP is specific for the rat 
and therefore works most effectively against rat complement.  Figure 60 shows the CH50 
of a baboon ijected with a 9 mg/kg bolus.  After 15 min, the CH50 was reduced to only 
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37.  The same dose if it were injected into a rat, would have eliminated complement 
activity, reducing the CH50 to 0 after 15 min.  It takes 45 min for the complement 
activity of a rt injected with only 3 mg/kg to reach CH50 of 37.  This clearly 
demonstrates the drastic in v vodifference in complement inhibiting activity possessed by 
rVCP between rat and baboon, and probably human.  To achieve the same level of 
complement inhibition, one would have to inject approximately 5 times as much rVCP in 
a baboon as a rat.  That means to sustain a CH50 of below 5 in a baboon, one would need 
to inject 30 mg/kg/hr following a 30 mg/kg bolus.   
To determine the means to which rVCP is eliminated from th  blood and 
ultimately from the body, urine samples were collected and analyzed for traces of the 
protein.  Knowing that the most likely mode of elimination of a protein of this size and 
charge is via glomerular filtration, large amounts of rVCP could likely be found in the 
urine.  Early studies of rat urine revealed that very large concentrations of rVCP was 
present and could be clearly visualized by SDS-PAGE analysis.  Although Western 
blotting would have more conclusively proven that this was in fact rVCP, the absence of 
the band in the urine before injection makes a strong case.  These rats, however, received 
rVCP that possessed high concentrations of endotoxin.  Interestingly, urine samples 
obtained from rats that received rVCP that contained no endotoxi  showed very small 
traces of rVCP, as detected by hemolysis assay but not by SDS-PAGE analysis.  The 
presence of the protein was determined, however, by testing the urine samples in the 
hemolysis assay.  The urine sample after injection of rVCP possessed a significant ability 
to inhibit complement, when compared to a sample taken before rVCP was injected.  This 
not only demonstrates the presence of rVCP in the urine, but also shows that at least 
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some of the protein is eliminated in an active, fully functional form.  It seems however, 
that the presence of endotoxin greatly increases the amount of rVCP being excreted in the 
urine.  This may therefore result in a decreased half-life in t e serum.  Fortunately, this 
does not discredit the pharmacokineti  studies described above, because almost all of the 
studies were performed using aliquots of the same batch of protein (16 mg/kg continuous 
infusion used a different batch that was not tested, figure 65 in appendix), which was 
tested and found to be nearly endotoxin free. 
Due to the rapid elimination of rVCP from the blood, presumably via glomerular 
filtration, attempts were made to modify the protein to increase its serum half-life.  Using 
standard amine coupling procedures, rVCP was covalently linked to BSA and to itself.  
Unfortunately, neither attempt proved fruitful.  When rVCP was linked to BSA, it was 
easily purified, but possessed no activity and was thus useless.  When rVCP was linked to 
itself, forming rVCP dimers in only low relative amounts, the protein resembled the 
monomeric protein too closely and could not be purified away from the uncoupled rVCP.  
In addition, the amount of rVCP dimers created was very low relative to the 
concentration of rVCP monomers.  Theoretically, creating rVCP dimersshoul  gr atly 
increase the protein's half-life, by making the protein near to the size of albumin, if a 
method of purification could be devised, possibly using gel filtration chromatography.  
Despite these failed attempts at modifying rVCP, if rVCP were to be seriously considered 
for use as a therapeutic agent, efforts would have to be made to increase the protein's 
serum half-li e.  Other than gene therapy, which could theoretically deliver a constant 
dose of rVCP where it is needed, protein modification may be the best solution.  As 
discussed in the introduction, many methods of protein modification have been employed 
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to increase a proteins half-life in the serum.  One effective method that was not 
investigated, although it has great potential, for use on rVCP, is PEGylation.  This 
method of modification is growing in popularity due to its ability to not only result in a 
favorable size and charge, but also reduce the protein's antigenicity (Reddy, 2000;
Mehvar, 2000).  The procedure for PEG modification of proteins is relatively 
straightforward and has been described for many other proteins (Reddy et al., 2001; 
Wang et al., 2000; Hershfield t al., 1987).  This procedure has significantly increased 
the half-life of many proteins, including several in clinical use, without affecting their 





















FUTURE STUDIES OF VCP 
 
Species Specificity Studies of rVCP and the Variola Virus Homologue
 In order to investigate the species specificity of rVCP and the variola virus 
homologue of VCP using Biacore and in vitro hemolysis assays, the variola virus gene 
must be cloned from the viral DNA.  Sergei N. Shchelkunov, a collaborator from the 
Department of Molecular Biology of Genomes, State Research Center of Virology and 
Biotechnology "Vector" Koltsovo, Novosibirsk Region, Russia, will PCR amplify the 
gene for cloning.  The primers that will be used to amplify the variola homologue of VCP 
are: (sense) 5' GTA TCT CTC GAG AAA AGA TGC TGT ACT ATT CCG TCA 3' 
making a Xho I restriction site and (anti-se se) 5' TTA ATT CGC GGC CGC TTA GCG 
TAC ACA TTT TGG 3' making a Not I restriction site.  Following gene amplification by 
PCR, the amplified product will be cloned into the P chia pastoris yeast expression 
system.  The same procedures and plasmids used to express rVCP (described in chapter 
2) will be used for expression of variola virus VCP. 
Once the variola virus homologue of VCP is in hand, the hemolysis assay will be 
performed to determine whether this protein possesses greater activity against human and 
babon complement than rVCP.  The hemolysis assay will also be used to determine 
whether the variola virus homologue of VCP possesses less activity against rat and 
mouse complement than exhibited by rVCP.  The Biacore will also be used to evaluate 
the strength of binding between rVCP and rat C3b or human C3b (purification and 
trypsinization described in chapter 4) and evaluate the strength of binding between the 
variola virus homologue of VCP and rat C3b or human C3b.  The results obtained using 
the hemolysis ass y and Biacore binding analysis will determine whether these proteins 
interact with complement in a species- fic mannor. 
It has already been shown that rVCP is much more effective in blocking 
rat/mouse complement than human/baboon, using the hemolysis assay (results presented 
in chapter 4).  It is possible that the variola virus homologue possesses greater activity 
(possibly binding affinity) against human/baboon complement than rVCP.  If the data 
obtained from this study matches that of the preliminary data, it will not only bring up 
interesting questions about host specificity but also lend valuable information for 
structure-function determination of the complement binding residues.  If a difference in 
the proteins' binding kinetics to human or rat C3b is found, then the only twelve amino 
acid dissimilarity between rVCP and the variola virus homologue of VCP will help 










rVCP Cell Binding and Kinetic Studies Using Electron Microscopy 
In order to investigate the cell binding and kinetics of rVCP, electron microscopy 
(EM) will be used.  Brendon Price, a collaborator from the Electron Microscope Unit, 
University of Cape Town, Rondebosch, South Africa, will carry out the EM experiments.  
Recombinant VCP, expressed from the Pichia pastoris yeast expression system, will be 
purified by heparin affinity chromatography as described in chapter 2.  Using HUVECs 
grown to confluency in 6-well plates, various concentrations of rVCP will be incubated 
with the cells for various time points.  Following incubation, the cells will be fixed, 
embedded, processed and viewed by EM.  The cells will be treated with chicken anti-
VCP IgY primary antibody, followed by biotinylated goat anti-chicken IgG secondary 
antibody and finally visualized using conjugated streptavidin-5 nm gol .  The position of 
the gold particles will be tracked to determine the location of rVCP, initially on the cell 
surface, and possibly within the cell at a later time point.  The data obained from this 
study will greatly increase our understanding of the kinetics and intracellular localization 
of rVCP following its binding to cell surface heparan sulfate.  This data may be useful for 
increasing the serum half-life of rVCP in vivo as well as providing a basic understanding 
of how the protein behaves after it is secreted from the vaccinia virus-infe ted cell during 







Pharmacokinetic and Xenotransplantation Studies in Baboons 
To determine the pharmacokinetics of rVCP in baboons, several baboons will 
receive large bolus I.V. injections and the serum CH50 will be monitored over time.  The 
baboons and technical assistance will be provided by Professor Del Kahn, head of the 
Surgical Transplant Service, University of Cape Town, Rondebosch, South Africa.  As 
described in chapter 2, rVCP will be expressed and purified by heparin affinity 
chromatography.  The kinetics of rVCP in the serum, determined by CH50, will be 
compared to that observed in the rat studies (see chapter 6).  The dosage of rVCP 
required to maintain a serum CH50 below 10 for an extended time (possibly several 
weeks) will be determined using the data collected.  The dosage of the variola virus 
homologue of VCP required to maintain a serum CH50 below 10 will also be evaluated, 
once it is cloned and produced.  An internal I.V. pump will be purchased and used to 
continuously deliver the required quantity of VCP for the desired time.  Once a 
satisfactory rVCP regimen and delivery strategy is achieved, pig to baboon 
xenotransplants can be attempted.  Pig livers will be transplanted into baboons, with and 
without rVCP.  Organ survival, histology and immunohistochemistry (for VCP, C3, and 








C3b/rVCP and Heparin/rVCP Co-crystallization Studies 
Dr. Jamie Rossjohn, St. Vincent's Institute of Medical Research, Fitzroy, 
Australia will perform the co-crystallization of rVCP and C3b.  C3 will be purified from 
human serum and partially trypsinized to form C3b, as described in chapter 4.  
Recombinant VCP will be produced using the Pichia pastoris yeast expression system 
and purified to nearly 100% by repeated heparin affinity chromatography (described in 
chapter 2).  The resulting crystal structure will provide conclusive results about the 
residues involved in rVCP binding to C3b.  These results will determine whether the 
complement binding residues defined by the hemolysis assay, SPR binding analysis, and 
homology with MCP, do in fact play a role in this interaction. 
Dr. Krishna Murthy from the Center for Biophysical Science and Engineering, 
University of Alabama at Birmingham, w o performed the X-ray crystallography of 
rVCP, will conduct the co-crystallization of rVCP and heparin.  Again, rVCP will be 
expressed using the Pichia pastoris yeast expression system and purified to nearly 100% 
repeated heparin affinity chromatography (described in chapter 2).  Using low molecular 
weight heparin, approximately 5 kDa molecular size (Sigma), rVCP will be co-
crystallized with heparin.  The resulting structure will provide conclusive results about 
the residues involved in rVCP binding to heparin.  This will determine whether the 
heparin binding sites defined by chromatography, SPR binding analysis, a d homology 





C3b/rVCP and Heparin/rVCP Binding Kinetics Using Biacore 
 Biacore kinetics analyses between C3b and rVCP, as well as Heparin and rVCP 
will be performed in collaboration with Dr. Shriha i Arjunwadkar, from the Department 
of Microbiology, Division of Virology, University of Cape Town, South Africa.  With 
C3b immobilized to the surface of a CM5 sensor chip, various concentrations (0.5 - 50 
nM) of rVCP will be passed over the surface and binding will be measured.  The binding 
plots will be overlaid and fit using the BIAevaluation software package.  The software 
will determine the Ka and Kd of this interaction automatically.  Similarly, with low 
molecular weight heparin immobilized to the surface of a sensor chip, various 
concentrations (0.5 - 50 nM) of rVCP will be injected and binding will be measured.  
Again, the binding plots will be overlaid and fit using the BIAevaluation software 
system.  Again, the software will determine the Ka and Kd of this interaction 
automatically.  The association and disassociation constants for rVCP binding to 
complement and heparin may provide very useful insights into these interactions.  By 
studying the kinetics of mammalian complement control proteins, kn wledge about the 
















Identification of C3 Fragments Involved in rVCP Binding Using Biacore 
 In collaboration with Dr. Seppo Meri from the Haartman Institute, University of 
Helsinki, Finland, surface plasmon resonance analysis will be used to identify the regions 
of C3 involved in binding rVCP.  Human C3 will be purified from human serum as 
described in chapter 4.  The C3b fragment of C3 will be produced from partial 
trypsinization, as described in chapter 4.  The C3c fragment will be purified using C3 and 
Activated Thiol Sepharose 4B (Pharmacia) as described previously (Jokiranta et al., 
2001).  Lastly, the C3d fragment of C3 will be generated and purified from C3 using a 
procedure described previously (Jokiranta et al., 2000).  SPR binding studies will be 
performed using a Biacore 2000 instrument and the data will be analyzed using the 
BIAevaluation software package.  C3 and each of the C3 fragments, C3b, C3c, and C3d 
will be immobilized to the surface of a CM5 sensor chip using standard amine coupling 
procedures described in chapter 4.  Various concentrations of rVCP, expressed and 
purified by heparin affinity chromatography, will be injected over the surface of each 
sensor chip to determine whether binding occurs.  The ability of rVCP to bind, as well as 
the relative strength of the binding, to C3 or the fragments of C3 will help identify the 









Protein Engineering and Use of VCP as an Immunomodulatory Agent 
 Complement has been shown to play an important role in many inflammatory 
conditions, such as Alzheimer's disease, rheumatoid arthritis, CNS injury and 
xenotransplant rejection.  In hopes of developing a therapeutic agent for se in treating 
such conditions, various complement-inhibiting proteins have been studied extensively 
for many years.  There have been proteins identified that are capable of blocking the 
complement cascade at nearly every step, from C1 (C1-Inhibitor) to the assembly of the 
membrane attack complex (sCD59), and a few proteins that can block at multiple steps 
(sCR1).  Many of these are membrane bound mammalian proteins used to prevent 
unwanted complement activation and tissue destruction in the absence of an invadi g 
microorganism.  In order to use them as a therapeutic agent, however, their 
transmembrane domain is removed and the protein expressed in a soluble form.  These 
soluble proteins are often very affective in blocking complement, both in vitro as well as 
in vivo.  However, the soluble mammalian complement control proteins are very large, 
generally consisting of 20 SCRs or more (>150 kDa molecular size).  VCP is the smallest 
known complement regulatory protein, possessing a similar function as exhibited by 
sCR1.  In addition, VCP expands its repertoire of functions by including heparin binding 
sites, making it both small and multifunctional. 
 It has been shown previously that VCP exhibits greater potency in inhibiting 
complement than an equal concentration of C4b-BP (Kotwal, 1994).  This shows that the 
small structure of VCP may improve its ability to bind the complement components C3b 
and C4b, thus improving its ability to block complement.  By determining the residues 
involved in this interaction with complement, a better understanding of the structural 
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basis for this potency may be acquired.  With the residues involved in both binding 
complement and facilitating its cleavage to an inactivated form by factor I determined, 
the structure of a comple ent inhibitor even smaller and possibly more potent than VCP 
may be created by protein engineering.  A short protein backbone can be created to 
display these critical residues in the specific spatial orientation displayed in VCP, 
required for complement binding.  With the size of the complement inhibitor reduced, 
absorption into the blood may become possible, allowing for I.P., SubQ, or I.M. 
administration to be effective.  In addition, if the synthetic protein can be made small 
enough, it may be able to pass across the blood brain barrier into the cerebral spinal fluid.  
With this being possible, damaging inflammation mediated by complement activation 
shortly following CNS injury may be modulated, perhaps resulting in significant neuronal 
sparing and return of neurological function. 
 The heparin binding ability of VCP endows it with many extremely novel 
functions, including the ability to block chemokine induced monocyte migration and 
preventing molecular and cellular interactions with cells.  Knowing theamino acids and 
their spatial orientations involved in VCP's ability to bind heparin may someday allow for 
the development of a short synthetic peptide, able to retain the novel functions displayed 
by VCP.  This synthetic peptide may be ten amino acids or less, and still maintain the 
ability to bind heparin and heparan sulfate proteoglycans, allowing for steric interference 
with unwanted molecular and cellular interactions with cells.  A synthetic peptide with 
this immunomodulatory ability could have therapeutic uses for preventing molecular and 
cellular mechanisms of graft rejection or even autoimmune diseases.  It could prove 
valuable in prolonging survival of xenografted organs by inhibiting cellular mechanisms 
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of graft rejection associated with accelerated rejection and acute cellular rejection 
processes.  The immune modulating ability that would be displayed by this peptide may 
be able to suppress an autoimmune reaction in diseases such as rheumatoid arthritis, 
systemic lupus erythematosus, and multiple sclerosis.  However, there is no indication of 
how long the peptide would be effective or if any side effects would result from extended 
use. 
 By using the complement and heparin binding regions identified within VCP, 
small synthetic therapeutic proteins, created by protein engineering, may be developed 
for use against many complement-media ed conditions.  This strategy would be less 
complex when designing a synthetic heparin binding peptide, and much more 
complicated when creating a synthetic complement binding protein.  Due to the fact that 
residues involved in binding complement are spread throughout nearly the entire length 
of VCP, it seems very likely that the vaccinia virus has already reduce the protein to its 
smallest functional unit.  It would therefore be exceedingly difficult to further reduce the 
number of amino acids making up the protein.  Spatially, four SCRs may be the minimal 
requirement for binding C3b and C4b, and facilitating their cleavage by factor I.  If this 
were in fact the case, VCP would remain a likely candidate for therapeutic use in 
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Figure 63.  Rat serum CH50 following 24 mg/kg SubQ bolus.  Following a 
subcutaneous bolus dose of 24 mg/kg, the complement activity was monitored 
periodically by CH50 assay.  The CH50 was measured every half-hour for four hours.  
As can be seen, no evident change in complement activity is evident.  The v rticle black 


















































Figure 64.  Baboon 479 CH50 following 9 mg/kg I.V. bolus.  Serum samples were 
tested for complement activity by CH50 assay.  CH50 activity was de ermined for 15 
min, 30 min, 60 min, and 120 min.  As can be seen, only a slight decrease in complement 
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Figure 65.  Rat serum CH50 following continuous 16 mg/kg/hr via catheter.  A rat
was administered rVCP at 16 mg/kg/hr by continual infussion and the serum CH50 was 
evaluated at 15 minute intervals for one hour.  The verticle black line represents CH50 
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Figure 66.  Rat serum CH50 following 6 mg/kg I.V. + 3 mg/kg/hr via pump.  
Following the bolus injection, serum CH50 was assayed at 15 min and every hour for 6 
hours.  As can be seen, the initial CH50 was reduced to near 0, but slowly returned 
















































Figure 67.  Rat Serum CH50 following 6 mg/kg I.V. + 6 mg/kg/hr via pump.  
Following the bolus injection, serum CH50 was assayed at 15 min and every hour for 3 
hours.  The initial CH50 was reduced to near 0, but quickly returned toward normal 
levels.  This was attributed to clogging of the injection line from using too high a 














































Figure 68.  Rat Serum CH50 following 6 mg/kg I.V. + 6 mg/kg/hr via catheter.  
Following the bolus injection, serum CH50 was assayed at 15 min and at 6 hours.  The 
CH50 was reduced to near 0, and remained that way for at least 6 hours.  The verticle 










































Scott Alan Smith 
1432 S. 3rd St. Apt. 34, Louisville, Kentucky 40208




Graduate: University of Louisville, School of Medicine, Department of 
Microbiology & Immunology 
  Louisville, KY 
    Ph.D. in Microbiol. & Immunol., 2002GPA: 3.93 
 
Undergraduate: California University of Pennsylvania 
    California, PA 
    B.S. in Biology, Pre-medicine, 1997  GPA: 3.91 
 Dean's List: Fall 1995, 1996, 1997; Spring 1996, 1997, 
1998; Summer 1996, 1997
    
Community College of Allegheny County (CCAC) 
    Pittsburgh, PA 
    A.S. in General Studies, 1995   GPA: 3.88 





Ph.D. Candidate, University of Louisville, School of Medicine, Department of 
Microbiology & Immunology, Louisville, KY, 2000-20 2 
 
Graduate Teaching Assistant, Department of Microbiology & Immunology, 
University of Louisville, School of Medicine, Louisville, KY, 1999-2001 
 
Research Assistant, Department of Virology, University of Cape Town, Cape 




Health Sciences Center-Graduate Student Association Representative for 
Department of Microbiology & Immunology, University of Louisville, 
School of Medicine, 1999-2000 
275 
Microbiology and Immunology Student Organization (MISO) Representative, 
Department of Microbiology and Immunology, University of Louisville, 




International Society for Leukocyte Biology, 1999-2000 
 
Honors and Awards 
  
· National Dean's List, 1994-1995 
· Phi Theta Kappa International Honors Society, 1994 
· Beta Beta Beta National Honorary Biological Society, 1997 
· Academic Excellence in the Biological Sciences Award, 1998 
· University of Louisville School of Medicine Student Travel Award, 1999 
· University of Louisville Graduate School Travel Award, 1999 
· University of Louisville Graduate Student Council Travel Award, 1999 
· First place winner of Research! Louisville Graduate Student Division, 2000 




Peer-Reviewed Research Articles: 
 
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, 
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J. 
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on 
poxvirus complement control proteins serve as putative heparin binding sites and 
contribute to inhibition of molecular interactions with human endothelial cells: a 
novel mechanism for evasion of host defense.  J. Virol. Jun. 74(12):5659-66, 2000 
[Cover of J. Virol. Oct. 74(20), 2000].   
 
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata 
C.M., and Kotwal G.J.  Crystal structure of a complement control protein that 
regulates both pathways of complement activation and binds heparan sulfate 
proteoglycans. Cell. Jan. 26, 104:301-1 , 2001. 
 
Hicks R.R., Keeling K.L., Yang M., Smith S.A., and Kotwal G.J.  Vaccinia virus 
complement control protein enhances functional recovery following traumatic brain 
injury.  J. Neurotrauma, Jun. 19(6):705-14, 2002. 
Smith S.A., Krishnasamy G., Murthy K.H., Cooper A., Bromek K., Barlow P.N., and 
Kotwal G.J.  Vaccinia virus complement control protein is monomeric, and retains 
structural and functional integrity after exposure to adverse conditions.  Bio him. 
Biophys. Acta., Jul. 29;1598(1-2):55-64, 2002. 
276 
Anderson J.B., Smith S.A., and Kotwal G.J.  Vaccinia virus complement control protein 
inhibits hyperacute xenorejection.  Transplant Proc., Jun. 34(4):1083-5, 2002. 
Anderson J.B., Smith S.A., Wijk R.V., Chien S., and Kotwal G.J.  Vaccinia virus 
complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat 
heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding 
and complement pathway activation.  Transpl. Immunol., In Press, 2002. 
Anderson J.B., Smith S.A., Wijk R.V., Chien S., and Kotwal G.J.  Vaccinia virus 
complement control protein inhibits hyperacute xenorejection in a mouse-t -
sensitized rat heterotopic heart xenograft model by blocking both xenoantibody 
binding.  Transplant Proc., In Press, 2002. 
Smith S.A., Arjunwadkar S., Krishnasamy G., Judge K., Murthy K.H., Pugh D.R., and 
Kotwal G.J.  Mapping of regions within the vaccinia virus complement control 
protein involved in binding to key complement components and heparin using surface 
plasmon resonance.  Submitted to Biochim. Biophys. Acta., 2002. 
Billings B.B., Smith S.A., Lahiri D., and Kotwal G.J.  Vaccinia virus encodes a 
neurovirulent virokine that acts as an enhancer of viral replication (EVR) in vivo i  
brain: Implications for a safe smallpox and a potential HIV vaccine.  Submitted to 
Nature Neuroscience, 2002. 
 
Peer-Reviewed Review Articles: 
 
Smith S.A., and Kotwal G.J.  Virokines: novel immunomodulatory agents.  Exp. Opi . 
Biol. Ther., 1(3):343- 57, 2001. 
 
Smith S.A., and Kotwal G.J.  Vaccinia virus.  In: Encyclopedia of Molecular Medicine.  
John Wiley & Sons Inc., Vol. 5, pp. 3324- 330, 2001. 
 
Smith S.A., and Kotwal G.J.  Immune response to poxvirus infections in various animals.  




Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, 
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J. 
Kotwal.  Surface-exposed K/R-X-K/R sites and overall positive charge on poxviral 
complement control proteins contribute to heparin binding and to additional 
functional features.  Presented at the Society for Leukocyte Biology 15th International 
Congress, Cambridge, United Kingdom, September 22-26, 1999 abstract #LB15-52. 
 
Keeling K.L., Hicks R.R., Yang M.Y., Smith S.A., Kotwal G.J.  Role of complement in 
traumatic head injury.  The 6th Annual Kentucky Spinal Cord and Head Injury 
Research Symposium, Lexington, KY, June 12-14, 2000.  Program and Abstracts. 
 
277 
Smith S.A., N.P. Mullin, R. Srisatjaluk, D.E. Justus, P.N. Barlow, and G.J. Kotwal.   
Surface- xposed K/R-X-K/R sites and overall positive charge on poxviral 
complement control proteins contribute to heparin binding and to additional 
functional features.  Presented at the University of Louisville Student Research Day, 
Louisville, KY, November 15, 1999. Research! Louisville 1999 Poster Abstracts, 
abstract #GR21. 
 
Keeling K.L., Hicks R.R., Yang M.Y., Smith S.A., Reynolds D.N., Kotwal G.J.  
Evaluation of the vaccinia virus complement control protein in modulation of 
inflammation in a rat head injury model.  The XIIIth International Poxvirus-Iridovirus 
Symposium, Montpellier, France, September 2-6, 2000.  Program and Abstracts, 
p.117, abstract #P67. 
 
Kotwal G.J., Smith S.A., F. Al  Mohanna, R. Purpar, R. Srisatjaluk, D.E. Justus, N.P. 
Mullin, J. Parkinson, and P.N. Barlow.  Heparin binding activity (due to putative 
K/R-X-K/R sites) of vaccinia virus complement control protein confers numerous 
functions with tremendous implications in viral evasion.  The XVIIIth International 
Complement Workshop, Salt Lake City, Utah, July 23-27, 2000.  Program and 
Abstracts, p.76, abstract #223. 
 
Smith S.A., Murthy K.H., Barlow P.N., and Kotwal G.J.  The 3-D crystal structure 
analysis of vaccinia virus complement control protein reveals a heat stable structure 
with distinct binding sites for complement components and heparan sulfate 
proteoglycans.  Presented at the University of Louisville Student Research Day, 
Louisville, KY, October 30, 2000. Research! Louisville 2000 Poster Abstracts, 
abstract #GR23 (First place). 
 
Smith S.A., Murthy K.H., Barlow P.N., and Kotwal G.J.  The 3-D crystal structure of 
vaccinia virus complement control protein reveals a stable structure with distinct 
binding sites for complement components and heparan sulfate proteoglycans.  
Presented at the 32nd Annual Midwest Student Biomedical Research Forum, Omaha, 
Nebraska, February 16 and 17, 2001.  Program and Abstracts, p.26, abstract #P25. 
 
Smith S.A., and Kotwal G.J.  Vaccinia virus complement control protein is functionally 
stable under adverse physical conditions due to structural features: structure-function 
relationships of a novel viral immunomodulator with therapeutic potential.  Presented 
at the 32nd Annual Midwest Student Biomedical Research Forum, Omaha, Nebraska, 
February 16 and 17, 2001.  Program and Abstracts, ab tract #O45. 
 
Hicks R.R., Keeling K.L., Yang M.Y., Kozawa S., Smith S.A., and Kotwal G.J.  Vaccinia 
virus complement control protein attenuates cognitive deficits following traumatic 
brain injury in rats.  The 11th International Congress of Immunology, Stockholm, 
Sweden, July 22- 7, 2001. Scand. J. Immunol. 2001 Jul-Aug; 54 (S1): 110. 
 
278 
